Heteroaryl heterocyclic compounds and uses thereof

Abstract

The present invention relates to heteroaryl heterocyclic compounds of formula (I), pharmaceutical compositions containing same, processes for preparing same, and uses thereof, wherein the variables are as defined in the specification. [Formula 1] TIFF2023515099000347.tif48170

Description

[Technical Field]

[0001] The present invention relates to heteroaryl heterocyclic compounds, pharmaceutical compositions containing same, methods for their preparation, and their uses. [Background technology]

[0002] Bruton's tyrosine kinase (BTK), a member of the non-receptor tyrosine protein Tec family (which includes BTK, LTK, TEC, BMX, and TXK), is widely expressed in hematopoietic cells, excluding T cells, NK cells, and differentiated plasma cells. BTK plays a key role in signal transduction mediated by the B cell antigen receptor (BCR) and Fcγ receptor (FcγR) in B cells and myeloid cells, respectively. It is a key regulator of B cell development, activation, signal transduction, and survival. BTK can control B cell development and differentiation by activating positive cell cycle regulators and differentiation factors, and can also control B cell survival and proliferation by regulating the expression of pro- and anti-apoptotic proteins. BTK also plays an important role in the migration and adhesion of B lymphoma cells. Additionally, BTK plays a role in many other hematopoietic signaling pathways, such as Toll-like receptor (TLR) and cytokine receptor-mediated TNF-α production in macrophages, IgE receptor (FceRI)-mediated signaling in mast cells, inhibition of Fas / APO-1-induced apoptotic signals in type B lymphoma cells, and collagen-induced platelet aggregation.

[0003] In humans, BTK gene mutations can cause the inherited immunodeficiency disease X-linked agammaglobulinemia (XLA). Point mutations in the BTK gene are implicated in human XLA patients and are associated with undetectable low BTK mRNA levels and BTK protein expression, resulting in a near-complete absence of B cell and immunoglobulin maturation and development, and a significantly attenuated sustained calcium signal in response to BCR stimulation. BTK mutations affect only the B cell population, eliminating the significant developmental defects in other immune cells seen in XLA patients. Spontaneous mutations in the BTK gene are also found in X-linked immunodeficient (xid) mice, which exhibit a similar but less severe phenotype. In xid mice or mice with a mutagenic BTK gene knockout, B cell differentiation is partially inhibited at the B cell stage, resulting in reduced numbers of mature B cells in the circulation and resistance to models of collagen-induced and staphylococcal-induced arthritis. Mounting evidence indicates that BTK is abundantly expressed on circulating B cells in patients with autoimmune diseases such as rheumatoid arthritis (RA), primary Sjögren's syndrome (pSS), and systemic lupus erythematosus (SLE), as well as in B-cell leukemia and lymphoma. Abnormal activation of BCR signaling has been identified in these autoimmune and B-cell-related diseases. Inhibition of B cells, the BCR signaling pathway, and BTK may slow the progression of these diseases to varying degrees.

[0004] Given the critical role of BTK in B cell development and function, BTK is considered a potential target for the treatment of B cell malignancies and autoimmune diseases. Various BTK inhibitors have been developed for clinical research in hematological malignancies and autoimmune diseases. Small molecule BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib, PRN1008, GDC-0853, etc.) have shown promising therapeutic efficacy. For example, the irreversible BTK inhibitor ibrutinib demonstrated relatively high and sustained efficacy with low toxicity in clinical trials. It was approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed mantle cell lymphoma (MCL) in 2013, chronic lymphocytic leukemia (CLL) in 2014, Waldenström's macroglobulinemia (WM) in 2015, and relapsed / refractory marginal zone lymphoma (MZL) in 2017, demonstrating the role of BTK in the treatment of chronic autoimmune diseases. Additionally, the irreversible BTK inhibitor acalabrutinib was approved for the treatment of adult MCL in 2017 and for the treatment of CLL in 2019; zanubrutinib was approved by the FDA for the treatment of MCL in November 2019; and a Phase III trial of PRN1008 for pemphigus is ongoing. Several irreversible BTK inhibitors (tirabrutinib, spebrutinib, and evobrutinib) and reversible BTK inhibitors (GDC-0853, ARQ-531, and LOXO-305) are in preclinical and clinical development.

[0005] Therefore, BTK inhibitors offer attractive therapeutic potential for the treatment of related diseases, particularly cancer, inflammatory diseases, or autoimmune diseases. Summary of the Invention

[0006] Compounds of formula (I) are provided: [ka] [In the formula, X1 and X2 are each independently CH or N; or X1 is N and X2 is CR 14 and R 14is C 1-6 is alkyl; X3 and X4 are each independently C or N; Y1 and Y2 are each independently CR 10 or N; R1 and R2 are each independently hydrogen, deuterium, halogen, or C 1-6 Alkyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-6 cycloalkyl and phenyl; or R1 and R2, together with the carbon atom to which they are attached, are selected from the following structure: [ka] and R6 independently represents deuterium, halogen, hydroxyl, C 1-6 Alkyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl and C 1-6 haloalkyl; or two R6 together with the carbon atoms to which they are attached form a 3- to 6-membered cycloalkyl; m is 0, 1, 2, 3, or 4; p is 1, 2, 3, or 4; Z is N or CR7; R7 is hydrogen, deuterium, C 1-6 Alkyl, halogen and C 1-6 selected from haloalkyl; or R1 and R2, together with the carbon atoms to which they are attached, [ka] with the proviso that R3 is halogen or both X1 and X2 are not simultaneously CH; R3 is hydrogen, deuterium, halogen or C 1-6 is haloalkyl; R4 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkynyl, -(C 1-3 alkyl)-OH, -(C 1-3 alkyl)-O-(C 1-3 alkyl), -O-(C1-3 alkyl), -CHO, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2 or 3-hydroxyl-oxetan-3-yl, 1-6 Alkyl or C 1-3 each alkyl optionally substituted with one or more deuterium or halo; Cy [ka] and R 11 is hydrogen, C 1-6 Alkyl and C 3-6 cycloalkyl, wherein C 1-6 alkyl is optionally substituted with one or more deuterium or halo; U, V and W are each independently N or CR 12 and;R 12 is hydrogen, deuterium or a halogen; R5 is hydrogen, C 1-6 Alkyl, -C(O)-(C 1-6 alkyl), -C(O)-(C 3-6 cycloalkyl), -C(O)-phenyl, -C(O)NH-(C 1-6 alkyl), -C(O)NH-(C 3-6 cycloalkyl), -C(O)N(C 1-6 alkyl), phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl, 1-6 Alkyl, C 3-6 The cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl are each optionally substituted with one or more groups selected from the following: 1) halogen; 2) oxo; 3)-CN; 4) C 1-6 alkyl; 5) C 2-6 Alkenyl; 6) C 2-6 Alkynyl; 7) C 1-6 Alkoxy; 8) C1-6 Haloalkyl; 9)-(C 1-6 alkyl)-OH; 10)-(C 1-6 alkyl)-O-(C 1-6 alkyl); 11)C 3-6 cycloalkyl; 12) Deuterium, halogen, hydroxyl, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-OH, 4- to 6-membered heterocyclyl, and deuterated 4- to 6-membered heterocyclyl, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl or 4- to 6-membered heterocyclyl is, respectively, deuterium, halogen, -NH2, -OH, -NH(C 1-6 alkyl), -N(C 1-6 alkyl)2 and -NH(C 3-6 the 3- to 12-membered heterocyclyl optionally substituted with one or more groups selected from cycloalkyl; 13) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-65- to 6-membered monocyclic heteroaryl optionally substituted with one or more groups selected from cycloalkyl and 4- to 6-membered heterocyclyl; 14) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N-(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 phenyl optionally substituted with one or more groups selected from cycloalkyl) and 4- to 6-membered heterocyclyl; 15)-NR a 'R a '' and R a ' and R a '' are each independently hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl, wherein the 4- to 6-membered heterocyclyl is -(C 1-6 and optionally substituted with one or more substituents of (alkyl)-OH, 1-6 -NR with one or more alkyl groups e 'R e Optionally replaced by '' and R e ' and R e '' are each independently hydrogen, C 1-6 Alkyl, -(C 1-6 alkyl)-OH and 4- to 6-membered heterocyclyl a 'R a ''; 16)-C(O)NR b 'R b '' and R b' and R b '' along with the N atom to which they are attached, deuterium, halogens, -OH, C 1-6 Alkyl, -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 cycloalkyl), -NH2, -NH(C 1-6 alkyl), -N(C 1-6 alkyl)2, -NH(C 3-6 cycloalkyl) and -(C 1-6 the —C(O)NR 2 —O—H ... b 'R b ''; and 17)-C(O)R c and R c is hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(C 1-6 alkyl)-OH and -(C 1-6 alkyl)-O-(C 1-6 alkyl) c ; R 10 are hydrogen, deuterium, halogens, CN, C 1-6 Alkyl or C 1-6 is haloalkyl; provided that R1 and R2, together with the carbon atoms to which they are attached, form the following structure: [ka] and Cy [ka] When substituted, the 3- to 12-membered heterocyclyl is C at both the 2- and 6-positions. 1-6not alkyl-substituted piperazin-1-yl. or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

[0007] The above compounds and active compounds (including compounds of the general structural formula and specific compounds) disclosed in the context of the present invention include pharmaceutically acceptable salts thereof encompassed within the scope above, or solvates, racemic mixtures, enantiomers, diastereomers or tautomers thereof, collectively referred to herein as "compounds of the present invention."

[0008] Also provided are pharmaceutical compositions comprising compounds of the invention and, optionally, a pharmaceutically acceptable excipient.

[0009] Also provided are methods for inhibiting BTK activity in vivo or in vitro, comprising contacting BTK with an effective amount of a compound of the invention.

[0010] Also provided is a method for treating or preventing a disease mediated by, or at least in part by, BTK, comprising administering to a subject in need thereof an effective amount of a compound of the invention.

[0011] Also provided is a method for treating or preventing cancer, an inflammatory disease, or an autoimmune disease, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0012] Also provided is the use of the compounds of the invention for treating or preventing a disease mediated by, or at least in part by, BTK.

[0013] Also provided is the use of a compound of the invention for treating or preventing cancer, an inflammatory disease, or an autoimmune disease.

[0014] Also provided is the use of a compound of the invention in the manufacture of a medicament for treating or preventing a disease mediated by, or at least in part by, BTK.

[0015] Also provided is the use of a compound of the invention in the manufacture of a medicament for treating or preventing cancer, an inflammatory disease, or an autoimmune disease.

[0016] Also provided are compounds of the present invention for inhibiting the activity of BTK in vivo or in vitro.

[0017] Also provided are compounds of the invention for use as pharmaceuticals.

[0018] Also provided is the use of the compounds of the invention for use as a pharmaceutical to treat or prevent a disease mediated by, or at least in part by, BTK, particularly to treat or prevent cancer, inflammatory disease, or autoimmune disease.

[0019] Also provided is a pharmaceutical combination comprising a compound of the present invention and at least one additional therapeutic agent, said therapeutic agent preferably being selected from an anti-inflammatory agent, an immunomodulatory agent or an anti-tumor active agent, said tumor active agent comprising a chemotherapeutic agent, an immune checkpoint inhibitor or agonist, and a targeted therapeutic agent.

[0020] Also provided are kits for treating or preventing diseases mediated by, or at least in part by, BTK. The kits can include a pharmaceutical composition of the invention and instructions for use, wherein the pharmaceutical composition includes a compound of the invention. [Brief explanation of the drawings]

[0021] [Figure 1] Growth curve of subcutaneously implanted tumor TMD8. [Figure 2] Inhibitory effect of the compounds of the present invention on B cell activation in mouse whole blood induced by anti-IgD antibody. [Figure 3] Inhibitory effect of the compounds of the present invention on B cell activation in mouse whole blood induced by anti-IgD antibody. [Figure 4] Effect of the compound of the present invention on the volume of arthritic paws in CIA (collagen-induced arthritis) rats (The volume of the hind paws was measured by a paw volume meter, and the data are expressed as the mean ± standard error, and each group is represented by a normal group, a vehicle control group (i.e., the model group in the figure), different doses of compound 19QD groups, and a 4 mg / kg GDC-0853 group (normal group: n=3, other groups: n=8)). DETAILED DESCRIPTION OF THE INVENTION

[0022] definition As used in this application, the following words, phrases and symbols are generally intended to have the meanings set forth below, except to the extent that the context in which they are used indicates otherwise.

[0023] A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent, e.g., -OR 3 is connected to R via an oxygen atom 3 refers to the bond to the rest of the molecule.

[0024] As used herein, the term "alkyl" refers to an alkyl group having 1 to 18 carbon atoms (C 1-18 ), preferably 1 to 10 carbon atoms (C 1-10 ), more preferably 1 to 6 carbon atoms (C 1-6 ), more preferably 1 to 4 carbon atoms (C 1-4 ) or 1 to 3 carbon atoms (C 1-3 ) refers to a straight-chain or branched saturated hydrocarbon radical containing 1 or more carbon atoms. When the term "alkyl" is preceded by a "C", it refers to the number of carbon atoms. For example, "C 1-6 "Alkyl" refers to an alkyl containing 1 to 6 carbon atoms. 1-3 "Alkyl" refers to an alkyl containing 1 to 3 carbon atoms. 1-6Examples of alkyl include, but are not limited to, methyl, ethyl, propyl (e.g., n-propyl, i-propyl), butyl (e.g., n-butyl, i-butyl, s-butyl and t-butyl), pentyl (e.g., n-pentyl, i-pentyl, neo-pentyl), hexyl, and the like.

[0025] The term "alkenyl" as used herein refers to an alkyl group containing one or more, e.g., one, two, or three, carbon-carbon double bonds (C=C) and 2 to 18 carbon atoms (C 2-18 ), preferably 2 to 10 carbon atoms (C 2-10 ), more preferably 2 to 6 carbon atoms (C 2-6 ), more preferably 2 to 4 carbon atoms (C 2-4 (Alkenyl) refers to a straight or branched chain unsaturated hydrocarbon radical containing 2 or more carbon atoms. When the term "alkenyl" is preceded by a "C", it refers to the number of carbon atoms. For example, "C 2-6 "Alkenyl" refers to an alkenyl containing 2 to 6 carbon atoms. 2-4 "Alkenyl" refers to an alkenyl containing 2 to 4 carbon atoms. 2-6 Examples of alkenyl include, but are not limited to, vinyl, propenyl (e.g., 2-propenyl), and butenyl (e.g., 2-butenyl), etc. The point of attachment of the alkenyl may or may not be on the double bond.

[0026] The term "alkynyl" as used herein refers to an alkyl group containing one or more, e.g., one, two, or three, carbon-carbon triple bonds (C≡C) and 2 to 18 carbon atoms (C 2-18 ), preferably 2 to 10 carbon atoms (C 2-10 ), more preferably 2 to 6 carbon atoms (C 2-6 ), more preferably 2 to 4 carbon atoms (C 2-4 ) refers to a straight or branched chain unsaturated hydrocarbon radical containing 1 or 2 carbon atoms. When the term "alkynyl" is preceded by a "C", it refers to the number of carbon atoms. For example, "C 2-6 "Alkynyl" refers to an alkynyl containing 2 to 6 carbon atoms. 2-4"Alkynyl" refers to an alkynyl containing 2 to 4 carbon atoms. 2-6 Examples of alkynyl include, but are not limited to, ethynyl, propynyl (e.g., 2-propynyl), and butynyl (e.g., 2-butynyl), etc. The point of attachment of an alkynyl may or may not be on the triple bond.

[0027] As used herein, the term "halogen" or "halo" means fluoro, chloro, bromo and iodo, preferably fluoro, chloro and bromo, more preferably fluoro and chloro.

[0028] The term "haloalkyl" as used herein refers to an alkyl group, as defined herein, in which one or more, e.g., 1, 2, 3, 4, or 5, hydrogen atoms are replaced with halogen atoms, and when a hydrogen atom is replaced with a halogen atom, the halogen atoms may be the same or different from each other. In one embodiment, the term "haloalkyl" as used herein refers to an alkyl group, as defined herein, in which two or more, e.g., 2, 3, 4, or 5, hydrogen atoms are replaced with halogen atoms, and the halogen atoms are the same as each other. In another embodiment, the term "haloalkyl" as used herein refers to an alkyl radical, as defined herein, in which two or more, e.g., 2, 3, 4, or 5, hydrogen atoms are replaced with halogen atoms, and the halogen atoms are different from each other. When the term "haloalkyl" is preceded by "C", it refers to the number of carbon atoms. For example, "C 1-6 "Haloalkyl" refers to a haloalkyl, as defined herein, containing 1 to 6 carbon atoms. 1-4 "Haloalkyl" refers to a haloalkyl, as defined herein, containing 1 to 4 carbon atoms. 1-6 Examples of haloalkyl include, but are not limited to, -CF3, -CHF2, -CH2F, -CH2CF3, -CH(CF3)2, and the like.

[0029] As used herein, the term "cycloalkyl" refers to a group having 3 to 12 ring carbon atoms (C 3-12 ), e.g., 3 to 8 ring carbon atoms (C 3-8 ), 5 to 7 ring carbon atoms (C 5-7 ), 4 to 7 ring carbon atoms (C 4-7 ) or 3 to 6 ring carbon atoms (C 3-6 "Cycloalkyl" refers to a saturated or partially unsaturated cyclic hydrocarbon radical having one or more rings, e.g., one, two, or three rings, preferably one or two rings. When the term "cycloalkyl" is preceded by "C", it refers to the number of carbon atoms. For example, "C 3-6 "Cycloalkyl" or "3- to 6-membered cycloalkyl" refers to a cycloalkyl containing 3 to 6 ring carbon atoms. The cycloalkyl may contain fused or bridged rings, or spirocyclic rings. The rings of a cycloalkyl may be saturated or have one or more, for example, one or two, double bonds (i.e., partially saturated), are not fully conjugated, and are not aryl as defined herein. C 3-6 Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, spiro[2.2]pentyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, and the like.

[0030] As used herein, the terms "heterocyclyl" and "heterocyclic" are used interchangeably and refer to saturated or partially unsaturated cyclic radicals having 3 to 12 ring atoms, e.g., 3 to 8 ring atoms, 4 to 8 ring atoms, 4 to 6 ring atoms, or 4 to 5 ring atoms, respectively, containing one or more, e.g., 1, 2, or 3, preferably 1 or 2, heteroatoms independently selected from N, O, and S in the ring, with the remaining ring atoms being carbon; it may have one or more rings, e.g., 1, 2, or 3, preferably 1 or 2 rings. Heterocyclyl also includes N or S heteroatoms optionally oxidized to various oxidation states. The point of attachment of a heterocyclyl may be on the N heteroatom or on a carbon. For example, "4- to 8-membered heterocyclyl" refers to a heterocyclyl having 4 to 8 (4, 5, 6, 7, or 8) ring atoms, including at least one, for example, 1, 2, or 3, preferably 1 or 2, heteroatoms independently selected from N, O, and S; "4- to 6-membered heterocyclyl" refers to a preferably monocyclic heterocyclyl having 4 to 6 (4, 5, or 6) ring atoms, including at least one, preferably 1 or 2, heteroatoms independently selected from N, O, and S (preferably N and O); and "4- to 5-membered heterocyclyl" refers to a monocyclic heterocyclyl having 4 to 5 ring atoms, including at least one, preferably 1 or 2, heteroatoms independently selected from N, O, and S (preferably N and O). Heterocyclyl also includes fused or bridged rings, or spiro rings. The ring of a heterocyclyl may be saturated or have one or more, e.g., one or two, double bonds (i.e., partially unsaturated), is not fully conjugated, and is not a heteroaryl as defined herein.Examples of heterocyclyl include, but are not limited to, 4- to 8-membered heterocyclyl, 4- to 6-membered heterocyclyl, and 4- to 5-membered heterocyclyl such as oxetanyl, azetidinyl, pyrrolidyl, tetrahydrofuranyl, dioxolanyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, piperidyl, piperazinyl, tetrahydropyridyl, pyrazinyl, pyrazolidinyl, and oxaspiro[3.3]heptyl, and preferably oxetanyl (oxetan-3-yl, etc.), azetidinyl, tetrahydropyranyl, morpholinyl (morpholino, etc.), piperazinyl (piperazin-1-yl, etc.), and tetrahydropyridyl (1,2,3,6-tetrahydropyridyl, etc.).

[0031] As used herein, the terms "aryl" and "aromatic ring" are used interchangeably and refer to a carbocyclic hydrocarbon radical of 6 to 14 carbon atoms, each consisting of one or more rings or fused rings, at least one of which is aromatic. Examples of aryl include, but are not limited to, phenyl, naphthalenyl, 1,2,3,4-tetrahydronaphthalenyl, phenanthryl, indenyl, indanyl, and azulenyl, with phenyl and naphthalenyl being preferred.

[0032] As used herein, the terms "heteroaryl" and "heteroaromatic ring" are used interchangeably and refer to a monocyclic, bicyclic, or tricyclic ring system having 5 to 15 ring atoms, preferably 5 to 12 ring atoms, more preferably 5 to 10 ring atoms, and most preferably 5 to 6 or 8 to 10 ring atoms, respectively, in which at least one ring is a 5- or 6-membered aromatic ring containing one or more, e.g., 1 to 4, heteroatoms independently selected from N, O, and S, and the S and N may be optionally oxidized to various oxidation states. When the total number of S and O atoms in a heteroaryl group exceeds 1, the S and O heteroatoms are not adjacent to one another. Preferably, the heteroaryl is a 5- to 12-membered heteroaryl. For example, heteroaryls include: 5- to 6-membered monocyclic heteroaryl, i.e., monocyclic aromatic hydrocarbyl having 5 or 6 ring atoms, wherein the ring atoms contain one or more, for example 1, 2 or 3 heteroatoms independently selected from N, O and S (preferably N), and the remaining ring atoms are carbon; the heteroaryl is preferably triazolyl, pyridyl, pyrazinyl, pyrimidyl, pyrazolyl, imidazolyl, isoxazolyl, triazinyl, oxazolyl, thiadiazolyl and pyridazinyl, more preferably triazolyl (e.g., 1H-1,2,3-triazole), pyridyl (e.g., pyridin-2-yl), pyrazinyl and pyrimidyl, and the like; and 8- to 10-membered bicyclic heteroaryl, i.e., bicyclic aromatic hydrocarbyl having 8, 9 or 10 ring atoms, wherein the ring atoms contain one or more, for example 1, 2, 3 or 4, preferably 1, 2 or 3 heteroatoms independently selected from N, O and S (preferably N), the remaining ring atoms being carbon atoms, and at least one ring being aromatic; preferably, the 8- to 10-membered bicyclic heteroaryl is 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine, such as 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl.

[0033] Examples of heteroaryl include, but are not limited to, pyridyl, N-oxidepyridyl, pyrazinyl, pyrimidyl, triazinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl (such as 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, and 1,3,4-oxadiazolyl), thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, triazolyl, thienyl, furanyl, pyranyl, pyrrolyl, and pyridazinyl; and benzoxazolyl, benzisoxazolyl, benzothienyl, benzisothienyl, benzothiazolyl, benzisothiazolyl, imidazopyridyl (such as imidazo[1,2-a]pyridyl), imidazopyridazinyl (such as imidazo[1,2-a]pyridyl). [1,2,4]triazolo[4,3-a]pyridyl and [1,2,4]triazolo[1,5-a]pyridyl), tetrazolopyridyl (tetrazolo[1,5-a]pyridyl), benzofuranyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolinyl, and 8- to 10-membered bicyclic heteroaryls such as 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine, and the like.

[0034] As used herein, the term "-OH" refers to a hydroxyl radical.

[0035] As used herein, the term "-CN" refers to a cyano radical.

[0036] The term "oxo" as used herein refers to =O.

[0037] Any asymmetric atom (e.g., carbon, etc.) in the compounds of Formula (I) may be present in a racemate or enantiomer, e.g., enriched in the (R), (S), or (RS) configuration. In some embodiments, the asymmetric atom has an enantiomeric excess of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or at least 100% for the (R) or (S) configuration, respectively.

[0038] When a structural formula or chemical name herein contains "(RS)," it refers to any mixture of the (R) and (S) configurations of the compound.

[0039] As used herein, the terms "optional" or "optionally" mean that the described event or circumstance may or may not occur, and the description includes both cases where the event or circumstance occurs and cases where the event or circumstance does not occur. For example, "optionally substituted with one or more" includes substituted and substituted with one, two, three, or more substituents. Those skilled in the art will understand that with respect to any group that contains one or more substituents, such group is not intended to introduce any substitution or substitution pattern that is sterically impractical, chemically incorrect, synthetically impractical, and / or substantially unstable.

[0040] As used herein, the term "substituted" or "substituted with" means that one or more (e.g., 1, 2, 3, or 4) hydrogens at the specified atom or group are replaced with one or more (e.g., 1, 2, 3, or 4) substituents, preferably substituents selected from a specified group of substituents or radicals, provided that the replacement does not exceed the normal valence of the specified atom. These substituents may be the same or different. As used herein, the term "substituted with one or more groups selected from" or "substituted with one or more" means that one or more hydrogens at the specified atom or group are independently replaced with one or more groups from a specified group of substituents or radicals, which may be the same or different. Preferably, "substituted with one or more groups selected from" or "substituted with one or more" means that the specified atom or group is independently substituted with one, two, three, or four radicals selected from a specified group of substituents or radicals, which may be the same or different. In some embodiments, when a substituent is oxo (i.e., =O), two hydrogens on a single atom are replaced by oxo. Any substituent can be any radical, provided that the combination of substituents and / or variables results in a chemically correct and stable compound. A chemically correct and stable compound is meant to refer to a compound that is stable enough to survive sufficient separation from the reaction mixture and whose chemical structure can be identified. Preferably, the substituents are those exemplified in the compounds of the embodiments of the present application.

[0041] Unless otherwise specified, substituents are named on the core structure. For example, when (cycloalkyl)alkyl is listed as a possible substituent, it is understood that the point of attachment of this substituent to the core structure is on the alkyl portion.

[0042] Those skilled in the art ("POSITA") will recognize that some of the compounds of formula (I) contain one or more chiral centers and can therefore exist in two or more stereoisomeric forms. Racemates of these isomers, individual isomers, and mixtures enriched in one enantiomer, as well as diastereomers when two chiral centers are present, and mixtures partially enriched in a particular diastereomer, are within the scope of the present invention. POSITA will further understand that the present invention encompasses all individual stereoisomers (e.g., enantiomers), racemic mixtures or partially resolved mixtures of compounds of formula (I), and, where appropriate, their individual tautomers.

[0043] Racemates can be used as is or separated into individual isomers. Separation can yield stereochemically pure compounds or mixtures enriched in one or more isomers. Methods for separating isomers are well known (see Allinger NL and Eliel EL in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) and include physical methods such as chromatography using chiral adsorbents. Individual isomers can be prepared in chiral form from chiral precursors. Alternatively, individual isomers can be chemically separated from a mixture by forming a diastereomeric salt with a chiral acid (e.g., 10-camphorsulfonic acid, camphoric acid, α-bromocamphoric acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid, etc.), partially crystallizing the salt, then liberating one or both of the separated bases, and optionally repeating these processes to obtain one or both isomers substantially free of the other, i.e., in a form having an optical purity of >95%. Alternatively, the racemate can be covalently linked to a chiral compound (auxiliary) to produce diastereomers, which can be separated by chromatography or fractional crystallization, after which the chiral auxiliary can be chemically removed to give the pure enantiomers, as known from POSITA.

[0044] As used herein, the term "tautomer" refers to a structural isomer of a compound produced by the rapid displacement of atoms at two positions within a molecule. Tautomers are readily interconverted into each other; for example, enol and ketone forms are typical tautomers.

[0045] "Pharmaceutically acceptable salt" is intended to mean a salt of a free acid or free base of a compound of formula (I) that is non-toxic, biologically acceptable, or biologically suitable for administration to a subject. For example, acid addition salts include salts derived from inorganic acids and organic acids. Examples of inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and nitric acid; examples of organic acids include p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, and fumaric acid. For example, see generally SM Berge et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977, 66:1-19, and Handbook of Pharmaceutical Salts, Properties, Selection, and Use, Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich, 2002.

[0046] Furthermore, if the compound of the present invention herein is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid addition salt. Conversely, if the product is a free base, an acid addition salt, particularly a pharmaceutically acceptable acid addition salt, can be produced by dissolving the free base in a suitable solvent and treating the solution with an acid, according to conventional procedures for preparing acid addition salts from base compounds. POSITA will recognize various synthetic methodologies that can be used, without undue experimentation, to prepare non-toxic, pharmaceutically acceptable acid or base addition salts.

[0047] The term "deuterated compound" or "deuteride" refers to a compound in which one or more, for example 1, 2, 3, 4 or 5, hydrogen atoms have been replaced with deuterium atoms (D).

[0048] The term "solvate" refers to a solvent addition form containing a stoichiometric or non-stoichiometric amount of solvent. Some compounds tend to trap a fixed molar ratio of solvent molecules in the solid state, thus forming a solvate. When the solvent is water, the solvate formed is a hydrate, and when the solvent is alcohol, the solvate formed is an alcoholate. A hydrate is formed by combining one or more water molecules, or less than one water molecule, with one molecule of a substance in which water retains the molecular state of HO; such a combination can form one or more hydrates, such as hemihydrate, monohydrate, and dihydrate.

[0049] As used herein, the terms "group" and "radical" are synonymous and are intended to refer to a functional group or fragment of a molecule capable of bonding to another fragment of the molecule.

[0050] The term "active ingredient" is used to refer to a chemical substance that has biological activity. In some embodiments, an "active ingredient" is a chemical substance that has pharmaceutical utility.

[0051] As used herein, the term "pharmaceutical combination" refers to a product obtainable by mixing or combining two or more active ingredients, including fixed or non-fixed combinations of active ingredients such as kits and pharmaceutical compositions. The term "fixed combination" means that two or more active ingredients (such as a compound of the invention and an additional therapeutic agent) are administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that two or more active ingredients (such as a compound of the invention and an additional therapeutic agent) are administered to a patient separately, simultaneously, concurrently, or sequentially, such that the administration provides therapeutically effective levels of the compounds to the patient.

[0052] The terms "treating" or "treatment" or "prevention" with respect to a disease or disorder refer to the administration of one or more pharmaceutical agents, particularly compounds of Formula (I) described herein, to a subject having, or exhibiting symptoms of, a disease or disorder, or a predisposition to a disease or disorder, with the intent to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disease or disorder, symptoms of the disease or disorder, or predisposition to the disease or disorder, in the context of achieving a therapeutic benefit. In some embodiments, the disease or disorder is a cancer, such as a solid tumor or a hematological malignancy, including lymphoma, leukemia, and myeloma. In another embodiment, the disease or disorder is an inflammatory disease or an autoimmune disease.

[0053] The terms "treating," "contacting," and "reacting," in the context of a chemical reaction, refer to the addition or mixing of two or more reagents under appropriate conditions to produce a indicated and / or desired product. It should be understood that the reaction that produces the indicated and / or desired product does not necessarily result directly from the combination of the two reagents that are initially added; i.e., there may be one or more intermediates produced in the mixture that ultimately result in the formation of the indicated and / or desired product.

[0054] The term "effective amount," as used herein, refers to an amount or dosage of a BTK inhibitor sufficient to generally provide a therapeutic benefit to a patient in need of treatment for a disease or disorder mediated, or at least in part, by BTK. Effective amounts or dosages of active ingredients of the present disclosure can be determined by methods such as modeling, dose escalation studies, or clinical trials, and by considering factors such as the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease or disorder, the subject's previous or ongoing treatments, the subject's health status and response to the drug, and the judgment of the treating physician.

[0055] Exemplary doses range from about 0.0001 to about 200 mg of active drug per kg of subject body weight per day, e.g., about 0.001 to 100 mg / kg / day, or about 0.01 to 35 mg / kg / day, or about 0.1 to 10 mg / kg / day, in single or divided dose units (e.g., bid, tid, qid). For a 70 kg human, an exemplary range of suitable doses is about 0.05 to about 7 g / day, or about 0.2 to about 5 g / day. Once improvement of the patient's disease or disorder is observed, the dose may be adjusted for maintenance treatment. For example, the dose or administration frequency, or both, may be reduced, depending on the symptoms, to a level at which the desired therapeutic effect is maintained. Of course, once symptoms have been alleviated to an appropriate level, treatment can be discontinued. However, if symptoms recur, the patient may require long-term intermittent treatment.

[0056] The terms "inhibition" or "inhibiting" refer to a reduction in baseline activity of a biological activity or process. The term "inhibition of BTK activity," for purposes of this disclosure, is an actual pharmaceutical activity and refers to a reduction in the activity of BTK as a direct or indirect response to the presence of a compound of the present invention, compared to the activity of BTK in the absence of the compound. The reduction in activity can be due to the direct interaction of the compound of the present invention with BTK, or due to the interaction of the compound of the present invention with one or more other factors that affect BTK activity. For example, the presence of a compound of the present invention can reduce BTK activity by directly binding to BTK, by reducing BTK activity (directly or indirectly) through another factor, or by reducing the amount of BTK present in a cell or organism (directly or indirectly).

[0057] As used herein, the term "subject" or "patient" refers to mammals and non-mammals. Mammals refer to members of the class Mammalia, including, but not limited to, humans; non-human primates such as chimpanzees and other ape and monkey species; farm animals such as cows, horses, sheep, goats, and pigs; domestic animals such as rabbits, dogs, and cats; and laboratory animals, including rodents such as rats, mice, and guinea pigs. Examples of non-mammals include, but are not limited to, birds, etc. The term "subject" or "patient" does not denote a particular age or sex. In some embodiments, the subject or patient is human.

[0058] In general, the term "about" is used herein to modify a numerical value above or below the stated value by a variance of 20%.

[0059] All technical and scientific terms used herein but not specifically defined have the meaning commonly understood by POSITA to which this disclosure belongs.

[0060] All numerical ranges herein shall be construed as disclosing each and every numerical value and subset of values ​​within the range, whether specifically disclosed or not. For example, when any range of values ​​is mentioned, it should be considered as referring to every value within the range of values, e.g., every integer within the range of values. For example, as used herein, C 1-6 means containing 1, 2, 3, 4, 5 or 6 C. The invention relates to all values ​​contained within ranges, to all smaller ranges and to the upper or lower limits of numerical ranges.

[0061] Detailed description of the embodiment (I): Embodiment 1. Compounds of formula (I): [ka] or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, During the ceremony, X1 and X2 are each independently CH or N; or X1 is N and X2 is CR 14 and R 14 is C 1-6 is alkyl; X3 and X4 are each independently C or N; Y1 and Y2 are each independently CR 10 or N; R1 and R2 are each independently hydrogen, deuterium, halogen, or C 1-6 Alkyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-6 cycloalkyl and phenyl; or R1 and R2, together with the carbon atom to which they are attached, are selected from the following structure: [ka] and R6 independently represents deuterium, halogen, hydroxyl, C 1-6 Alkyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl and C 1-6 haloalkyl; or two R6 together with the carbon atoms to which they are attached form a 3- to 6-membered cycloalkyl; m is 0, 1, 2, 3, or 4; p is 1, 2, 3, or 4; Z is N or CR7; R7 is hydrogen, deuterium, C 1-6 Alkyl, halogen and C 1-6 selected from haloalkyl; or R1 and R2, together with the carbon atoms to which they are attached, [ka] with the proviso that R3 is halogen or both X1 and X2 are not simultaneously CH; R3 is hydrogen, deuterium, halogen or C1-6 is haloalkyl; R4 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkynyl, -(C 1-3 alkyl)-OH, -(C 1-3 alkyl)-O-(C 1-3 alkyl), -O-(C 1-3 alkyl), -CHO, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2 or 3-hydroxyl-oxetan-3-yl, 1-6 Alkyl or C 1-3 each alkyl optionally substituted with one or more deuterium or halo; Cy [ka] and R 11 is hydrogen, C 1-6 Alkyl and C 3-6 cycloalkyl, wherein C 1-6 alkyl is optionally substituted with one or more deuterium or halo; U, V and W are each independently N or CR 12 and;R 12 is hydrogen, deuterium or a halogen; R5 is hydrogen, C 1-6 Alkyl, -C(O)-(C 1-6 alkyl), -C(O)-(C 3-6 cycloalkyl), -C(O)-phenyl, -C(O)NH-(C 1-6 alkyl), -C(O)NH-(C 3-6 cycloalkyl), -C(O)N(C 1-6 alkyl), phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl, 1-6 Alkyl, C 3-6 The cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl are each optionally substituted with one or more groups selected from the following: 1) halogen; 2) oxo; 3)-CN; 4) C 1-6 alkyl; 5) C 2-6 Alkenyl; 6) C 2-6 Alkynyl; 7) C 1-6 Alkoxy; 8) C 1-6 Haloalkyl; 9)-(C 1-6 alkyl)-OH; 10)-(C 1-6 alkyl)-O-(C 1-6 alkyl); 11)C 3-6 cycloalkyl; 12) Deuterium, halogen, hydroxyl, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-OH, 4- to 6-membered heterocyclyl, and deuterated 4- to 6-membered heterocyclyl, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl or 4- to 6-membered heterocyclyl is, respectively, deuterium, halogen, -NH2, -OH, -NH(C 1-6 alkyl), -N(C 1-6 alkyl)2 and -NH(C 3-6 the 3- to 12-membered heterocyclyl optionally substituted with one or more groups selected from cycloalkyl; 13) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 5- to 6-membered monocyclic heteroaryl optionally substituted with one or more groups selected from cycloalkyl and 4- to 6-membered heterocyclyl; 14) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N-(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 phenyl optionally substituted with one or more groups selected from cycloalkyl) and 4- to 6-membered heterocyclyl; 15)-NR a 'R a '' and R a ' and R a '' are each independently hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl, wherein the 4- to 6-membered heterocyclyl is -(C 1-6 and optionally substituted with one or more substituents of (alkyl)-OH, 1-6 -NR with one or more alkyl groups e 'R e Optionally replaced by '' and R e ' and R e '' are each independently hydrogen, C 1-6 Alkyl, -(C1-6 alkyl)-OH and 4- to 6-membered heterocyclyl a 'R a ''; 16)-C(O)NR b 'R b '' and R b ' and R b '' along with the N atom to which they are attached, deuterium, halogens, -OH, C 1-6 Alkyl, -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 cycloalkyl), -NH2, -NH(C 1-6 alkyl), -N(C 1-6 alkyl)2, -NH(C 3-6 cycloalkyl) and -(C 1-6 the —C(O)NR 2 —O—H ... b 'R b ''; and 17)-C(O)R c and R c is hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(C 1-6 alkyl)-OH and -(C 1-6 alkyl)-O-(C 1-6 alkyl) c ; R 10 are hydrogen, deuterium, halogens, CN, C 1-6 Alkyl or C 1-6 is haloalkyl; provided that R1 and R2, together with the carbon atoms to which they are attached, form the following structure: [ka] and Cy [ka] When substituted, the 3- to 12-membered heterocyclyl is C at both the 2- and 6-positions. 1-6 rather than alkyl-substituted piperazin-1-yl; For example, X1 and X2 are each independently CH or N; or X1 is N and X2 is CR 14 and R 14 is C 1-6 is alkyl; X3 is N and X4 is C; Both Y1 and Y2 are CH; R3 is hydrogen, deuterium, or halogen; R1 and R2, together with the carbon atoms to which they are attached, form the following structure: [ka] R6 independently represents a halogen, a hydroxyl, or a C 1-6 Alkyl and C 1-6 haloalkyl; m is 0, 1, or 2; and p is 1, 2, or 3; or R1 and R2, together with the carbon atoms to which they are attached, [ka] Forming provided that R3 is halogen or both X1 and X2 are not simultaneously CH; R4 is -(C 1-3 alkyl)-OH; Cy [ka] and;R 11 is C 1-6 is alkyl; Both U and V are CH; and R5 is [ka] is selected from R 21 is C 1-6 alkyl; R 22 independently, C 1-6 Alkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) or 4- to 6-membered heterocyclyl; A1, A2 and A3 are each independently CH; R 13 is C 1-6 a 6-membered heterocyclyl optionally substituted with one or more substituents selected from alkyl and 4-membered heterocyclyl; However, when a 6-membered heterocyclyl is substituted, both the 2- and 6-positions are C 1-6 Instead of alkyl-substituted piperazin-1-yl, Preferably, R1 and R2 together with the carbon atoms to which they are attached [ka] Forming provided that R3 is halogen or both X1 and X2 are not simultaneously CH; For example, R1 and R2, together with the carbon atoms to which they are attached, may form the following structure: [ka] R6 independently represents deuterium, halogen, hydroxyl, C 1-6 Alkyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl and C 1-6 haloalkyl; m is 0, 1, or 2; Preferably, m is 0.

[0062] Embodiment 2. R1 and R2, together with the carbon atoms to which they are attached, [ka] i.e., the compound has the formula (IA): [ka] or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein

[0063] Embodiment 3. R1 and R2, together with the carbon atoms to which they are attached, [ka] wherein X3 is N, X4 is C, Y1 is CH, and Cy is [ka] and the compound has formula (II): [ka] is a compound of During the ceremony, X1 and X2 are each independently CH or N; or X1 is N and X2 is CR 14 and R 14 is C 1-6 alkyl; Y2 is CH or N; R3 is hydrogen, deuterium, halogen or C 1-6 is haloalkyl; R4 is hydrogen, halogen, -CN, C 1-6 Alkyl, -(C 1-3 alkyl)-OH, -(C 1-3 Deuterated alkyl)-OH, -(C 1-3 alkyl)-O-(C 1-3 alkyl), -O-(C 1-3 alkyl), -CHO, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2 or 3-hydroxyl-oxetan-3-yl, and C 1-6alkyl is optionally substituted with one or more halo; W is N or CR 12 and R 12 is hydrogen or halogen; R5 is hydrogen, C 1-6 Alkyl, -C(O)-(C 1-6 alkyl), -C(O)-(C 3-6 cycloalkyl), -C(O)-phenyl, -C(O)NH-(C 1-6 alkyl), -C(O)NH-(C 3-6 cycloalkyl), -C(O)N(C 1-6 alkyl), phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl, 1-6 Alkyl, C 3-6 The cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl are each optionally substituted with one or more groups selected from the following: 1) halogen; 2) oxo; 3)-CN; 4) C 1-6 alkyl; 5) C 2-6 Alkenyl; 6) C 2-6 Alkynyl; 7) C 1-6 Alkoxy; 8) C 1-6 Haloalkyl; 9)-(C 1-6 alkyl)-OH; 10)-(C 1-6 alkyl)-O-(C 1-6 alkyl); 11)C 3-6 cycloalkyl; 12) Halogen, hydroxyl, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-O-(C1-6 alkyl), -(C 1-6 alkyl)-OH, 4- to 6-membered heterocyclyl, 4- to 6-membered fluoroheterocyclyl, and deuterated 4- to 6-membered heterocyclyl, 1-6 the 3- to 12-membered heterocyclyl, wherein the alkyl is optionally substituted with one or more —OH; 13) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl))-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 5- to 6-membered monocyclic heteroaryl optionally substituted with one or more substituents selected from cycloalkyl and 4- to 6-membered heterocyclyl; 14) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 phenyl optionally substituted with one or more substituents selected from cycloalkyl) and 4- to 6-membered heterocyclyl; 15)-NR a 'Ra '' and R a ' and R a '' are each independently hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl, wherein the 4- to 6-membered heterocyclyl is -(C 1-6 and optionally substituted with one or more substituents of (alkyl)-OH, 1-6 -NR with one or more alkyl groups e 'R e Optionally replaced by '' and R e ' and R e '' are each independently hydrogen, C 1-6 Alkyl, -(C 1-6 alkyl)-OH and 4- to 6-membered heterocyclyl a 'R a '; 16)-C(O)NR b 'R b '' and R b ' and R b '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and the 4- to 6-membered heterocyclyl is not selected from halogen, —OH, C 1-6 Alkyl, -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 cycloalkyl) and -(C 1-6 the —C(O)NR optionally substituted with one or more substituents selected from —OH, —C(O)NR b 'R b ''; and 17)-C(O)R c and R c But hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and -(C1-6 alkyl)-O-(C 1-6 alkyl) c ; R6 is halogen, C 1-6 alkyl or hydroxyl; and m is 0, 1, 2 or 3; Preferably W is N or CR 12 and R 12 is a halogen; and / or Preferably, R5 is a 5-6 membered monocyclic heteroaryl or an 8-10 membered bicyclic heteroaryl optionally substituted with one or more groups selected from: 1) C 1-6 alkyl; and 2) C 1-6 4- to 6-membered heterocycloalkyl optionally substituted with alkyl and 4- to 6-membered heterocyclyl; Preferably, the 5-6 membered monocyclic heteroaryl is a 5 membered monocyclic heteroaryl, more preferably triazolyl; The compound of embodiment 2, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein the 8-10 membered bicyclic heteroaryl is preferably an 8 membered bicyclic heteroaryl, more preferably 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazinyl.

[0064] Embodiment 4. R1 and R2, together with the carbon atoms to which they are attached, [ka] wherein X3 is N, X4 is C, Y1 is CH, and Cy is [ka] and the compound has formula (III): [ka] is a compound of During the ceremony X1 and X2 are each independently CH or N; or X1 is N and X2 is CR 14 and R 14 is C 1-6 alkyl; Y2 is CH or N; R3 is hydrogen, deuterium, halogen or C 1-6 is haloalkyl; R4 is hydrogen, halogen, -CN, C 1-6 Alkyl, -(C 1-3 alkyl)-OH, -(C 1-3 Deuterated alkyl)-OH, -(C 1-3 alkyl)-O-(C 1-3 alkyl), -O-(C 1-3 alkyl), -CHO, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2 or 3-hydroxyl-oxetan-3-yl, and C 1-6 alkyl is optionally substituted with one or more halo; U and V are each independently selected from N or CH; R5 is hydrogen, C 1-6 Alkyl, -C(O)-(C 1-6 alkyl), -C(O)-(C 3-6 cycloalkyl), -C(O)-phenyl, -C(O)NH-(C 1-6 alkyl), -C(O)NH-(C 3-6 cycloalkyl), -C(O)N(C 1-6 alkyl), phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl, 1-6 Alkyl, C 3-6 The cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl are each optionally substituted with one or more groups selected from the following: 1) halogen; 2) oxo; 3)-CN; 4) C 1-6 alkyl; 5) C 2-6 Alkenyl; 6) C 2-6 Alkynyl; 7) C 1-6 Alkoxy; 8) C 1-6 Haloalkyl; 9)-(C 1-6 alkyl)-OH; 10)-(C 1-6 alkyl)-O-(C 1-6 alkyl); 11)C 3-6 cycloalkyl; 12) Halogen, hydroxyl, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-OH, 4- to 6-membered heterocyclyl, 4- to 6-membered fluoroheterocyclyl, and deuterated 4- to 6-membered heterocyclyl, 1-6 the 3- to 12-membered heterocyclyl, wherein the alkyl is optionally substituted with one or more —OH; 13) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl))-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-65- to 6-membered monocyclic heteroaryl optionally substituted with one or more substituents selected from cycloalkyl and 4- to 6-membered heterocyclyl; 14) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 phenyl optionally substituted with one or more substituents selected from cycloalkyl) and 4- to 6-membered heterocyclyl; 15)-NR a 'R a '' and R a ' and R a '' are each independently hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl, wherein the 4- to 6-membered heterocyclyl is -(C 1-6 and optionally substituted with one or more substituents of (alkyl)-OH, 1-6 -NR with one or more alkyl groups e 'R e Optionally replaced by '' and R e ' and R e '' are each independently hydrogen, C 1-6 Alkyl, -(C 1-6 alkyl)-OH and 4- to 6-membered heterocyclyl a 'R a ''; 16)-C(O)NR b 'R b '' and R b' and R b '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and the 4- to 6-membered heterocyclyl is not selected from halogen, —OH, C 1-6 Alkyl, -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 cycloalkyl) and -(C 1-6 the —C(O)NR optionally substituted with one or more substituents selected from —OH, —C(O)NR b 'R b ''; and 17)-C(O)R c and R c But hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and -(C 1-6 alkyl)-O-(C 1-6 alkyl) c ; R6 is halogen, C 1-6 is alkyl or hydroxyl; m is 0, 1, 2 or 3; R 11 is hydrogen, C 1-6 Alkyl or C 1-6 is a deuterated alkyl; However, when 3- to 12-membered heterocyclyl is substituted, both the 2- and 6-positions are C 1-6 rather than alkyl-substituted piperazin-1-yl; Preferably, U is CH and V is N or CH; more preferably, both U and V are CH; Preferably R 11 is C 1-3 alkyl, preferably methyl or ethyl, more preferably methyl; Preferably, the 5-6 membered monocyclic heteroaryl is a 6 membered monocyclic heteroaryl, more preferably pyridyl, pyrazinyl and pyrimidyl; Preferably, the 5-6 membered monocyclic heteroaryl is a 5 membered monocyclic heteroaryl, more preferably triazolyl; Preferably, the 8-10 membered bicyclic heteroaryl is a 9 membered bicyclic heteroaryl, more preferably 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazinyl; and / or Preferably, the 3- to 12-membered heterocyclyl is a 4- to 8-membered heterocyclyl, more preferably a 4- to 6-membered heterocyclyl; provided that, when substituted, the 3- to 12-membered heterocyclyl is C 1-6 rather than alkyl-substituted piperazin-1-yl; More preferably, the 3- to 12-membered heterocyclyl is oxetanyl, azetidinyl, tetrahydropyranyl, morpholinyl, piperazinyl, or tetrahydropyridyl; provided that the 3- to 12-membered heterocyclyl, when substituted, is preferably C at both the 2- and 6-positions. 1-6 The compound of embodiment 2, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, which is not alkyl-substituted piperazin-1-yl.

[0065] Embodiment 5. The compound of any of embodiments 1-4, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein both X1 and X2 are CH, or one of X1 and X2 is N and the other is CH, preferably both X1 and X2 are CH.

[0066] Embodiment 6. X1 is N and X2 is CR 14 and R 14 C 1-6The compound of any of embodiments 1-4, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein R is 1 or 2; R is 2 or 3; or R is 3 or 4; or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof;

[0067] Embodiment 7. The compound of any of embodiments 1-6, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein Y2 is CH.

[0068] Embodiment 8. The compound of any of embodiments 1-7, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein R3 is hydrogen or halogen.

[0069] Embodiment 9. R4 is C 1-6 Alkyl, -(C 1-3 alkyl)-OH, -(C 1-3 Deuterated alkyl)-OH, -(C 1-3 alkyl)-O-(C 1-3 alkyl) or -CHO, 1-6 alkyl optionally substituted with one or more halo; Preferably, R4 is C 1-6 Alkyl or -(C 1-3 alkyl)-O-(C 1-3 alkyl), and 1-6 The alkyl is substituted with one or more halo; Preferably, R4 is hydroxymethyl, hydroxydeuteromethyl, hydroxyethyl, methoxymethyl or fluoromethyl; More preferably, R4 is hydroxymethyl or hydroxydeuteromethyl; The compound of any of embodiments 1-8, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein more preferably R4 is hydroxymethyl.

[0070] Embodiment 10. R3 is hydrogen and R4 is -(C 1-3 10. The compound of any of embodiments 1-9, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein R is (alkyl)-OH.

[0071] Embodiment 11. R5 is hydrogen, -C(O)-(C 1-6 alkyl), -C(O)-(C 3-6 cycloalkyl), -C(O)-phenyl, -C(O)NH-(C 1-6 alkyl), -C(O)NH-(C 3-6 cycloalkyl) or -C(O)N(C 1-6 11. The compound of any of embodiments 1-10, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein R is 1 or 2;

[0072] Embodiment 12. R5 is a 5- to 6-membered monocyclic heteroaryl or an 8- to 10-membered bicyclic heteroaryl, each of which is optionally substituted with one or more groups selected from the following: C 3-6 cycloalkyl; One or more Cs 1-6 3- to 12-membered heterocyclyl optionally substituted with alkyl, 1-6 the 3- to 12-membered heterocyclyl in which the alkyl is substituted with one or more —OH; and -NR a 'R a '' and R a ' and R a '' are each independently hydrogen and C 1-6 alkyl, wherein C 1-6 Alkyl is -NR e 'R eOptionally substituted with '' and R e ' and R e '' are each independently, C 1-6 Alkyl, -(C 1-6 alkyl)-OH and 4- to 6-membered heterocyclyl a 'R a ''; provided that R1 and R2, together with the carbon atoms to which they are attached, form the following structure: [ka] and Cy [ka] When substituted, the 3- to 12-membered heterocyclyl is C at both the 2- and 6-positions. 1-6 The compound of any of embodiments 1-10, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, which is not alkyl-substituted piperazin-1-yl.

[0073] Embodiment 13. R5, [ka] Selected from; During the ceremony, R 21 is C 1-6 Alkyl, C 1-6 Haloalkyl and -(C 1-6 alkyl)-O-(C 1-6 alkyl); n is 0, 1 or 2; R 22 and R 23 are each independently hydrogen, -CN, or C 1-6 Alkyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl), 4-6 membered heterocyclyl or -C(O)R cSelected from;R c is hydrogen, C 1-6 Alkyl or -(C 1-6 alkyl)-O-(C 1-6 alkyl); R 24 is hydrogen, C 1-6 Alkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) or -C(O)NR b 'R b '' is selected from R b ' and R b '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl; preferably R5 is [ka] and; A1, A2 and A3 are each independently CH or N; R 13 is selected from the following: 1) Hydrogen; 2) C 1-6 alkyl; 3) C 1-6 Alkoxy; 4) halogen; 5) C 3-6 cycloalkyl; 6) Oxo, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-O-(C 1-6 alkyl), 4- to 6-membered heterocyclyl, and deuterated 4- to 6-membered heterocyclyl, 1-6 the 3- to 12-membered heterocyclyl, wherein the alkyl is optionally substituted with one or more —OH; 7) phenyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl; 8)-NR a 'R a 'But', R a ' and R a'' are each independently hydrogen, C 1-6 Alkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl, wherein the 4- to 6-membered heterocyclyl is -(C 1-6 alkyl)-OH, 1-6 -NR with one or more alkyl groups e 'R e Optionally replaced by '' and R e ' and R e '' are each independently hydrogen, C 1-6 Alkyl, -(C 1-6 alkyl)-OH and 4- to 6-membered heterocyclyl a 'R a '; and 9)-C(O)NR b 'R b '' and R b ' and R b '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and the 4- to 6-membered heterocyclyl is one or more C 1-6 the —C(O)NR optionally substituted with alkyl; b 'R b ''; provided that R1 and R2, together with the carbon atoms to which they are attached, form the following structure: [ka] and Cy [ka] When substituted, the 3- to 12-membered heterocyclyl is C at both the 2- and 6-positions. 1-6 The compound of any of embodiments 1-10, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, which is not alkyl-substituted piperazin-1-yl.

[0074] Embodiment 14. R13 is a 3- to 12-membered heterocyclyl, preferably [ka] and; provided that R1 and R2, together with the carbon atoms to which they are attached, form the following structure: [ka] and Cy [ka] When substituted, the 3- to 12-membered heterocyclyl is C at both the 2- and 6-positions. 1-6 The compound of embodiment 13, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, which is not alkyl-substituted piperazin-1-yl.

[0075] Embodiment 15. R 13 But C 1-6 piperazinyl optionally substituted with one or more substituents selected from alkyl and 4- to 5-membered heterocyclyl; provided that R1 and R2, together with the carbon atoms to which they are attached, form the following structure: [ka] and Cy [ka] When the piperazinyl is substituted, both the 2- and 6-positions are C 1-6 The compound of embodiment 13, a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, which is not alkyl-substituted piperazin-1-yl.

[0076] Embodiment 16. R5, [ka] Selected from; During the ceremony, R 24 , R 24 ', R 25 , R 25 ', R 27 and R 27 ' are each independently hydrogen, oxo, and C 1-6 alkyl; R 26 is C 1-6 Alkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) or tetrahydrofuranyl; R 28 is C 1-6 Alkoxy; R 29 is hydrogen or -(C 1-6 alkyl)-OH; R 30 is C 1-6 is alkyl; A1, A2 and A3 are each independently CH or N; The compound of any of embodiments 1-13, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein preferably both A1 and A2 are CH, or one of A1 and A2 is N and the other is CH, more preferably both A1 and A2 are CH.

[0077] Embodiment 17. R5 [ka] A1, A2 and A3 are each independently CH or N, and R 24 and R 24 ' are each independently hydrogen, oxo, and C 1-6 alkyl; Preferably R 24 is C 1-6Alkyl (e.g., C 1-3 alkyl, more preferably methyl); R5 is preferably [ka] A1, A2 and A3 are each independently CH or N, and R 24 ' is C 1-6 Alkyl (e.g., C 1-3 alkyl, more preferably methyl), and more preferably [ka] 17. The compound of any of embodiments 1-16, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein:

[0078] Embodiment 18. R 24 and R 24 ' are each independently hydrogen and C 1-6 18. The compound of embodiment 16 or 17, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein R is selected from alkyl.

[0079] Embodiment 19. The compound of any of embodiments 13-18, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein A1, A2 and A3 are all CH, or A1 is N and A2 and A3 are both CH, or A3 is N and A1 and A2 are both CH.

[0080] Embodiment 20. R5, [ka] Selected from; R 21 C1-6 alkyl; R 22 But hydrogen, C 1-6 A1 and A2 are each selected from alkyl and 4-membered heterocyclyl; A1 and A2 are each CH; R 24 and R 24 ' are each independently hydrogen and C 1-6 14. The compound of any of embodiments 1-13, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein R is selected from alkyl.

[0081] Embodiment 21. [ka] but, [ka] and R 11 C 1-6 Alkyl or C 1-6 is a deuterated alkyl; Preferably R 11 C 1-3 alkyl, preferably methyl or ethyl, more preferably methyl; Preferably R 11 C 1-3 The compound of any of embodiments 4-20, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, which is deuteroalkyl, preferably trideuteromethyl.

[0082] Embodiment 22. Both X1 and X2 are CH, or one of X1 and X2 is N and the other is CH; Y2 is CH; R3 is hydrogen; and R4 is -(C 1-3 alkyl)-OH; U is CH, V is N or CH, and R 11 is C 1-3 alkyl; R5 is [ka] Selected from R 24 and R 24 ' are each independently hydrogen, oxo, and C 1-6 alkyl, where A1 and A2 are both CH, or A1 is N and A2 is CH; R6 is C 1-6 22. The compound of any of embodiments 4-21, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein m is alkyl; and m is 0 or 2.

[0083] Embodiment 23. Both U and V are CH and R 11 The compound of any of embodiments 4-22, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein is methyl.

[0084] Embodiment 24. R6 is C 1-3 The compound of any of embodiments 1-23, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein m is alkyl; and m is 2.

[0085] Embodiment 25. R6 is C 1-3 The compound of any of embodiments 1-24, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein m is alkyl and m is 1.

[0086] Embodiment 26. R6 is C 1-6 The compound of any of embodiments 1-24, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein m is alkyl or hydroxyl and m is 3.

[0087] Embodiment 27. R6 together with the five-membered ring to which they are attached [ka] 27. The compound of any of embodiments 1-26, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, which forms:

[0088] Embodiment 28. the 3- to 12-membered heterocyclyl is selected from oxetanyl, azetidinyl, tetrahydropyranyl, morpholinyl, piperazinyl, tetrahydropyridyl, azaoxaspiro[5.3]nonyl, diazabicyclo[2.2.1]heptyl, diazaspiro[5.2]octyl, diazabicyclo[4.4.0]decyl, azaoxaspiro[5.4]decyl, and diazabicyclo[3.1.1]heptyl; provided that R1 and R2, together with the carbon atoms to which they are attached, form the following structure: [ka] and Cy [ka] When substituted, the 3- to 12-membered heterocyclyl is C at both the 2- and 6-positions. 1-6 rather than alkyl-substituted piperazin-1-yl; Preferably, the 3- to 12-membered heterocyclyl is selected from: [ka] provided that R1 and R2, together with the carbon atoms to which they are attached, form the following structure: [ka] and Cy [ka] When substituted, the 3- to 12-membered heterocyclyl is C at both the 2- and 6-positions. 1-6 The compound of any of embodiments 1-27, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, which is not alkyl-substituted piperazin-1-yl.

[0089] Embodiment 29. Both X1 and X2 are CH; Y2 is CH; R3 is hydrogen; and R4 is -(C 1-3 alkyl)-OH; both U and V are CH; and R 11 is methyl; R5 is [ka] Selected from R 24 C 1-3 alkyl, and A1 and A2 are both CH; and R6 together with the 5-membered ring to which they are attached [ka] or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, which forms

[0090] Embodiment 30. The compound of formula (IB) [ka] or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein

[0091] Embodiment 31. 3. The compound of formula (IV): [ka] is a compound of During the ceremony, X1 and X2 are each independently CH or N; or X1 is N and X2 is CR 14 and R 14 is C 1-6 alkyl; Y2 is CH or N; R3 is hydrogen, deuterium, halogen or C 1-6 is haloalkyl; R4 is hydrogen, halogen, -CN, C 1-6 Alkyl, -(C 1-3 alkyl)-OH, -(C 1-3 Deuterated alkyl)-OH, -(C 1-3 alkyl)-O-(C 1-3 alkyl), -O-(C 1-3 alkyl), -CHO, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2 or 3-hydroxyl-oxetan-3-yl, 1-6 alkyl is optionally substituted with one or more halo; U and V are each independently selected from N or CH; Z is N or CH; R5 is hydrogen, C 1-6 Alkyl, -C(O)-(C 1-6 alkyl), -C(O)-(C 3-6 cycloalkyl), -C(O)-phenyl, -C(O)NH-(C 1-6 alkyl), -C(O)NH-(C 3-6 cycloalkyl), -C(O)N(C 1-6 alkyl), phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl, 1-6 Alkyl, C 3-6 The cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl are each optionally substituted with one or more groups selected from the following: 1) halogen; 2) oxo; 3)-CN; 4) C1-6 alkyl; 5) C 2-6 Alkenyl; 6) C 2-6 Alkynyl; 7) C 1-6 Alkoxy; 8) C 1-6 Haloalkyl; 9)-(C 1-6 alkyl)-OH; 10)-(C 1-6 alkyl)-O-(C 1-6 alkyl); 11)C 3-6 cycloalkyl; 12) Halogen, hydroxyl, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-OH, 4- to 6-membered heterocyclyl, 4- to 6-membered fluoroheterocyclyl, and deuterated 4- to 6-membered heterocyclyl, 1-6 the 3- to 12-membered heterocyclyl, wherein the alkyl is optionally substituted with one or more —OH; 13) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C3-6 5- to 6-membered monocyclic heteroaryl optionally substituted with one or more substituents selected from cycloalkyl and 4- to 6-membered heterocyclyl; 14) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 phenyl optionally substituted with one or more substituents selected from cycloalkyl) and 4- to 6-membered heterocyclyl; 15)-NR a 'R a '' and R a ' and R a '' are each independently hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl, wherein the 4- to 6-membered heterocyclyl is -(C 1-6 and optionally substituted with one or more substituents of (alkyl)-OH, 1-6 -NR with one or more alkyl groups e 'R e Optionally replaced by '' and R e ' and R e '' are each independently hydrogen, C 1-6 Alkyl, -(C 1-6 alkyl)-OH and 4- to 6-membered heterocyclyl a 'R a ''; 16)-C(O)NR b 'R b '' and Rb ' and R b '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and the 4- to 6-membered heterocyclyl is not selected from halogen, —OH, C 1-6 Alkyl, -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 cycloalkyl) and -(C 1-6 the —C(O)NR optionally substituted with one or more substituents selected from —OH, —C(O)NR b 'R b ''; and 17)-C(O)R c and R c But hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and -(C 1-6 alkyl)-O-(C 1-6 alkyl) c ; R6 is halogen, C 1-6 is alkyl or hydroxyl; m is 0, 1, 2, or 3; and R 11 is hydrogen, C 1-6 Alkyl or C 1-6 is a deuterated alkyl; Preferably, both X1 and X2 are CH, or one of X1 and X2 is N and the other is CH. Preferably, both X1 and X2 are CH; Preferably, Y2 is CH; Preferably, R3 is hydrogen or halogen; Preferably, R4 is C 1-6 Alkyl, -(C 1-3 alkyl)-OH, -(C 1-3 Deuterated alkyl)-OH, -(C 1-3 alkyl)-O-(C1-3 alkyl) or -CHO, 1-6 The alkyl is optionally substituted with one or more halogens; more preferably, R4 is -(C 1-3 alkyl)-OH; Preferably, R4 is C 1-6 Alkyl or -(C 1-3 alkyl)-O-(C 1-3 alkyl), and 1-6 The alkyl is substituted with one or more halo; Preferably, R4 is hydroxymethyl, hydroxydeuteromethyl, hydroxyethyl, methoxymethyl, or fluoromethyl; more preferably, R4 is hydroxymethyl; Preferably, R3 is hydrogen and R4 is -(C 1-3 alkyl)-OH; Preferably [ka] teeth, [ka] and R 11 is C 1-6 Alkyl or C 1-6 is a deuterated alkyl; Preferably Z is CH; Preferably, U is CH and V is N or CH; more preferably, both U and V are CH; Preferably, both U and V are CH and R 11 is methyl; Preferably R 11 is C 1-3 alkyl, preferably methyl or ethyl, more preferably methyl; Preferably R 11 is C 1-3 deuteroalkyl, preferably trideuteromethyl; Preferably, R6 is halogen; Preferably, R6 is C 1-3 is alkyl; Preferably, m is 0 or 1; Preferably, the 5-6 membered monocyclic heteroaryl is a 6 membered monocyclic heteroaryl, more preferably pyridyl, pyrazinyl and pyrimidyl; Preferably, the 5-6 membered monocyclic heteroaryl is a 5 membered monocyclic heteroaryl, more preferably triazolyl; Preferably, the 8-10 membered bicyclic heteroaryl is a 9 membered bicyclic heteroaryl, more preferably 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazinyl; and / or The compound of embodiment 30, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein preferably the 3- to 12-membered heterocyclyl is a 4- to 6-membered heterocyclyl, more preferably oxetanyl, azetidinyl, tetrahydropyranyl, morpholinyl, piperazinyl, or tetrahydropyridyl.

[0092] The compound of any of embodiments 30-31, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein Y2 is CH.

[0093] Embodiment 33. R5 is hydrogen, -C(O)-(C 1-6 alkyl), -C(O)-(C 3-6 cycloalkyl), -C(O)-phenyl, -C(O)NH-(C 1-6 alkyl), -C(O)NH-(C 3-6 cycloalkyl) or -C(O)N(C 1-6 The compound of any of embodiments 30-32, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein R is 1 or 2;

[0094] Embodiment 34. R5 is a 5- to 6-membered monocyclic heteroaryl or an 8- to 10-membered bicyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl or the 8- to 10-membered bicyclic heteroaryl is one or more groups selected from the following: C 3-6 cycloalkyl; One or more Cs 1-6 3- to 12-membered heterocyclyl optionally substituted with alkyl, 1-6 the 3- to 12-membered heterocyclyl in which the alkyl is substituted with one or more —OH; and -NR a 'R a '' and R a ' and R a '' are each independently hydrogen and C 1-6 alkyl, wherein C 1-6 Alkyl is -NR e 'R e Optionally substituted with '' and R e ' and R e '' are each independently, C 1-6 Alkyl, -(C 1-6 alkyl)-OH and 4- to 6-membered heterocyclyl a 'R a '' or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, optionally substituted with

[0095] Embodiment 35. R5, [ka] Selected from; During the ceremony, R 21 is C 1-6 Alkyl, C 1-6 Haloalkyl and -(C 1-6 alkyl)-O-(C 1-6 alkyl); n is 0, 1 or 2; R 22 and R 23 are each independently hydrogen, -CN, or C 1-6 Alkyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl), 4-6 membered heterocyclyl or -C(O)R c and R c is hydrogen, C 1-6 Alkyl or -(C 1-6 alkyl)-O-(C 1-6 alkyl); R 24 is hydrogen, C 1-6 Alkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl), or -C(O)NR b 'R b '' is selected from R b ' and R b '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl; A1, A2, and A3 are each independently CH or N; and R 13 is selected from the following: 1) Hydrogen; 2) C 1-6 alkyl; 3) C 1-6 Alkoxy; 4) halogen; 5) C 3-6 cycloalkyl; 6) Oxo, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-O-(C 1-6 alkyl), 4- to 6-membered heterocyclyl, and deuterated 4- to 6-membered heterocyclyl, 1-6 the 4- to 8-membered heterocyclyl, wherein the alkyl is optionally substituted with one or more —OH; 7) phenyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl; 8)-NR a 'R a '' and R a ' and R a ' are each independently hydrogen, C 1-6 Alkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl, wherein the 4- to 6-membered heterocyclyl is selected from one or more -(C 1-6 alkyl)-OH, 1-6 -NR with one or more alkyl groups e 'R e Optionally replaced by '' and R e ' and R e '' are each independently hydrogen, C 1-6 Alkyl, -(C 1-6 alkyl)-OH and 4- to 6-membered heterocyclyl a 'R a ''; and 9)-C(O)NR b 'R b '' and R b ' and R b '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and the 4- to 6-membered heterocyclyl is one or more C 1-6 the —C(O)NR optionally substituted with alkyl; b 'R b ''; Preferably R5 is [ka] A1 and A2 are each independently CH or N, and R 13 is oxo, C 1-6 Alkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl; Preferably, R5 is [ka] A1 and A2 are each independently CH or N; R a ' and R a '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, said 4- to 6-membered heterocyclyl being oxo, C 1-6 Alkyl, C 1-6 optionally substituted with one or more substituents selected from alkoxy and 4- to 6-membered heterocyclyl; Preferably R5 is [ka] and R 22 is hydrogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl), 4-6 membered heterocyclyl or -C(O)R c and R c is hydrogen, C 1-6 Alkyl or -(C 1-6 alkyl)-O-(C 1-6 alkyl); Preferably, R 13 is C 1-6 piperazinyl optionally substituted with one or more substituents selected from alkyl and 4- to 5-membered heterocyclyl; Preferably, R5 is: [ka] is selected from R 24 , R 24 ', R 25 , R 25 ', R 27 and R 27 ' are independently hydrogen, oxo, and C 1-6 alkyl; R 26 is C 1-6Alkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) or tetrahydrofuranyl; R 28 is C 1-6 Alkoxy; R 29 is hydrogen or -(C 1-6 alkyl)-OH; R 30 is C 1-6 is alkyl; and A1, A2 and A3 are each independently CH or N; Preferably, R5 is [ka] A1, A2 and A3 are each independently CH or N, and R 24 and R 24 ' are each independently hydrogen, oxo, and C 1-6 alkyl; Preferably R 24 C 1-6 Alkyl (e.g., C 1-3 alkyl, more preferably methyl), R5 is preferably [ka] A1, A2 and A3 are each independently CH or N, and R 24 ' is C 1-6 Alkyl (e.g., C 1-3 alkyl, more preferably methyl), and more preferably [ka] and; Preferably R 24 and R 24 ' are each independently hydrogen and C 1-6 alkyl; Preferably, A1, A2 and A3 are all CH, or A1 is N and A2 and A3 are both CH, or A3 is N and A1 and A2 are both CH; The compound of any of embodiments 30-34, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein preferably A1, A2 and A3 are all CH.

[0096] Embodiment 36. Both X1 and X2 are CH, or one of X1 and X2 is N and the other is CH; Y2 is CH; R3 is hydrogen; R4 is -(C 1-3 alkyl)-OH; Z is CH; U is CH and V is N or CH; R5 [ka] A1 and A2 are each independently CH or N, and R 13 But, oxo, C 1-6 Alkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl; R 22 is hydrogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl), 4-6 membered heterocyclyl or -C(O)R c and R c But hydrogen, C 1-6 Alkyl or -(C 1-6 alkyl)-O-(C 1-6 alkyl); R6 is hydrogen or halogen; m is 0, 1 or 2; R 11 C 1-3 is alkyl; Preferably, R5 is [ka] Selected from R 24 and R 24 ' are each independently hydrogen, oxo, and C 1-6 alkyl, where both A1 and A2 are CH, or A1 is N and A2 is CH; The compound of any of embodiments 30-35, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein more preferably both A1 and A2 are CH.

[0097] Embodiment 37. 2. A compound of embodiment 1, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, selected from: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]

[0098] Embodiment 38. A pharmaceutical composition comprising a compound of any of embodiments 1-37 and / or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

[0099] Embodiment 39. A method of inhibiting the activity of BTK in vivo or in vitro, comprising contacting BTK with an effective amount of a compound of any of embodiments 1-37 and / or a pharmaceutically acceptable salt thereof.

[0100] Embodiment 40. 37. Use of a compound of any of embodiments 1-37 and / or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease mediated by, or at least in part by, BTK, preferably for treating or preventing cancer, an inflammatory disease, or an autoimmune disease, wherein said cancer is preferably a solid tumor or a hematological malignancy, including lymphoma, leukemia, and myeloma; more preferably said cancer is a B-cell malignancy, diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, Burkitt's lymphoma, non-Burkitt's high-grade B-cell malignant lymphoma, extranodal marginal zone B-cell lymphoma, small lymphocytic lymphoma (SLL), lymphoblastic lymphoma, lymphocytic leukemia, myeloid leukemia, and the inflammatory disease or autoimmune disease is preferably selected from human acute myeloid leukemia (AML), chronic myeloid leukemia (CML), human acute monocytic leukemia, acute lymphoblastic leukemia (ALL), B-cell acute lymphoblastic leukemia (B-ALL), hairy cell leukemia, chronic lymphocytic leukemia (CLL) (such as high-risk CLL), myelodysplastic syndrome, acute lymphoblastic leukemia, myeloma (such as multiple myeloma), or graft-versus-host disease; and the inflammatory disease or autoimmune disease is preferably selected from systemic inflammation and local inflammation. the use of the above-mentioned conditions selected from the group consisting of inflammatory bowel disease, arthritis, rheumatoid arthritis, inflammation associated with immunosuppression, organ transplant reflex, allergic diseases, ulcerative colitis, Crohn's disease, dermatitis, asthma, lupus erythematosus, Sjogren's syndrome, multiple sclerosis, scleroderma (also known as systemic sclerosis), multiple sclerosis osteoporosis, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, antineutrophil cytoplasmic antibody vasculitis, chronic obstructive pulmonary disease, psoriasis, psoriatic syndrome, pemphigus vulgaris, and diseases associated with kidney transplantation.

[0101] Embodiment 41. A method of treating or preventing a disease in a subject, comprising administering to said subject in need thereof an effective amount of a compound of any of Embodiments 1-37 and / or a pharmaceutically acceptable salt thereof, wherein said disease is a disease mediated by BTK, or at least in part by BTK; said disease is preferably cancer, an inflammatory disease, or an autoimmune disease; said disease is preferably a solid tumor or a hematological malignancy, including lymphoma, leukemia, and myeloma; said cancer is more preferably a B-cell malignancy, diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, Burkitt's lymphoma, non-Burkitt's high-grade B-cell malignancy, extranodal marginal zone B-cell lymphoma, small lymphocytic lymphoma (SLL), lymphoblastic leukemia, lymphoblastic leukemia, lymphoma and the inflammatory disease or autoimmune disease is selected from human lymphoma, lymphocytic leukemia, myeloid leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), human acute monocytic leukemia, acute lymphocytic leukemia (ALL), B-cell acute lymphocytic leukemia (B-ALL), hairy cell leukemia, chronic lymphocytic leukemia (CLL) (such as high-risk CLL), myelodysplastic syndrome, acute lymphoblastic leukemia, myeloma (such as multiple myeloma), or graft-versus-host disease; and the inflammatory disease or autoimmune disease is preferably selected from human lymphoma, lymphocytic leukemia, myelogenous leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), human acute monocytic leukemia, acute lymphocytic leukemia (ALL), B-cell acute lymphocytic leukemia (B-ALL), hairy cell leukemia, chronic lymphocytic leukemia (CLL) (such as high-risk CLL), myelodysplastic syndrome, acute lymphoblastic leukemia, myeloma (such as multiple myeloma), or graft-versus-host disease; or systemic inflammation and local inflammation, arthritis, rheumatoid arthritis, inflammation associated with immunosuppression, organ transplant reflex, allergic diseases, ulcerative colitis, Crohn's disease, dermatitis, asthma, lupus erythematosus, Sjogren's syndrome, multiple sclerosis, scleroderma, multiple sclerosis osteoporosis, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, antineutrophil cytoplasmic antibody vasculitis, chronic obstructive pulmonary disease, psoriasis, psoriatic syndromes, pemphigus vulgaris, and diseases associated with kidney transplantation.

[0102] Embodiment 42. The compound of any of embodiments 1-37 and / or a pharmaceutically acceptable salt thereof for use as a medicament.

[0103] Embodiment 43. The compound of any of embodiments 1-37 and / or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of a disease mediated by or at least in part by BTK, preferably for use in the treatment or prevention of cancer, an inflammatory disease, or an autoimmune disease, wherein said cancer is preferably a solid tumor or a hematological malignancy, including lymphoma, leukemia, and myeloma; more preferably said cancer is a B-cell malignancy, diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, Burkitt's lymphoma, non-Burkitt's high-grade B-cell malignant lymphoma, extranodal marginal zone B-cell lymphoma, small lymphocytic lymphoma (SLL), lymphoblastic lymphoma, lymphocytic leukemia, myeloid leukemia, acute myeloid leukemia, and the inflammatory disease or autoimmune disease is preferably selected from systemic inflammation and local inflammation, arthritis, lymphoid tumors, and the like. The compound and / or a pharmaceutically acceptable salt thereof is selected from the group consisting of horse arthritis, inflammation associated with immunosuppression, organ transplant reflex, allergic disease, ulcerative colitis, Crohn's disease, dermatitis, asthma, lupus erythematosus, Sjogren's syndrome, multiple sclerosis, scleroderma, multiple sclerosis osteoporosis, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, antineutrophil cytoplasmic antibody vasculitis, chronic obstructive pulmonary disease, psoriasis, psoriatic syndrome, pemphigus vulgaris, and diseases associated with kidney transplantation.

[0104] Embodiment 44. A pharmaceutical combination comprising the compound of any of embodiments 1-37 and / or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent, wherein said therapeutic agent is preferably selected from an anti-inflammatory agent, an immunomodulatory agent or an anti-tumor active agent, wherein said anti-tumor active agent comprises a chemotherapeutic agent, an immune checkpoint inhibitor or agonist, and a targeted therapeutic agent.

[0105] Embodiment 45. Compounds of formula (VI): [ka] or solvates, racemic mixtures, enantiomers, diastereomers and tautomers thereof, X1, X2, X3, X4, R1, R2 and R3 are as defined in any of embodiments 1 to 34; R 31 ' is -CHO, -C 1-3 Alkyl-OH, -C 1-3 Alkyl-OAc, C 1-3 Alkyl, -C(O)-C 1-3 Alkyl or C 1-3 haloalkyl, and R 32 is halogen, -B(OH)2, -B(OC 1-6 alkyl)2, [ka] and R d is hydrogen or C 1-6 The compound is alkyl.

[0106] Embodiment 46. [ka] wherein Z is N or CR7; R7 and R8 are each independently hydrogen or halogen; and R9 is halogen or C 1-6 The compound of embodiment 45, wherein n is alkyl; and n is 1 or 2.

[0107] Embodiment 47. The compound of embodiment 45, selected from: [ka] [ka]

[0108] Detailed Description of the Embodiments (II): Embodiment 1. Compounds of formula (I): [ka] or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, During the ceremony, X1 and X2 are each independently CH or N; X3 and X4 are each independently C or N; Y1 and Y2 are each independently CR 10 or N; R1 and R2 are each independently hydrogen, deuterium, halogen, or C 1-6 Alkyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-6 cycloalkyl and phenyl; or R1 and R2, together with the carbon atom to which they are attached, are selected from the following structure: [ka] and R6 independently represents deuterium, halogen, hydroxyl, C 1-6 Alkyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl and C 1-6haloalkyl; or two R6 together with the carbon atoms to which they are attached form a 3- to 6-membered cycloalkyl; m is 0, 1, 2, 3, or 4; p is 1, 2, 3, or 4; Z is N or CR7; R7 is hydrogen, deuterium, C 1-6 Alkyl, halogen and C 1-6 haloalkyl; R3 is hydrogen, deuterium, halogen or C 1-6 is haloalkyl; R4 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkynyl, -(C 1-3 alkyl)-OH, -(C 1-3 alkyl)-O-(C 1-3 alkyl), -O-(C 1-3 alkyl), -CHO, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2 or 3-hydroxyl-oxetan-3-yl, 1-6 Alkyl or C 1-3 each alkyl optionally substituted with one or more deuterium or halo; Cy [ka] and R 11 is hydrogen, C 1-6 Alkyl and C 3-6 cycloalkyl, wherein C 1-6 alkyl is optionally substituted with one or more deuterium or halo; U, V and W are each independently N or CR 12 and;R 12 is hydrogen, deuterium or a halogen; R5 is hydrogen, C 1-6 Alkyl, -C(O)-(C 1-6 alkyl), -C(O)-(C 3-6 cycloalkyl), -C(O)NH-(C 1-6 alkyl), -C(O)NH-(C 3-6 cycloalkyl), -C(O)N(C 1-6alkyl), phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl, 1-6 Alkyl, C 3-6 The cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl are each optionally substituted with one or more groups selected from the following: 1) halogen; 2) oxo; 3)-CN; 4) C 1-6 alkyl; 5) C 2-6 Alkenyl; 6) C 2-6 Alkynyl; 7) C 1-6 Alkoxy; 8) C 1-6 Haloalkyl; 9)-(C 1-6 alkyl)-OH; 10)-(C 1-6 alkyl)-O-(C 1-6 alkyl); 11) Deuterium, halogen, hydroxyl, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-OH and 4- to 8-membered heterocyclyl optionally substituted with one or more groups selected from 4- to 6-membered heterocyclyl, 1-6 Alkyl, C 3-6 Cycloalkyl or 4- to 6-membered heterocyclyl is deuterium, halogen, -NH2, -NH(C 1-6 alkyl), -N(C 1-6 alkyl)2 and -NH(C 3-6 the 4- to 8-membered heterocyclyl optionally substituted with one or more groups selected from cycloalkyl; 12) Halogen, -CN, -(C1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 5- to 6-membered monocyclic heteroaryl optionally substituted with one or more groups selected from cycloalkyl and 4- to 6-membered heterocyclyl; 13) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N-(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 phenyl optionally substituted with one or more groups selected from cycloalkyl) and 4- to 6-membered heterocyclyl; 14)-NR a 'R a '' and R a ' and R a '' are each independently hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl, wherein the 4- to 6-membered heterocyclyl is -(C 1-6the —NR 2 optionally substituted with one or more substituents of —OH; a 'R a ''; 15)-C(O)NR b 'R b '' and R b ' and R b '' along with the N atom to which they are attached, deuterium, halogens, -OH, C 1-6 Alkyl, -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 cycloalkyl), -NH2, -NH(C 1-6 alkyl), -N(C 1-6 alkyl)2, -NH(C 3-6 cycloalkyl) and -(C 1-6 the —C(O)NR 2 —O—H ... b 'R b ''; and 16)-C(O)R c and R c is hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(C 1-6 alkyl)-OH and -(C 1-6 alkyl)-O-(C 1-6 alkyl) c ; R 10 are hydrogen, deuterium, halogens, CN, C 1-6 Alkyl or C 1-6 It is haloalkyl.

[0109] Embodiment 2. The compound has formula (IA): [ka] or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein

[0110] Embodiment 3. The compound has formula (II): [ka] is a compound of During the ceremony, X1 and X2 are each independently CH or N; Y2 is CH or N; R3 is hydrogen, deuterium, halogen or C 1-6 is haloalkyl; R4 is hydrogen, halogen, -CN, C 1-6 Alkyl, -(C 1-3 alkyl)-OH, -(C 1-3 Deuterated alkyl)-OH, -(C 1-3 alkyl)-O-(C 1-3 alkyl), -O-(C 1-3 alkyl), -CHO, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2 or 3-hydroxyl-oxetan-3-yl; W is N or CR 12 and R 12 is hydrogen or halogen; R5 is C 1-6 alkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl, each optionally substituted with one or more groups selected from: 1) halogen; 2) oxo; 3)-CN; 4) C 1-6 alkyl; 5) C 2-6 Alkenyl; 6) C 2-6 Alkynyl; 7) C 1-6 Alkoxy; 8) C1-6 Haloalkyl; 9)-(C 1-6 alkyl)-OH; 10)-(C 1-6 alkyl)-O-(C 1-6 alkyl); 11) Halogen, hydroxyl, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-OH, 4- to 6-membered heterocyclyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl and 4- to 6-membered fluoroheterocyclyl; 12) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl))-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 5- to 6-membered monocyclic heteroaryl optionally substituted with one or more substituents selected from cycloalkyl and 4- to 6-membered heterocyclyl; 13) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O(C 1-6 alkyl), -(C1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 phenyl optionally substituted with one or more substituents selected from cycloalkyl) and 4- to 6-membered heterocyclyl; 14)-NR a 'R a '' and R a ' and R a '' are each independently hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl, wherein the 4- to 6-membered heterocyclyl is -(C 1-6 the —NR 2 optionally substituted with one or more substituents of —OH; a 'R a '; 15)-C(O)NR b 'R b '' and R b ' and R b '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and the 4- to 6-membered heterocyclyl is not selected from halogen, —OH, C 1-6 Alkyl, -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 cycloalkyl) and -(C 1-6 the —C(O)NR optionally substituted with one or more substituents selected from —OH, —C(O)NR b 'R b ''; and 16)-C(O)R c and R c But hydrogen, C 1-6Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and -(C 1-6 alkyl)-O-(C 1-6 alkyl) c ; R6 is halogen or C 1-6 is alkyl; and m is 0, 1 or 2; Preferably W is N or CR 12 and R 12 is a halogen; Preferably, R5 is a 5-6 membered monocyclic heteroaryl or an 8-10 membered bicyclic heteroaryl optionally substituted with one or more groups selected from: 1) C 1-6 alkyl; and 2) C 1-6 4- to 6-membered heterocycloalkyl optionally substituted with alkyl and 4- to 6-membered heterocyclyl; Preferably, the 5-6 membered monocyclic heteroaryl is a 5 membered monocyclic heteroaryl, more preferably triazolyl; The compound of embodiment 2, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein the 8-10 membered bicyclic heteroaryl is preferably an 8 membered bicyclic heteroaryl, more preferably 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazinyl.

[0111] Embodiment 4. The compound has formula (III): [ka] is a compound of During the ceremony X1 and X2 are each independently CH or N; Y2 is CH or N; R3 is hydrogen, deuterium, halogen or C 1-6 is haloalkyl; R4 is hydrogen, halogen, -CN, C1-6 Alkyl, -(C 1-3 alkyl)-OH, -(C 1-3 Deuterated alkyl)-OH, -(C 1-3 alkyl)-O-(C 1-3 alkyl), -O-(C 1-3 alkyl), -CHO, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2 or 3-hydroxyl-oxetan-3-yl; U and V are each independently selected from N or CH; R5 is C 1-6 alkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl, each optionally substituted with one or more groups selected from: 1) halogen; 2) oxo; 3)-CN; 4) C 1-6 alkyl; 5) C 2-6 Alkenyl; 6) C 2-6 Alkynyl; 7) C 1-6 Alkoxy; 8) C 1-6 Haloalkyl; 9)-(C 1-6 alkyl)-OH; 10)-(C 1-6 alkyl)-O-(C 1-6 alkyl); 11) Halogen, hydroxyl, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-OH, 4- to 6-membered heterocyclyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl and 4- to 6-membered fluoroheterocyclyl; 12) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl))-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 5- to 6-membered monocyclic heteroaryl optionally substituted with one or more substituents selected from cycloalkyl and 4- to 6-membered heterocyclyl; 13) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 phenyl optionally substituted with one or more substituents selected from cycloalkyl) and 4- to 6-membered heterocyclyl; 14)-NR a 'R a '' and R a ' and R a '' are each independently hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl, wherein the 4- to 6-membered heterocyclyl is -(C1-6 the —NR 2 optionally substituted with one or more substituents of —OH; a 'R a ''; 15)-C(O)NR b 'R b '' and R b ' and R b '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and the 4- to 6-membered heterocyclyl is not selected from halogen, —OH, C 1-6 Alkyl, -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 cycloalkyl) and -(C 1-6 the —C(O)NR optionally substituted with one or more substituents selected from —OH, —C(O)NR b 'R b ''; and 16)-C(O)R c and R c But hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and -(C 1-6 alkyl)-O-(C 1-6 alkyl) c ; R6 is halogen or C 1-6 is alkyl; m is 0, 1 or 2; R 11 is hydrogen, C 1-6 Alkyl or C 1-6 is a deuterated alkyl; Preferably, U is CH and V is N or CH; more preferably, both U and V are CH; Preferably R 11 is C 1-3 alkyl, preferably methyl or ethyl, more preferably methyl; Preferably, the 5-6 membered monocyclic heteroaryl is a 6 membered monocyclic heteroaryl, more preferably pyridyl, pyrazinyl and pyrimidyl; Preferably, the 5-6 membered monocyclic heteroaryl is a 5 membered monocyclic heteroaryl, more preferably triazolyl; Preferably, the 8-10 membered bicyclic heteroaryl is a 9 membered bicyclic heteroaryl, more preferably 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazinyl; and The compound of embodiment 2, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein preferably the 4-8 membered heterocyclyl is a 4-6 membered heterocyclyl, more preferably oxetanyl, azetidinyl, tetrahydropyranyl, morpholinyl, piperazinyl, or tetrahydropyridyl.

[0112] Embodiment 5. The compound of any of embodiments 1-4, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein both X1 and X2 are CH, or one of X1 and X2 is N and the other is CH, preferably both X1 and X2 are CH.

[0113] Embodiment 6. The compound of any of embodiments 1-5, wherein Y2 is CH; or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof.

[0114] Embodiment 7. The compound of any of embodiments 1-6, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein R3 is hydrogen or halogen.

[0115] Embodiment 8. R4 is C1-6 Alkyl, -(C 1-3 alkyl)-OH, -(C 1-3 deuterated alkyl)-OH or -CHO; Preferably, the compound of any of embodiments 1-7, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein R4 is hydroxymethyl or hydroxydeuteromethyl.

[0116] Embodiment 9. R3 is hydrogen and R4 is -(C 1-3 The compound of any of embodiments 1-8, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein R is (alkyl)-OH.

[0117] Embodiment 10. R5, [ka] is selected from During the ceremony, R 21 is C 1-6 Alkyl, C 1-6 Haloalkyl and -(C 1-6 alkyl)-O-(C 1-6 alkyl); n is 0, 1 or 2; R 22 and R 23 are each independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl), 4-6 membered heterocyclyl or -C(O)R c and R c is hydrogen, C 1-6 Alkyl or -(C 1-6 alkyl)-O-(C 1-6 alkyl); A1 and A2 are each independently CH or N; R 13 is selected from the following: 1) Hydrogen; 2) C 1-6 alkyl; 3) Oxo, C 1-6 Alkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl; 4) phenyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl; 5)-NR a 'R a '' and R a ' and R a '' are each independently hydrogen, C 1-6 Alkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl, wherein the 4- to 6-membered heterocyclyl is -(C 1-6 the —NR optionally substituted with —(alkyl)-OH; a 'R a ''; and 6)-C(O)NR b 'R b '' and R b ' and R b '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and the 4- to 6-membered heterocyclyl is one or more C 1-6 the —C(O)NR optionally substituted with alkyl; b 'R b ''; Preferably, R5 is [ka] 10. The compound of any of embodiments 1-9, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein:

[0118] Embodiment 11. R 13 But C 1-6 The compound of embodiment 10, which is piperazinyl optionally substituted with one or more substituents selected from alkyl and 4- to 5-membered heterocyclyl, a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

[0119] Embodiment 12. R5, [ka] Selected from; During the ceremony, R 24 , R 24 ', R 25 , R 25 ', R 27 and R 27 ' are each independently hydrogen, oxo, and C 1-6 alkyl; R 26 is C 1-6 Alkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) or tetrahydrofuranyl; R 28 is C 1-6 Alkoxy; R 29 is hydrogen or -(C 1-6 alkyl)-OH; R 30 is C 1-6 is alkyl; A1 and A2 are each independently CH or N; Preferably, both A1 and A2 are CH, or one of A1 and A2 is N and the other is CH; The compound of any of embodiments 1-10, a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein more preferably both A1 and A2 are CH.

[0120] Embodiment 13. R5, [ka] Selected from R 24 and R 24 ' are each independently hydrogen, oxo, and C 1-6 alkyl; Preferably, R 24 C 1-6 Alkyl (C 1-3 alkyl, more preferably methyl), [ka] is preferably [ka] and R 24 ' is C 1-6 Alkyl (C 1-3 alkyl, more preferably methyl), and more preferably [ka] 13. The compound of any of embodiments 1-12, a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein:

[0121] Embodiment 14. R 24 and R 24 ' are each independently hydrogen and C 1-6 14. The compound of embodiment 12 or 13, a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein the compound is selected from alkyl.

[0122] Embodiment 15. The compound of any of embodiments 10-14, wherein both A1 and A2 are CH, or A1 is N and A2 is CH, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

[0123] Embodiment 16. R5, [ka] is selected from During the ceremony, R 21 is C 1-6 alkyl; R 22 is hydrogen, C 1-6 A1 and A2 are each selected from alkyl and 4-membered heterocyclyl; A1 and A2 are each CH; and R 24 and R 24 ' are each independently hydrogen and C 1-6 The compound of any of embodiments 1-10, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein R is selected from alkyl.

[0124] Embodiment 17 . [ka] but, [ka] and R 11 C 1-6 Alkyl or C 1-6 is a deuterated alkyl; Preferably R 11 C 1-3 alkyl, preferably methyl or ethyl, more preferably methyl; Preferably R 11 C 1-3The compound of any of embodiments 4-16, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein the alkyl is deuteroalkyl, preferably trideuteromethyl.

[0125] Embodiment 18. Both X1 and X2 are CH, or one of X1 and X2 is N and the other is CH; Y2 is CH; R3 is hydrogen; and R4 is -(C 1-3 alkyl)-OH; U is CH, V is N or CH, and R 11 C 1-3 alkyl; R5 is [ka] Selected from R 24 and R 24 ' are each independently hydrogen, oxo, and C 1-6 alkyl, where A1 and A2 are both CH, or A1 is N and A2 is CH; R6 is C 1-6 The compound of any of embodiments 4-17, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein m is alkyl; and m is 0 or 2.

[0126] Embodiment 19. Both U and V are CH and R 11 The compound of any of embodiments 4-18, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein is methyl.

[0127] Embodiment 20. R6 is C 1-3 20. The compound of any of embodiments 1-19, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein m is alkyl; and m is 2.

[0128] Embodiment 21. R6 together with the five-membered ring to which they are attached [ka] 21. The compound of any of embodiments 1-20, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, which forms:

[0129] Embodiment 22. The compound has formula (IB) [ka] or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein

[0130] Embodiment 23. The compound has formula (IV): [ka] is a compound of During the ceremony, X1 and X2 are each independently CH or N; Y2 is CH or N; R3 is hydrogen, deuterium, halogen or C 1-6 is haloalkyl; R4 is hydrogen, halogen, -CN, C 1-6 Alkyl, -(C 1-3 alkyl)-OH, -(C 1-3 Deuterated alkyl)-OH, -(C 1-3 alkyl)-O-(C 1-3 alkyl), -O-(C 1-3 alkyl), -CHO, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2 or 3-hydroxyl-oxetan-3-yl; U and V are each independently selected from N or CH; Z is N or CH; R5 is C 1-6 alkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl, each optionally substituted with one or more groups selected from: 1) halogen; 2) oxo; 3)-CN; 4) C 1-6 alkyl; 5) C 2-6 Alkenyl; 6) C 2-6 Alkynyl; 7) C 1-6 Alkoxy; 8) C 1-6 Haloalkyl; 9)-(C 1-6 alkyl)-OH; 10)-(C 1-6 alkyl)-O-(C 1-6 alkyl); 11) Halogen, hydroxyl, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6 alkyl)-OH, 4- to 6-membered heterocyclyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl and 4- to 6-membered fluoroheterocyclyl; 12) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -(C 1-6alkyl)-NH2, -(C 1-6 alkyl))-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 5- to 6-membered monocyclic heteroaryl optionally substituted with one or more substituents selected from cycloalkyl and 4- to 6-membered heterocyclyl; 13) Halogen, -CN, -(C 1-6 alkyl)-CN, -(C 1-6 alkyl)-OH, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O(C 1-6 alkyl), -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 phenyl optionally substituted with one or more substituents selected from cycloalkyl) and 4- to 6-membered heterocyclyl; 14)-NR a 'R a '' and R a ' and R a '' are each independently hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4-6 membered heterocyclyl, wherein the 4-6 membered heterocyclyl is -(C 1-6 the —NR 2 optionally substituted with one or more substituents of —OH; a 'R a ''; 15)-C(O)NR b 'R b '' and R b ' and R b'' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and the 4- to 6-membered heterocyclyl is not selected from halogen, —OH, C 1-6 Alkyl, -(C 1-6 alkyl)-NH2, -(C 1-6 alkyl)-NH(C 1-6 alkyl), -(C 1-6 alkyl)-N(C 1-6 alkyl)2, -(C 1-6 alkyl)-NH(C 3-6 cycloalkyl) and -(C 1-6 the —C(O)NR optionally substituted with one or more substituents selected from —OH, —C(O)NR b 'R b ''; and 16)-C(O)R c and R c But hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and -(C 1-6 alkyl)-O-(C 1-6 alkyl) c ; R6 is halogen or C 1-6 is alkyl; m is 0, 1, or 2; and R 11 is hydrogen, C 1-6 Alkyl or C 1-6 is a deuterated alkyl; Preferably, both X1 and X2 are CH, or one of X1 and X2 is N and the other is CH; Preferably, both X1 and X2 are CH; Preferably, Y2 is CH; Preferably, R3 is hydrogen or halogen; Preferably, R4 is C 1-6 Alkyl, -(C 1-3 alkyl)-OH, -(C 1-3 deuterated alkyl)-OH or -CHO; more preferably R4 is -(C 1-3 alkyl)-OH; Preferably, R4 is hydroxymethyl or hydroxydeuteromethyl; Preferably, R3 is hydrogen and R4 is -(C 1-3 alkyl)-OH; Preferably [ka] teeth [ka] and R 11 is C 1-6 Alkyl or C 1-6 is a deuterated alkyl; Preferably Z is CH; Preferably, U is CH and V is N or CH; more preferably, both U and V are CH; Preferably, both U and V are CH and R 11 is methyl; Preferably R 11 is C 1-3 alkyl, preferably methyl or ethyl, more preferably methyl; Preferably R 11 is C 1-3 deuteroalkyl, preferably trideuteromethyl; Preferably, R6 is halogen; Preferably, m is 0 or 1; Preferably, the 5-6 membered monocyclic heteroaryl is a 6 membered monocyclic heteroaryl, more preferably pyridyl, pyrazinyl and pyrimidyl; Preferably, the 5-6 membered monocyclic heteroaryl is a 5 membered monocyclic heteroaryl, more preferably triazolyl; Preferably, the 8-10 membered bicyclic heteroaryl is a 9 membered bicyclic heteroaryl, more preferably 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazinyl; 23. The compound of embodiment 22, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein preferably the 4-8 membered heterocyclyl is a 4-6 membered heterocyclyl, more preferably oxetanyl, azetidinyl, tetrahydropyranyl, morpholinyl, piperazinyl, or tetrahydropyridyl.

[0131] Embodiment 24. The compound of any of embodiments 22-23, or a pharmaceutically acceptable salt, or solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, wherein Y2 is CH.

[0132] Embodiment 25. R5, [ka] Selected from; During the ceremony, R 21 is C 1-6 Alkyl, C 1-6 Haloalkyl and -(C 1-6 alkyl)-O-(C 1-6 alkyl); n is 0, 1 or 2; R 22 and R 23 are each independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl), 4-6 membered heterocyclyl or -C(O)R c and R c is hydrogen, C 1-6 Alkyl or -(C 1-6 alkyl)-O-(C 1-6 alkyl); A1 and A2 are each independently CH or N; and R 13 is selected from: 1) Hydrogen; 2) C 1-6 alkyl; 3) Oxo, C 1-6 Alkyl, C 1-6 Alkoxy, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl; 4) phenyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl; 5)-NR a 'R a '' and R a ' and R a '' are each independently hydrogen, C 1-6 Alkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) and 4- to 6-membered heterocyclyl, wherein the 4- to 6-membered heterocyclyl is selected from one or more -(C 1-6 the —NR optionally substituted with —(alkyl)-OH; a 'R a ''; and 6)-C(O)NR b 'R b '' and R b ' and R b '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and the 4- to 6-membered heterocyclyl is one or more C 1-6 the —C(O)NR optionally substituted with alkyl; b 'R b ''; Preferably R5 is [ka] A1 and A2 are each independently CH or N; R a ' and R a '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, said 4- to 6-membered heterocyclyl being oxo, C 1-6 Alkyl, C 1-6optionally substituted with one or more substituents selected from alkoxy and 4- to 6-membered heterocyclyl; Preferably R 13 is C 1-6 piperazinyl optionally substituted with one or more substituents selected from alkyl and 4- to 5-membered heterocyclyl; Preferably, R5 is selected from: [ka] Selected from; In the formula, R 24 , R 24 ', R 25 , R 25 ', R 27 and R 27 ' are each independently hydrogen, oxo, and C 1-6 alkyl; R 26 is C 1-6 Alkyl, -(C 1-6 alkyl)-O-(C 1-6 alkyl) or tetrahydrofuranyl; R 28 is C 1-6 Alkoxy; R 29 is hydrogen or -(C 1-6 alkyl)-OH; R 30 is C 1-6 is alkyl; and A1 and A2 are each independently CH or N; Preferably, R5 is [ka] Selected from R 24 and R 24 ' are each independently hydrogen, oxo, and C 1-6 alkyl; More preferably, R 24 C 1-6 Alkyl (C 1-3 alkyl, more preferably methyl), [ka] teeth [ka] and R 24 ' is C 1-6 Alkyl (C 1-3 alkyl, more preferably methyl), and more preferably [ka] and; Preferably R 24 and R 24 ' are each independently hydrogen and C 1-6 alkyl; Preferably, one of A1 and A2 is N and the other is CH; Preferably, A1 is N and A2 is CH; The compound of any of embodiments 22-24, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein preferably both A1 and A2 are CH.

[0133] Embodiment 26. Both X1 and X2 are CH, or one of X1 and X2 is N and the other is CH; Y2 is CH; R3 is hydrogen; R4 is -(C 1-3 alkyl)-OH; Z is CH; U is CH and V is N or CH; R5 is [ka] Selected from R 24 and R 24 ' are each independently hydrogen, oxo, and C 1-6alkyl, where both A1 and A2 are CH, or A1 is N and A2 is CH; R6 is hydrogen or halogen; m is 0, 1 or 2; R 11 is C 1-3 is alkyl; The compound of any of embodiments 22-25, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein preferably both A1 and A2 are CH.

[0134] Embodiment 27. 2. A compound of embodiment 1, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer thereof, selected from: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]

[0135] Embodiment 28. A pharmaceutical composition comprising a compound of any of embodiments 1-27 and / or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

[0136] Embodiment 29. 28. A method of inhibiting the activity of BTK in vivo or in vitro, comprising contacting BTK with an effective amount of a compound of any of embodiments 1-27 and / or a pharmaceutically acceptable salt thereof.

[0137] Embodiment 30. 27. Use of a compound of any of embodiments 1-27 and / or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease mediated by, or at least in part by, BTK, preferably for treating or preventing cancer, an inflammatory disease, or an autoimmune disease, wherein the cancer is preferably a solid tumor or a hematological malignancy, including lymphoma, leukemia, and myeloma; more preferably, the cancer is a B-cell malignancy, diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, Burkitt's lymphoma, non-Burkitt's high-grade B-cell malignant lymphoma, extranodal marginal zone B-cell lymphoma, small lymphocytic lymphoma (SLL), lymphoblastic lymphoma, lymphocytic leukemia, myeloid leukemia, and the inflammatory disease or autoimmune disease is preferably selected from human acute myeloid leukemia (AML), chronic myeloid leukemia (CML), human acute monocytic leukemia, acute lymphoblastic leukemia (ALL), B-cell acute lymphoblastic leukemia (B-ALL), hairy cell leukemia, chronic lymphocytic leukemia (CLL) (such as high-risk CLL), myelodysplastic syndrome, acute lymphoblastic leukemia, myeloma (such as multiple myeloma), or graft-versus-host disease; and the inflammatory disease or autoimmune disease is preferably selected from systemic inflammation and local inflammation. the use of the above-mentioned conditions selected from the group consisting of inflammatory bowel disease, arthritis, rheumatoid arthritis, inflammation associated with immunosuppression, organ transplant reflex, allergic diseases, ulcerative colitis, Crohn's disease, dermatitis, asthma, lupus erythematosus, Sjogren's syndrome, multiple sclerosis, scleroderma (also known as systemic sclerosis), multiple sclerosis osteoporosis, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, antineutrophil cytoplasmic antibody vasculitis, chronic obstructive pulmonary disease, psoriasis, psoriatic syndrome, pemphigus vulgaris, and diseases associated with kidney transplantation.

[0138] Embodiment 31. A method of treating or preventing a disease in a subject, comprising administering to said subject in need thereof an effective amount of a compound of any of Embodiments 1-27 and / or a pharmaceutically acceptable salt thereof, wherein said disease is a disease mediated by BTK, or at least in part by BTK; said disease is preferably cancer, an inflammatory disease, or an autoimmune disease; said disease is preferably a solid tumor or a hematological malignancy, including lymphoma, leukemia, and myeloma; said cancer is more preferably a B-cell malignancy, diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, Burkitt's lymphoma, non-Burkitt's high-grade B-cell malignant lymphoma, extranodal marginal zone B-cell lymphoma, small lymphocytic lymphoma (SLL), lymphoblastic leukemia, lymphoblastic leukemia, lymphoma and the inflammatory disease or autoimmune disease is selected from human lymphoma, lymphocytic leukemia, myeloid leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), human acute monocytic leukemia, acute lymphocytic leukemia (ALL), B-cell acute lymphocytic leukemia (B-ALL), hairy cell leukemia, chronic lymphocytic leukemia (CLL) (such as high-risk CLL), myelodysplastic syndrome, acute lymphoblastic leukemia, myeloma (such as multiple myeloma), or graft-versus-host disease; and the inflammatory disease or autoimmune disease is preferably selected from human lymphoma, lymphocytic leukemia, myelogenous leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), human acute monocytic leukemia, acute lymphocytic leukemia (ALL), B-cell acute lymphocytic leukemia (B-ALL), hairy cell leukemia, chronic lymphocytic leukemia (CLL) (such as high-risk CLL), myelodysplastic syndrome, acute lymphoblastic leukemia, myeloma (such as multiple myeloma), or graft-versus-host disease; or systemic inflammation and local inflammation, arthritis, rheumatoid arthritis, inflammation associated with immunosuppression, organ transplant reflex, allergic diseases, ulcerative colitis, Crohn's disease, dermatitis, asthma, lupus erythematosus, Sjogren's syndrome, multiple sclerosis, scleroderma, multiple sclerosis osteoporosis, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, antineutrophil cytoplasmic antibody vasculitis, chronic obstructive pulmonary disease, psoriasis, psoriatic syndromes, pemphigus vulgaris, and diseases associated with kidney transplantation.

[0139] Embodiment 32. The compound of any of embodiments 1-27 and / or a pharmaceutically acceptable salt thereof for use as a pharmaceutical.

[0140] Embodiment 33. 28. The compound of any of embodiments 1-27 and / or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of a disease mediated by or at least in part by BTK, preferably for use in the treatment or prevention of cancer, an inflammatory disease, or an autoimmune disease, wherein said cancer is preferably a solid tumor or a hematological malignancy, including lymphoma, leukemia, and myeloma; more preferably said cancer is a B-cell malignancy, diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, Burkitt's lymphoma, non-Burkitt's high-grade B-cell malignant lymphoma, extranodal marginal zone B-cell lymphoma, small lymphocytic lymphoma (SLL), lymphoblastic lymphoma, lymphocytic leukemia, myeloid leukemia, acute myeloid leukemia, and the inflammatory disease or autoimmune disease is preferably selected from systemic inflammation and local inflammation, arthritis, lymphoid tumors, and the like. The compound and / or a pharmaceutically acceptable salt thereof is selected from the group consisting of horse arthritis, inflammation associated with immunosuppression, organ transplant reflex, allergic disease, ulcerative colitis, Crohn's disease, dermatitis, asthma, lupus erythematosus, Sjogren's syndrome, multiple sclerosis, scleroderma, multiple sclerosis osteoporosis, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, antineutrophil cytoplasmic antibody vasculitis, chronic obstructive pulmonary disease, psoriasis, psoriatic syndrome, pemphigus vulgaris, and diseases associated with kidney transplantation.

[0141] Embodiment 34. A pharmaceutical combination comprising the compound of any of embodiments 1-27 and / or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent, wherein said therapeutic agent is preferably selected from an anti-inflammatory agent, an immunomodulatory agent or an anti-tumor active agent, wherein said anti-tumor active agent comprises a chemotherapeutic agent, an immune checkpoint inhibitor or agonist, and a targeted therapeutic agent.

[0142] Embodiment 35. Compounds of formula (V): [ka] or solvates, racemic mixtures, enantiomers, diastereomers and tautomers thereof, X1, X2, X3, X4, R1, R2 and R3 are as defined in any of embodiments 1 to 27; R 31 is -OH, oxo(=O) or -O-(C 1-6 alkyl), and R 32 is halogen, -B(OH)2, -B(OC 1-6 alkyl)2, [ka] and R d is hydrogen or C 1-6 It is alkyl.

[0143] Embodiment 36. [ka] and Z is N or CR7; R7 and R8 are each independently hydrogen or halogen; R9 is halogen or C 1-6 36. The compound of embodiment 35, wherein n is alkyl; and n is 1 or 2.

[0144] Embodiment 37. A compound selected from the following: [ka]

[0145] The various embodiments of the present invention (including the examples below) and the features of the various embodiments should be understood as being mutually combinable in any combination, and unless the context indicates otherwise, all the various solutions obtained by these mutual combinations are included within the scope of the present invention, just as the solutions obtained by specifically and individually listing these mutual combinations herein.

[0146] General synthesis method The compounds of formula (I) and / or pharmaceutically acceptable salts thereof described herein can be synthesized using commercially available starting materials by methods known in the art or by methods disclosed in this patent application. The synthetic routes shown in Schemes 1 and 2 illustrate general synthetic methods for preparing the compounds of the present invention, and the synthetic routes shown in Schemes 3 to 6 illustrate general synthetic methods for preparing material 1-1 used in Schemes 1 and 2.

[0147] Scheme 1: [ka]

[0148] As shown in Scheme 1, a compound of Formula 1-1 is reacted with a dihaloarylaldehyde compound of Formula 1-2 under the catalysis of cuprous iodide to obtain a compound of Formula 1-3. The carbon-nitrogen coupling reaction catalyzed by cuprous iodide is carried out under appropriate conditions. The solvent used can be selected from polar solvents such as 1,4-dioxane and DMF, and the base used can be selected from Cs2CO3, Na2CO3, K3PO4, etc. The compound of Formula 1-3 is reduced under appropriate conditions to obtain a compound of Formula 1-4. The reducing agent used can be selected from sodium borohydride, potassium borohydride, lithium borohydride, etc., and the solvent used can be selected from polar solvents such as methanol, ethanol, or a mixture of methanol and dichloromethane. The hydroxyl of the compound of Formula 1-4 is acetylated to obtain a compound of Formula 1-5. The compound of formula 1-5 is reacted with bis(pinacolato)diboron under appropriate conditions to give the boronic acid or boronate compound of formula 1-6. The compound of formula 1-6 is reacted with the halide of formula 1-7 via Suzuki coupling under the catalysis of an appropriate palladium reagent to give the compound of formula 1-8. The palladium-catalyzed Suzuki coupling reaction is carried out under appropriate conditions. The solvent used can be selected from polar solvents such as 1,4-dioxane, DMF, THF, or a mixture of 1,4-dioxane and water. The base used can be selected from Cs2CO3, Na2CO3, K3PO4, etc., and the catalyst used can be selected from Pd(dppf)Cl2·CH2Cl2, Pd(PPh3)4, Pd(OAc)2, etc. The compound of formula (I-1) of the present invention can be obtained by deacetylating the compound of formula 1-8 under appropriate alkaline conditions. The base used can be selected from potassium carbonate, sodium carbonate, lithium hydroxide, etc., and the solvent used can be selected from polar solvents such as methanol, ethanol, or a mixed solvent of methanol and water.

[0149] Scheme 2: [ka]

[0150] As shown in Scheme 2, a compound of Formula 1-3 is reacted with a boronic acid or boric acid ester of Formula 2-1 in a Suzuki coupling reaction catalyzed by an appropriate palladium reagent to obtain a compound of Formula 2-2. The palladium-catalyzed Suzuki coupling reaction is carried out under appropriate conditions. The solvent used can be selected from polar solvents such as 1,4-dioxane, DMF, THF, or a mixture of 1,4-dioxane and water. The base used can be selected from Cs2CO3, Na2CO3, K3PO4, etc., and the catalyst used can be selected from Pd(dppf)Cl2·CH2Cl2, Pd(PPh3)4, Pd(OAc)2, etc. Reduction of the compound of Formula 2-2 under appropriate conditions provides a compound of Formula (I-1). The reducing agent used can be selected from sodium borohydride, potassium borohydride, lithium borohydride, etc., and the solvent used can be selected from polar solvents such as methanol, ethanol, or a mixture of methanol and dichloromethane.

[0151] Scheme 3: [ka]

[0152] As shown in Scheme 3, the compound of Formula 3-1 is subjected to a substitution reaction with bromoacetaldehyde diethyl acetal under appropriate conditions to obtain a compound of Formula 3-2. The base used can be selected from cesium carbonate, etc., and the solvent used can be selected from polar solvents such as DMF or 1,4-dioxane. The compound of Formula 3-2 is hydrolyzed in an alkaline solution to obtain a compound of Formula 3-3. The base used can be selected from lithium hydroxide, potassium carbonate, sodium carbonate, etc., and the solvent used can be selected from polar solvents such as methanol, ethanol, or a mixture of methanol and water. The compound of Formula 3-3 is subjected to a condensation reaction with HATU and aqueous ammonia to obtain a compound of Formula 3-4. The compound of Formula 3-4 is ring-closed in acetic acid to obtain a compound of Formula 3-5.

[0153] Scheme 4: [ka]

[0154] As shown in Scheme 4, compounds of formula 3-2 can undergo a ring closure reaction with ammonium acetate in acetic acid to give compounds of formula 3-5.

[0155] Scheme 5: [ka]

[0156] As shown in Scheme 5, the compound of formula 3-1 is reacted with O-(2,4-dinitrophenyl)hydroxylamine to give the compound of formula 5-1, which is subjected to a ring-closure reaction with ammonium acetate in formamide solution to give the compound of formula 5-2.

[0157] Scheme 6: [ka]

[0158] As shown in Scheme 6, compounds of formula 3-1 undergo a substitution reaction with hydrazine hydrate to give compounds of formula 6-1, which undergo a ring-closure reaction with triethyl orthoformate in DMF solution to give compounds of formula 6-2.

[0159] The substituents of the compounds thus obtained can be further modified to give other desired compounds. Synthetic chemical transformations are described, for example, in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) and their successors.

[0160] The compounds of the present invention may be purified by column chromatography, high performance liquid chromatography, crystallization, or other suitable methods prior to use.

[0161] Pharmaceutical Compositions and Uses The compounds of the invention herein (e.g., compounds of any of the embodiments described herein) are used alone or in combination with one or more additional therapeutic agents to formulate pharmaceutical compositions comprising: (a) an effective amount of a compound of the invention; (b) a pharmaceutically acceptable excipient (e.g., one or more pharmaceutically acceptable carriers); and, optionally, (c) at least one additional therapeutic agent.

[0162] A pharmaceutically acceptable excipient refers to an excipient that is compatible with the active ingredient of the composition (and in some embodiments, can stabilize the active ingredient) and is not harmful to the subject being treated. For example, solubilizing agents such as cyclodextrins (which form specific, more soluble complexes with the compounds of the present invention) can be used as pharmaceutical excipients for delivering the active ingredient. Examples of other excipients or carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and dyes such as D&C Yellow #10. Suitable pharmaceutically acceptable excipients are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference in the art.

[0163] Pharmaceutical compositions containing the compounds of the invention herein can be administered in a variety of known ways, including orally, topically, rectally, parenterally, by inhalation spray, or via an implanted reservoir. As used herein, the term "parenteral" includes subcutaneous, intradermal, intravenous, intramuscular, intra-articular, intra-arterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

[0164] The pharmaceutical compositions described herein can be prepared in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid formulations, or suppositories. In some embodiments, the pharmaceutical compositions comprising the compounds of the invention herein are formulated for intravenous infusion, topical administration, or oral administration.

[0165] Oral compositions can be any orally acceptable dosage form, including but not limited to tablets, capsules, emulsions, and aqueous suspensions, dispersions and solutions.The carriers commonly used for tablets include lactose and cornstarch.Lubricants such as magnesium stearate are also commonly added to tablets.For oral administration in capsule form, useful diluents include lactose and dry cornstarch.When aqueous suspensions or emulsions are orally administered, active ingredients can be suspended or dissolved in the oil phase combined with emulsifiers or suspending agents.If necessary, certain sweeteners, flavors or colorants can be added.

[0166] In some embodiments, the compounds of the present invention may be present in tablets in amounts of 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 50 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 125 mg, 150 mg, 200 mg, 250 mg, 300 mg, 400 mg, or 500 mg. In some embodiments, the compounds of the present invention may be present in capsules in amounts of 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 50 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 125 mg, 150 mg, 200 mg, 250 mg, 300 mg, 400 mg, or 500 mg.

[0167] Sterile injectable compositions (e.g., aqueous or oleaginous suspensions) can be formulated according to techniques known in the art using appropriate dispersing or wetting agents (e.g., Tween 80) and suspending agents. Sterile injectable compositions can also be sterile injectable solutions or suspensions in non-toxic, parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol. Pharmaceutically acceptable excipients and solvents that can be used include mannitol, water, Ringer's solution, and isotonic sodium chloride solution. Additionally, sterile, fixed oils are conventionally used as solvents or suspending media (e.g., synthetic monoglycerides or diglycerides). Fatty acids, such as oleic acid and its glyceride derivatives, and natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially their polyoxyethylated versions, can be used as sterile injectable media. These oil solutions or suspensions can also contain long-chain alcohol diluents or dispersants, or carboxymethylcellulose or similar dispersing agents.

[0168] Compositions for inhalation can be prepared according to techniques well known in the art of pharmaceutical formulation and can be prepared as solutions in saline using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons and / or other solubilizing or dispersing agents known in the art.

[0169] Topical compositions can be formulated in the form of oils, creams, lotions, ointments, etc. Suitable carriers for the compositions include vegetable or mineral oils, white petrolatum (white soft paraffin), branched-chain fats and oils, animal fats, and high molecular weight alcohols (greater than C12). In some embodiments, the pharmaceutically acceptable carrier is one in which the active ingredient is soluble. Optionally, emulsifiers, stabilizers, humectants, and antioxidants, as well as agents imparting color or fragrance, can also be included. Additionally, transdermal penetration enhancers can be used in these topical formulations. Examples of such enhancers can be found in U.S. Pat. Nos. 3,989,816 and 4,444,762.

[0170] Creams can be formulated from a mixture of mineral oil, self-emulsifying beeswax, and water to which is added the active ingredient dissolved in a small amount of oil, such as almond oil. An example of such a cream is one containing, by weight, about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil, and about 1 part almond oil. Ointments can be formulated by mixing a solution of the active ingredient in a vegetable oil, such as almond oil, with warm soft paraffin and allowing the mixture to cool. An example of such an ointment is one containing about 30% by weight almond oil and about 70% by weight white soft paraffin.

[0171] The effectiveness of the compounds of the present invention in inhibiting BTK activity can be evaluated using appropriate in vitro assays. The compounds of the present invention can be further examined by in vivo assays for additional efficacy in preventing or treating cancer. For example, the compounds of the present invention can be administered to animals (e.g., mouse models) with cancer to assess their therapeutic efficacy. Successful preclinical results can predict the dosage range and route of administration for animals, such as humans.

[0172] Compounds of the invention may be shown to have sufficient preclinical utility to merit clinical trials where they are expected to demonstrate beneficial therapeutic or prophylactic effects, for example, in cancer patients.

[0173] As used herein, the term "cancer" refers to a cellular disorder characterized by uncontrolled or unregulated cell proliferation, decreased cell differentiation, an inappropriate ability to invade surrounding tissues, and / or an ability to establish new growth at ectopic sites. The term "cancer" includes, but is not limited to, solid tumors and hematological malignancies such as leukemia, lymphoma, or myeloma. The term "cancer" includes diseases of the skin, tissues, organs, bone, cartilage, blood, and blood vessels. The term "cancer" further includes primary cancers, as well as metastatic, recurrent, and refractory cancers.

[0174] Non-limiting examples of solid tumors include pancreatic cancer; bladder cancer; colorectal cancer; breast cancer, including metastatic breast cancer; prostate cancer, including androgen-dependent prostate cancer and androgen-independent prostate cancer; testicular cancer; kidney cancer, including, for example, metastatic renal cell carcinoma; urothelial carcinoma; liver cancer; hepatocellular carcinoma; lung cancer, including, for example, non-small cell lung cancer (NSCLC), bronchioloalveolar carcinoma (BAC), and lung adenocarcinoma; ovarian cancer, including, for example, advanced epithelial carcinoma or primary peritoneal carcinoma; cervical cancer; endometrial cancer; gastric cancer; esophageal cancer; head and neck cancer, including, for example, squamous cell carcinoma of the head and neck; melanoma and basal carcinoma. neuroendocrine carcinomas, including metastatic neuroendocrine tumors; brain tumors, including, for example, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma; bone cancer; sarcomas, including, for example, Kaposi's sarcoma; adrenal carcinoma; mesothelial carcinoma; choriocarcinoma; muscle carcinoma; connective tissue cancer; and thyroid cancer.

[0175] Non-limiting examples of hematological malignancies include acute myeloid leukemia (AML); chronic myeloid leukemia (CML), including accelerated phase CML and CML blast phase (CML-BP); acute lymphocytic leukemia (ALL); chronic lymphocytic leukemia (CLL), including high-risk CLL; human acute monocytic leukemia (M(5)); hairy cell leukemia; lymphocytic leukemia; chronic lymphocytic leukemia; myelogenous leukemia; myelodysplastic syndrome or acute lymphoblastic leukemia; small lymphocytic lymphoma (SLL), lymphoblastic lymphoma, and Hodgkin's lymphoma; non-Hodgkin's lymphoma (NHL); follicular lymphoma; mantle cell lymphoma (MCL). B-cell lymphoma; T-cell lymphoma; diffuse large B-cell lymphoma (DLBCL); large B-cell lymphoma (LBCL); follicular lymphoma, marginal zone lymphoma, Burkitt lymphoma, non-Burkitt high-grade B-cell lymphoma, extranodal marginal zone B-cell lymphoma; multiple myeloma (MM); Waldenstrom's macroglobulinemia; myelodysplastic syndromes (MDS), including refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), and refractory anemia with excess blasts in transformation (RAEB-T); and myeloproliferative syndromes.

[0176] In some embodiments, the hematological malignancy is relapsed or refractory diffuse large B-cell lymphoma (DLBCL), relapsed or refractory mantle cell lymphoma, relapsed or refractory follicular lymphoma, relapsed or refractory CLL, relapsed or refractory SLL, and relapsed or refractory multiple myeloma.

[0177] The compounds of the invention can be used to achieve beneficial therapeutic or prophylactic effects, for example, in subjects with cancer.

[0178] The compounds of the invention can be used to achieve beneficial therapeutic or prophylactic effects, for example, in subjects with autoimmune diseases or in subjects with inflammatory diseases.

[0179] The term "autoimmune disease" refers to a disease or disorder caused by and / or directed against an individual's own tissues or organs, or their co-segregates or manifestations, or conditions resulting therefrom. Examples of autoimmune diseases include, but are not limited to, chronic obstructive pulmonary disease (COPD), allergic rhinitis, lupus erythematosus, myasthenia gravis, Sjögren's syndrome, multiple sclerosis (MS), scleroderma (also known as systemic sclerosis), osteoporosis, arthritis (such as rheumatoid arthritis (RA) and collagen-induced arthritis), psoriasis, inflammatory bowel disease, asthma, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, antineutrophil cytoplasmic antibody vasculitis, chronic obstructive pulmonary disease, sicca syndrome, pemphigus vulgaris, and diseases associated with kidney transplantation, as well as myeloproliferative disorders such as myelofibrosis and post-polycythemia vera / essential thrombocythemia myelofibrosis (PV / ET). In some embodiments, the autoimmune disease is selected from arthritis, such as rheumatoid arthritis (RA) and collagen-induced arthritis.

[0180] The term "inflammatory disease" or "inflammatory condition" refers to a pathological condition that causes inflammation, particularly due to neutrophil chemotaxis. Non-limiting examples of inflammatory diseases include systemic and local inflammation, inflammation associated with immunosuppression, organ transplant reflexes, allergic diseases, inflammatory skin diseases (including psoriasis and atopic dermatitis), systemic sclerosis and sclerosis, responses associated with inflammatory bowel disease (e.g., IBD, Crohn's disease, and ulcerative colitis), ischemia-reperfusion injury, including surgical tissue reperfusion injury, myocardial ischemia such as myocardial infarction, cardiac arrest, reperfusion after cardiac surgery and abnormal coronary contractile responses after percutaneous transluminal coronary angioplasty, surgical tissue reperfusion injury in stroke and abdominal aortic aneurysm, cerebral edema secondary to stroke, cranial injury and hemorrhagic shock, asphyxiation, adult respiratory distress syndrome, acute lung injury, and Behçet's disease. These include dermatomyositis; polymyositis; multiple sclerosis (MS); dermatitis; meningitis; encephalitis; uveitis; osteoarthritis; lupus nephritis; autoimmune diseases such as rheumatoid arthritis (RA), Sjögren's syndrome, and vasculitis; diseases associated with leukocyte leakage; sepsis or central nervous system (CNS) inflammatory diseases secondary to trauma, and multi-organ injury syndrome; alcoholic hepatitis; bacterial pneumonia; antigen-antibody complex-mediated diseases including glomerulonephritis; anemia; sarcoidosis; immunopathological reactions to tissue / organ transplants; and pulmonary inflammation including pleuritis, alveolitis, vasculitis, pneumonia, chronic bronchitis, bronchiectasis, diffuse panbronchiolitis, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis (IPF), and cystic fibrosis. Preferably, the symptoms include, but are not limited to, chronic inflammation, autoimmune diabetes, rheumatoid arthritis (RA), rheumatoid spondylitis, gouty arthritis and other joint diseases, multiple sclerosis (MS), asthma, systemic lupus erythematosus, adult respiratory distress syndrome, Behcet's disease, psoriasis, chronic pulmonary inflammatory disease, graft versus host reaction, Crohn's disease, ulcerative colitis, inflammatory bowel disease (IBD), Alzheimer's disease and fever, and any inflammation and related diseases and related conditions.

[0181] Additionally, compounds of the present invention (e.g., compounds of any of the embodiments described herein) can be administered in combination with an additional therapeutic agent for the treatment of a disease or disorder described herein, such as cancer, inflammatory disease, or autoimmune disease. The additional active ingredient may be administered separately from the compound of the present invention or may be included with such an ingredient in a pharmaceutical composition of the present disclosure, such as a fixed-dose combination pharmaceutical. In some embodiments, the additional active ingredient is one known or discovered to be effective in treating a disease mediated by, or at least in part by, BTK, such as another BTK inhibitor or a compound active against another target relevant to the particular disease. This combination may serve to increase efficacy (e.g., by including in the combination a compound that enhances the potency or efficacy of a compound of the present invention), reduce one or more side effects, or reduce the required dose of a compound of the present invention.

[0182] In some embodiments, a compound of the invention (such as any compound herein) can be administered in combination with an additional therapeutic agent, such as an anti-inflammatory agent, an immunomodulatory agent, or an anti-tumor active agent, including chemotherapeutic agents, immune checkpoint inhibitors or agonists, and targeted therapeutic agents. As used herein, the term "anti-tumor active agent" refers to any agent administered to a subject suffering from cancer for the purpose of treating the cancer, such as chemotherapeutic agents, immune checkpoint inhibitors or agonists, and targeted therapeutic agents.

[0183] Non-limiting examples of chemotherapeutic agents include topoisomerase I inhibitors (e.g., irinotecan, topotecan, camptothecin and their analogs or metabolites, and doxorubicin); topoisomerase II inhibitors (e.g., etoposide, teniposide, mitoxantrone, idarubicin, and daunorubicin); alkylating agents (e.g., melphalan, chlorambucil, busulfan, thiotepa, ifosfamide, carmustine, lomustine, semustine, streptozocin, decarbazine, methotrexate, mitomycin C, and cyclophosphamide). DNA intercalators (e.g., cisplatin, oxaliplatin, and carboplatin); and free radical generators such as bleomycin; nucleoside mimetics (e.g., 5-fluorouracil, capecitabine, gemcitabine, fludarabine, cytarabine, azacitidine, mercaptopurine, thioguanine, pentostatin, and hydroxyurea); paclitaxel, docetaxel, and related analogs; vincristine, vinblastine, and related analogs; thalidomide and related analogs (e.g., CC-5013 and CC-4047).

[0184] Non-limiting examples of immune checkpoint inhibitors or agonists include PD-1 inhibitors, e.g., anti-PD-1 antibodies such as pembrolizumab and nivolumab; PD-L1 inhibitors, e.g., anti-PD-L1 antibodies such as atezolizumab, durvalumab, and avelumab; CTLA-4 inhibitors, e.g., anti-CTLA-4 antibodies such as ipilimumab; and BTLA inhibitors, LAG-3 inhibitors, TIM3 inhibitors, TIGIT inhibitors, VISTA inhibitors, OX-40 agonists, and the like.

[0185] Targeted therapeutic agents include various small molecule or polymeric targeted therapeutic agents, non-limiting examples of which include: protein tyrosine kinase inhibitors (such as imatinib mesylate and gefitinib); proteasome inhibitors (such as bortezomib); NF-κB inhibitors, including IκB kinase inhibitors; PI3Kδ inhibitors; SYK inhibitors; Bcl2 inhibitors; antibodies that bind to proteins overexpressed in cancer and downregulate cell replication, such as anti-CD20 antibodies (such as rituximab, ibritumomab tiuxetan, and tositumomab), anti-Her2 monoclonal antibodies (trastuzumab), anti-EGFR antibodies (cetuximab), and anti-VEGFR antibodies (bevacizumab); anti-angiogenic agents such as lenalidomide; and protein or enzyme inhibitors of other proteins or enzymes known to be upregulated, overexpressed, or activated in cancer, the inhibition of which can downregulate cell replication. [Example]

[0186] The following examples are purely illustrative and should not be construed as limiting in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but those skilled in the art should understand that some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, temperatures are in degrees Celsius, and pressures are at or near atmospheric pressure. All MS data were determined using an Agilent 6120 or Agilent 1100. All NMR data were generated using a Varian 400MR instrument. All reagents and materials used in the present invention, except for synthetic intermediates, are commercially available. Reference GDC-0853 (fenebrutinib) was purchased from Shanghai Linkchem Medical Technology Co., Ltd. All compound names, except for reagents, were generated using Chemdraw 16.0.

[0187] When an atom with an open valence is present in any structure disclosed herein, the vacancy is balanced with a hydrogen atom, which has been omitted for convenience.

[0188] In this application, if there is a discrepancy between the name and structure of a compound and both are given for the compound, the structure of the compound shall prevail unless the context indicates that the structure of the compound is incorrect and the name is correct.

[0189] Abbreviations are used in the examples below. [Table 1]

[0190] Example 1: Synthesis of compounds Intermediate I-1 4-chloro-2-(1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)nicotinaldehyde [ka]

[0191] Step 1: 2-chlorocyclopentan-1-ene-1-carbaldehyde Phosphorus oxychloride (4.45 mL, 47.7 mmol) was added dropwise to DMF (4.6 mL, 59.6 mmol) under nitrogen at 0-5°C. The reaction mixture was stirred at 0-5°C for 10 minutes and then at room temperature for an additional 15 minutes. Cyclopentanone (2.5 g, 29.8 mmol) was added dropwise to the reaction mixture at 0-5°C and allowed to react at room temperature for 1 hour. The mixture was then poured into ice water (pH adjusted to 5 with aqueous sodium carbonate) and 100 mL of water was added. The reaction mixture was extracted with petroleum ether / ethyl acetate = 10 / 1 (100 mL × 2). The organic phases were collected, combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and concentrated to give the desired product (2.4 g, 62% yield), which was used directly in the next step.

[0192] Step 2: (E)-3-(2-chlorocyclopent-1-en-1-yl)ethyl acrylate 2-Chlorocyclopentan-1-ene-1-carbaldehyde (2.4 g, 18.4 mmol) and ethoxy(formylmethylene)triphenylphosphorane (6.4 g, 18.4 mmol) were added to dichloromethane (30 mL) under nitrogen and reacted at reflux for 6 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (3.3 g, 89% yield). [M+H] + 201.1

[0193] Step 3: Ethyl 1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carboxylate To a solution of (E)-3-(2-chlorocyclopent-1-en-1-yl)ethyl acrylate (3.3 g, 16.5 mmol) in DMSO (20 mL) was added sodium azide (1.6 g, 24 mmol) under nitrogen and the reaction was allowed to proceed at 65°C for 16 hours. Water (200 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL x 2). The organic phases were collected, combined, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (700 mg, 24% yield). [M+H] + 180.1. 1 H NMR (400 MHz, CDCl3): δ 8.81 (s, 1H), 6.65 (s, 1H), 4.30-4.26 (m, 2H), 2.75-2.55 (m, 4H), 2.42-2.40 (m, 2H), 1.35-1.31 (m, 3H)

[0194] Step 4: 1-(2,2-diethoxyethyl)-1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carboxylate ethyl To a solution of ethyl 1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carboxylate (700 mg, 3.9 mmol) in DMF (5 mL), cesium carbonate (3.2 g, 9.7 mmol) and bromoacetaldehyde diethyl acetal (1.55 g, 7.8 mmol) were added and the mixture was reacted at 100 °C for 16 hours. Water (50 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL x 2). The organic phases were collected, combined, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (1.0 g, 92% yield). [M+Na] + 318.1

[0195] Step 5: 1-(2,2-diethoxyethyl)-1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carboxylic acid To a solution of ethyl 1-(2,2-diethoxyethyl)-1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carboxylate (1.0 g, 3.6 mmol) in ethanol (10 mL) and water (10 mL), lithium hydroxide monohydrate (650 mg, 14.4 mmol) was added and the mixture was allowed to react at 80 °C for 12 hours. The ethanol was removed under reduced pressure, the pH was adjusted to 5-6 with concentrated hydrochloric acid, and water (20 mL) was added. The reaction mixture was extracted with ethyl acetate (20 mL × 2), and the organic phases were collected, combined, dried over anhydrous sodium sulfate, and concentrated to give the desired product (800 mg, 83% yield). [MH] - 266.1

[0196] Step 6: 1-(2,2-diethoxyethyl)-1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carboxamide To a solution of 1-(2,2-diethoxyethyl)-1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carboxylic acid (800 mg, 3 mmol) in DMF (5 mL) was added triethylamine (0.84 mL, 6 mmol) and HATU (1.7 g, 4.5 mmol) under nitrogen at 0-5 °C. After reacting at room temperature for 30 min, the reaction mixture was poured into concentrated aqueous ammonia (20 mL) and stirred for 10 min. Water (20 mL) was added, and the reaction mixture was extracted with dichloromethane (20 mL × 2). The organic phases were collected, combined, and concentrated to give the desired product (1.0 g, 125% yield), which was used directly in the next step.

[0197] Step 7: 7,8-Dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one 1-(2,2-Diethoxyethyl)-1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carboxamide (1.0 g, 3.75 mmol) was dissolved in acetic acid (10 mL) and reacted at 100°C for 4 hours (the acetic acid was removed under reduced pressure and the pH was adjusted to 8 with aqueous ammonia). Water (20 mL) was added, and the mixture was extracted with dichloromethane (20 mL x 2). The organic phases were collected, combined, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane / methanol) to give the desired product (600 mg, 92% yield). [M+H] + 175.1

[0198] Step 8: 4-chloro-2-(1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)nicotinaldehyde To a solution of 7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one (600 mg, 3.5 mmol) and 2-bromo-4-chloronicotinaldehyde (1.1 g, 5.1 mmol) in 1,4-dioxane (30 mL) was added cuprous iodide (665 mg, 3.5 mmol), 4,7-dimethoxy-1,10-phenanthroline (580 mg, 2.45 mmol), and cesium carbonate (2.2 g, 7.0 mmol) under nitrogen. The mixture was reacted at 90 °C for 12 hours and then cooled to room temperature. The mixture was concentrated under reduced pressure in vacuo, and the resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (400 mg, 37% yield). [M+H] + 314.0

[0199] The intermediates in the table below were prepared using the corresponding materials and reagents according to the preparation process of intermediate I-1. [Table 2]

[0200] Intermediate I-2 (5-((5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)boronic acid [ka]

[0201] Step 1: t-butyl (2R,5S)-2,5-dimethyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate To a solution of 5-bromo-2-nitropyridine (7.0 g, 32.7 mmol) and t-butyl (2R,5S)-2,5-dimethylpiperazine-1-carboxylate (10.0 g, 49.0 mmol) in 1,4-dioxane (150 mL) was added Xant-phos (3.8 g, 0.64 mmol), Pd2(dba)3 (3.0 g, 0.32 mmol), and cesium carbonate (21.3 g, 65.3 mmol) under nitrogen. The mixture was reacted at 100 °C for 16 hours and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure in vacuo, and the resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product. [M+H] + 337.1

[0202] Step 2: (2R,5S)-2,5-dimethyl-1-(6-nitropyridin-3-yl)piperazine To a solution of t-butyl (2R,5S)-2,5-dimethyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate obtained in Step 1 in methanol (10 mL) was added concentrated hydrochloric acid (3 mL) under nitrogen. The reaction mixture was stirred at room temperature for 30 minutes, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (methanol / water) to give the desired product (3.3 g, 43% yield over two steps). [M+H] + 237.1

[0203] Step 3: (2S,5R)-2,5-dimethyl-1-(6-nitropyridin-3-yl)-4-(oxetan-3-yl)piperazine To a solution of (2R,5S)-2,5-dimethyl-1-(6-nitropyridin-3-yl)piperazine (3.3 g, 14.0 mmol) and oxetan-3-one (3.1 g, 42.0 mmol) in methanol (20 mL) was added zinc chloride (5.7 g, 42.0 mmol) and sodium cyanoborohydride (2.6 g, 42.0 mmol) under nitrogen. The reaction mixture was stirred at 50 °C for 5 hours, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (methanol / water) to give the desired product (3.3 g, 80% yield). [M+H] + 293.1

[0204] Step 4: 5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-amine A mixture of (2S,5R)-2,5-dimethyl-1-(6-nitropyridin-3-yl)-4-(oxetan-3-yl)piperazine (3.3 g, 11.3 mmol) and 10% palladium-carbon (50% water, 400 mg) in methanol (50 mL) was introduced with hydrogen at room temperature and reacted for 12 hours. The reaction mixture was filtered, and the filtrate was collected and concentrated under reduced pressure in vacuo to give the desired product (2.94 g, 99% yield), which was used directly in the next step. [M+H] + 263.1

[0205] Step 5: 5-Bromo-3-((5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-1-methylpyridin-2(1H)-one To a solution of 5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-amine (2.94 g, 11.2 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (3.0 g, 11.2 mmol) in 1,4-dioxane (150 mL) was added Xantphos (325 mg, 0.56 mmol), Pd2(dba)3 (515 mg, 0.56 mmol), and cesium carbonate (7.3 g, 22.5 mmol) under nitrogen. The mixture was reacted at 100 °C for 16 hours and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure in vacuo, and the resulting residue was purified by silica gel column chromatography (methanol / dichloromethane) to give the desired product (4.7 g, 93% yield). [M+H] + 448.1, 450.0

[0206] Step 6: (5-((5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)boronic acid To a solution of 5-bromo-3-((5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-1-methylpyridin-2(1H)-one (4.7 g, 10.5 mmol), bis(pinacolato)diboron (13.3 g, 52.4 mmol) in 1,4-dioxane (200 mL) was added Xphos (500 mg, 1.05 mmol), Pd(dba) (480 mg, 0.52 mmol), and potassium acetate (3.0 g, 31.4 mmol) under nitrogen. The mixture was reacted at 60 °C for 16 h and then cooled to room temperature. The reaction mixture was filtered, the filtrate was collected and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (methanol / water) to give the target compound (2.3 g, 53% yield). [M+H] + 414.2

[0207] The intermediates in the table below were prepared using the corresponding materials and reagents according to the preparation process of intermediate I-2. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4]

[0208] Intermediate I-3 5-Bromo-3-((5-ethyl(2-methoxyethyl)amino)pyridin-2-yl)amino)-1-methylpyridin-2(1H)-one [ka]

[0209] Step 1: N-(2-methoxyethyl)-6-nitropyridin-3-amine To a solution of 5-fluoro-2-nitropyridine (4.26 g, 30 mmol) and 2-methoxyethylamine (2.48 g, 33 mmol) in DMSO (30 mL) was added triethylamine (21.2 g, 210 mmol). The mixture was reacted at 100 °C for 4 hours and then cooled to room temperature. The reaction mixture was poured into water (200 mL) and extracted with ethyl acetate (200 mL x 2). The organic phases were collected, combined, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (methanol / dichloromethane) to give the desired product (5.92 g, 100% yield). [M+H] + 198.1

[0210] Step 2: N-ethyl-N-(2-methoxyethyl)-6-nitropyridin-3-amine To a solution of N-(2-methoxyethyl)-6-nitropyridin-3-amine (986 mg, 5.0 mmol) in DMF (10 mL) was added 60% sodium hydride (mineral oil dispersion) (240 mg, 6.0 mmol) under nitrogen at 0-5 °C and stirred at the same temperature for 1 h. Bromoethane was added to the mixture, and the reaction was continued at 60 °C for 2 h and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure in vacuo, and the resulting residue was dissolved in dichloromethane (100 mL) and washed with water (50 mL). The organic phase was collected and concentrated under reduced pressure in vacuo to give the desired product (1.13 g, 100% yield), which was used directly in the next step. [M+H] + 226.1

[0211] Process 3:N 5 -ethyl-N 5 -(2-Methoxyethyl)pyridine-2,5-diamine A mixture of N-ethyl-N-(2-methoxyethyl)-6-nitropyridin-3-amine (1.13 g, 5.0 mmol) and 10% palladium-carbon (50% water, 200 mg) in methanol (20 mL) was charged with hydrogen at room temperature and reacted for 16 hours. The reaction mixture was filtered, the filtrate was collected and concentrated under reduced pressure in vacuo, and the resulting residue was purified by silica gel column chromatography (methanol / water) to give the desired product (875 mg, 90% yield). [M+H] + 196.1

[0212] Step 4: 5-Bromo-3-((5-ethyl(2-methoxyethyl)amino)pyridin-2-yl)amino)-1-methylpyridin-2(1H)-one N in 1,4-dioxane (5 mL) 5 -ethyl-N 5 To a solution of 195 mg (1.0 mmol) of 2-(2-methoxyethyl)pyridine-2,5-diamine and 267 mg (1.0 mmol) of 3,5-dibromo-1-methylpyridin-2(1H)-one under nitrogen, Xantphos (58 mg (0.1 mmol), Pd2(dba)3 (92 mg (0.1 mmol), and cesium carbonate (652 mg (2.0 mmol) were added. The mixture was reacted at 100 °C for 16 hours and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure in vacuo, and the resulting residue was purified by silica gel column chromatography (methanol / dichloromethane) to give the desired product (257 mg, 67% yield). [M+H] + 381.1, 383.1

[0213] The intermediates in the table below were prepared using the corresponding materials and reagents according to the preparation process of intermediate I-3. [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] [Table 4-6] [Table 4-7] [Table 4-8]

[0214] Intermediate I-4 (3-(acetoxymethyl)-2-(7,7-dimethyl-1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)pyridin-4-yl)boronic acid [ka]

[0215] Step 1: 2-(4-chloro-3-(hydroxymethyl)pyridin-2-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one To a solution of 4-chloro-2-(7,7-dimethyl-1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)nicotinaldehyde (1.71 g, 5.0 mmol) (Intermediate I-55) in methanol (5 mL) and dichloromethane (15 mL) under nitrogen at 0-5 °C, sodium borohydride (0.13 g, 3.5 mmol) was added, and the mixture was allowed to react at the same temperature for 10 min. Saturated aqueous ammonium chloride solution (5 mL) was added, and the mixture was extracted with dichloromethane (30 mL × 2). The organic phases were collected, combined, and concentrated in vacuo under reduced pressure to give the desired product (1.72 g, 100% yield), which was used directly in the next step. [M+H] + 344.1

[0216] Step 2: Acetic acid (4-chloro-2-(7,7-dimethyl-1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin)-2-yl)pyridin-3-yl)methyl ester To a solution of 2-(4-chloro-3-(hydroxymethyl)pyridin-2-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one (1.72 g, 5.0 mmol) and triethylamine (2.53 g, 25 mmol) in dichloromethane (30 mL), acetyl chloride (1.18 g, 15 mmol) was added under nitrogen at 0-5 °C. The mixture was reacted at the same temperature for 1 h. Water (20 mL) and dichloromethane (30 mL) were added, and the organic phases were collected, combined, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (1.65 g, 86% yield). [M+H] + 386.1

[0217] Step 3: (3-(acetoxymethyl)-2-(7,7-dimethyl-1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin)-2-yl)pyridin-4-yl)boronic acid To a solution of acetic acid (4-chloro-2-(7,7-dimethyl-1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)pyridin-3-yl)methyl ester (3.0 g, 7.79 mmol), bis(pinacolato)diboron (5.9 g, 23.3 mmol) in 1,4-dioxane (120 mL) was added Xphos (333 mg, 0.7 mmol), Pd(dppf)Cl2CHCl2 (570 mg, 0.7 mmol), and potassium acetate (2.3 g, 23.3 mmol) under nitrogen. The mixture was reacted at 90 °C for 16 h and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure in vacuo, and the resulting residue was purified by silica gel column chromatography (methanol / water) to give the desired product (2.9 g, 94% yield). [M+H] + 396.1

[0218] The intermediates in the table below were prepared using the corresponding materials and reagents according to the preparation process of intermediate I-4. [Table 5]

[0219] Intermediate I-5 5-Bromo-3-((1-ethyl-1H-1,2,3-triazol-4-yl)amino)-1-methylpyrazin-2(1H)-one [ka]

[0220] 3,5-Dibromo-1-methylpyrazin-2(1H)-one (5.0 g, 18.7 mmol) and 1-ethyl-1H-1,2,3-triazol-4-amine (2.1 g, 18.7 mmol) were dissolved in N-methylpyrrolidone (7 mL) under nitrogen. The mixture was reacted at 120 °C for 3 hours and then cooled to room temperature. The mixture was filtered, and the filter cake was washed with methanol (5 mL) to give the desired product (3.9 g, 50% yield). [M+H] + 299.0, 301.0

[0221] The intermediates in the table below were prepared using the corresponding materials and reagents according to the preparation process of intermediate I-5. [Table 6]

[0222] Intermediate I-13 (S)-5-Bromo-1,6-dimethyl-3-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)pyridin-2(1H)-one [ka]

[0223] Step 1: 3,5-Dibromo-6-methylpyridin-2(1H)-one To a solution of 6-methylpyridin-2(1H)-one (949 mg, 8.7 mmol) in DMF (30 mL) was added NBS (3.1 g, 17.4 mmol) under nitrogen. The mixture was reacted at room temperature for 4 hours. The reaction mixture was poured into water (50 mL), and the precipitated solid was collected and washed with methanol to give the desired product, which was used directly in the next step.

[0224] Step 2: 3,5-Dibromo-1,6-dimethylpyridin-2(1H)-one To a solution of 3,5-dibromo-6-methylpyridin-2(1H)-one (2.3 g, 8.7 mmol) in DMF (30 mL) was added iodomethane (1.3 g, 8.7 mmol) and cesium carbonate (1.6 g, 11.3 mmol) under nitrogen. The mixture was allowed to react at room temperature for 2 hours. The reaction mixture was poured into water (50 mL), and the precipitated solid was collected. The solid was then washed with methanol to give the desired product (2.2 g, 92% yield over two steps). [M+H] + 281.8

[0225] Step 3: (S)-5-Bromo-1,6-dimethyl-3-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)pyridin-2(1H)-one Intermediate I-13 was prepared according to the corresponding steps of intermediate I-2 using 3,5-dibromo-1,6-dimethylpyridin-2(1H)-one and the corresponding reagents. [M+H] + 448.1, 450.1

[0226] Intermediate I-16 (S)-6-Chloro-2-ethyl-4-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)pyridazin-3(2H)-one [ka]

[0227] Step 1: 4-Bromo-6-chloro-2-ethylpyridazin-3(2H)-one To a solution of 4-bromo-6-chloro-3(2H)-one (1.0 g, 4.8 mmol) in DMF (20 mL) was added 60% sodium hydride (mineral oil dispersion) (0.46 g, 11.5 mmol) under nitrogen at 0-5°C. The mixture was allowed to react for 30 minutes at 0-5°C. Iodoethene (1.5 g, 9.6 mmol) was then added, and the reaction mixture was allowed to react at room temperature for 5 minutes. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layers were collected, combined, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (methanol / water) to give the desired product (0.91 g, 80% yield). [M+H] + 238.9

[0228] Step 2: (S)-6-chloro-2-ethyl-4-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)pyridazin-3(2H)-one Intermediate I-16 was prepared according to the corresponding steps of intermediate I-2 using 4-bromo-6-chloro-2-ethylpyridazin-3(2H)-one and the corresponding reagents. [M+H] + 405.1

[0229] Intermediate I-31 5-Bromo-1-methyl-3-((1-(2,2,2-trifluoroethyl)-1H-1,2,3-triazol-4-yl)amino)pyridin-2(1H)-one [ka]

[0230] Step 1: 4-nitro-1-(2,2,2-trifluoroethyl)-1H-1,2,3-triazole To a solution of 4-nitro-1H-1,2,3-triazole (4.0 g, 35.1 mmol), 2-trifluoroethanol (5.12 mL, 43.8 mmol), and triphenylphosphine (18.4 g, 43.8 mmol) in tetrahydrofuran (180 mL) was added DIAD (13.9 g, 43.8 mmol) under nitrogen at 0-5°C. The mixture was reacted at 60°C for 16 hours, then cooled to room temperature and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (4.61 g, 68% yield). [M+H] + 197.0

[0231] Step 2: 5-Bromo-1-methyl-3-((1-(2,2,2-trifluoroethyl)-1H-1,2,3-triazol-4-yl)amino)pyridin-2(1H)-one Intermediate I-31 was prepared according to the corresponding steps of intermediate I-3 using 4-nitro-1-(2,2,2-trifluoroethyl)-1H-1,2,3-triazole and the corresponding reagents. [M+H] + 352.0, 353.9

[0232] The intermediates in the table below were prepared according to the preparation steps of intermediates I-31, I-3 and I-5 using the corresponding materials and reagents. [Table 7]

[0233] Intermediate I-37 5-Bromo-1-methyl-3-((1'-(oxetan-3-yl)-1',2',3',6'-tetrahydro-[3,4'-bispyridin]-6-yl)amino)pyridin-2(1H)-one [ka]

[0234] Step 1: t-Butyl 6-nitro-3',6'-dihydro-[3,4'-bispyridine]-1'(2'H)carboxylate To a solution of 1-nitrogen-tert-butyl-4,5-cyclohexene-4-borate (4.41 g, 15 mmol), 5-fluoro-2-nitropyridine (3.03 g, 15 mmol) in 1,4-dioxane (20 mL) and water (2 mL) under nitrogen, Pd(dppf)Cl2CHCl2 (612 mg, 0.75 mmol) and sodium carbonate (3.18 g, 30 mmol) were added. The mixture was reacted at 100 °C for 3 hours, then cooled to room temperature and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (4.58 g, 100% yield). [M+H] + 306.1

[0235] Step 2: 5-Bromo-1-methyl-3-((1'-(oxetan-3-yl)-1',2',3',6'-tetrahydro-[3,4'-bispyridin]-6-yl)amino)pyridin-2(1H)-one Intermediate I-37 was prepared according to the corresponding steps of intermediate I-2 using t-butyl 6-nitro-3',6'-dihydro-[3,4'-bispyridine]-1'(2'H)carboxylate and the corresponding reagents. [M+H] + 417.0, 419.0

[0236] The intermediates in the table below were prepared using the corresponding materials and reagents according to the process for preparing intermediate I-37. [Table 8]

[0237] Intermediate I-43 (S)-5-Bromo-1-methyl-3-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyrazin-2-yl)amino)pyridin-2(1H)-one [ka]

[0238] Step 1: t-butyl (S)-3-methyl-4-(5-nitropyrazin-2-yl)piperazine-1-carboxylate To a solution of 2-bromo-5-nitropyrazine (1.22 g, 6.0 mmol) and t-butyl (S)-3-methylpiperazine-1-carboxylate (1.00 g, 5.0 mmol) in DMF (10 mL) was added potassium carbonate (1.38 g, 10 mmol). The mixture was reacted at 80 °C for 4 hours, then cooled to room temperature and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (1.50 g, 93% yield). [M+H-56] + 268.1

[0239] Step 2: (S)-5-Bromo-1-methyl-3-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyrazin-2-yl)amino)pyridin-2(1H)-one Intermediate I-43 was prepared according to the corresponding steps of intermediate I-2 using t-butyl (S)-3-methyl-4-(5-nitropyrazin-2-yl)piperazine-1-carboxylate and the corresponding reagents. [M+H] + 435.1, 437.1

[0240] Intermediate I-44 (S)-5-Bromo-1-methyl-3-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyrimidin-2-yl)amino)pyridin-2(1H)-one [ka]

[0241] Step 1: 5-bromo-N,N-bis(4-methoxybenzyl)pyrimidin-2-amine To a solution of 5-bromopyrimidin-2-amine (3.48 g, 20 mmol) in tetrahydrofuran (60 mL) under nitrogen at 0-5°C, 60% sodium hydride (mineral oil dispersion) (1.72 g, 43 mmol) was added. The mixture was reacted at 0-5°C for 30 minutes, then p-methoxybenzyl chloride (7.83 g, 50 mmol) was added, and the reaction mixture was reacted at 75°C for 8 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic phases were collected, combined, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (2.07 g, 25% yield). [M+H] + 414.1, 416.1

[0242] Step 2: t-butyl (S)-4-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)-3-methylpiperazine-1-carboxylate To a solution of 5-bromo-N,N-bis(4-methoxybenzyl)pyrimidin-2-amine (2.07 g, 5.0 mmol) and t-butyl (S)-3-methylpiperazine-1-carboxylate (10.0 g, 49.0 mmol) in toluene (30 mL) was added BINAP (311 mg, 0.50 mmol), Pd2(dba)3 (229 mg, 0.25 mmol), and sodium tert-butoxide (960 mg, 10 mmol) under nitrogen. The mixture was reacted at 80 °C for 8 hours and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure in vacuo, and the resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (1.60 g, 30% yield). [M+H] + 534.3

[0243] Step 3: (S)-5-(2-methylpiperazin-1-yl)pyrimidin-2-amine A solution of t-butyl (S)-4-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)-3-methylpiperazine-1-carboxylate (1.60 g, 3.0 mmol) in trifluoroacetic acid (10 mL) was stirred at room temperature under nitrogen for 30 minutes and concentrated in vacuo under reduced pressure to give the desired product, which was used directly in the next step. [M+H] + 194.1

[0244] Step 4: t-butyl (S)-4-(2-aminopyrimidin-5-yl)-3-methylpiperazine-1-carboxylate To a solution of (S)-5-(2-methylpiperazin-1-yl)pyrimidin-2-amine obtained in the previous step and di-tert-butyl dicarbonate (720 mg, 3.3 mmol) in dichloromethane (10 mL) was added triethylamine (455 mg, 4.5 mmol). The mixture was allowed to react at room temperature for 1 hour. The mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (dichloromethane / methanol) to give the desired product (880 mg, 100% yield over two steps). [M+H] + 294.1

[0245] Step 5: (S)-5-Bromo-1-methyl-3-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyrimidin-2-yl)amino)pyridin-2(1H)-one Intermediate I-44 was prepared according to the corresponding steps of intermediate I-2 using t-butyl (S)-4-(2-aminopyrimidin-5-yl)-3-methylpiperazine-1-carboxylate and the corresponding reagents. [M+H] + 435.0, 437.0

[0246] Intermediate I-45 5-Bromo-1-methyl-3-((5-((tetrahydro-2H-pyran-3-yl)amino)pyridin-2-yl)amino)pyridin-2(1H)-one [ka]

[0247] Step 1: 6-nitro-N-(tetrahydro-2H-pyran-3-yl)pyridin-3-amine To a solution of tetrahydro-2H-pyran-3-amine (0.61 g, 6.0 mmol) and 5-bromo-2-nitropyridine (1.46 g, 7.2 mmol) in 1,4-dioxane (50 mL) was added BINAP (0.37 g, 0.60 mmol), Pd2(dba)3 (0.55 g, 0.60 mmol), and cesium carbonate (3.91 g, 12 mmol) under nitrogen. The mixture was reacted at 100 °C for 16 hours and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure in vacuo, and the resulting residue was purified by silica gel column chromatography (dichloromethane / methanol) to give the desired product (0.72 g, 54% yield). [M+H] + 224.1

[0248] Step 2: 5-Bromo-1-methyl-3-((5-((tetrahydro-2H-pyran-3-yl)amino)pyridin-2-yl)amino)pyridin-2(1H)-one Intermediate I-45 was prepared according to the corresponding steps of intermediate I-3 using 6-nitro-N-(tetrahydro-2H-pyran-3-yl)pyridin-3-amine and the corresponding reagents. [M+H] + 379.0, 381.0

[0249] The intermediates in the table below were prepared using the corresponding materials and reagents according to the process for preparing intermediate I-45. [Table 9]

[0250] Intermediate I-47 5-Bromo-1-methyl-3-((5-(morpholine-4-carbonyl)pyridin-2-yl)amino)pyridin-2(1H)-one [ka]

[0251] Step 1: (6-aminopyridin-3-yl)(morpholino)ketone A solution of 6-aminonicotinic acid (1.38 g, 10 mmol) and CDI (1.95 g, 12 mmol) in DMF (12 mL) was reacted under nitrogen at 70 °C for 1 hour and then stirred at room temperature for 1 hour. Morpholine (1.74 g, 20 mmol) was added to the mixture, and the mixture was reacted at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure in vacuo, and the resulting residue was purified by silica gel column chromatography (dichloromethane / methanol) to give the desired product (1.05 g, 51% yield). [M+H] + 208.1

[0252] Step 2: 5-Bromo-1-methyl-3-((5-(morpholine-4-carbonyl)pyridin-2-yl)amino)pyridin-2(1H)-one Intermediate I-47 was prepared according to the corresponding steps of intermediate I-3 using (6-aminopyridin-3-yl)(morpholino)ketone and the corresponding reagents. [M+H] + 393.0, 395.0

[0253] The intermediates in the table below were prepared using the corresponding materials and reagents according to the process for preparing intermediate I-47. [Table 10]

[0254] Intermediate I-52 4-chloro-2-(6-fluoro-1-oxopyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde [ka]

[0255] Step 1: 1-(2,2-diethoxyethyl)-7-fluoro-1H-indole-2-carboxylate ethyl To a solution of ethyl 7-fluoro-1H-indole-2-carboxylate (2.07 g, 10 mmol) in DMF (15 mL) was added 2-bromo-1,1-diethoxyethane (4.0 g, 20 mmol) and cesium carbonate (8.2 g, 25 mmol). The mixture was reacted at 110 °C for 16 hours, then cooled to room temperature, poured into water, and extracted with ethyl acetate. The organic phases were collected, combined, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (2.5 g, 77% yield). [M+H-EtOH] + 278.1

[0256] Step 2: 6-Fluoropyrazino[1,2-a]indol-1(2H)-one To a solution of ethyl 1-(2,2-diethoxyethyl)-7-fluoro-1H-indole-2-carboxylate (2.5 g, 7.7 mmol) in acetic acid (50 mL) was added ammonium acetate (12 g, 154 mmol). The mixture was reacted at 110 °C for 16 hours, then cooled to room temperature and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (2.5 g, 77% yield). [M+H] + 203.0

[0257] Step 3: 4-chloro-2-(6-fluoro-1-oxopyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde Intermediate I-52 was prepared according to the corresponding steps of intermediate I-1 using 6-fluoropyrazino[1,2-a]indol-1(2H)-one and the corresponding reagents. [M+H] + 342.0

[0258] The intermediates in the table below were prepared according to the preparation steps of intermediates I-52 and I-1 using the corresponding materials and reagents. [Table 11]

[0259] Intermediate I-58 4-chloro-2-(7,7-difluoro-1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde [ka]

[0260] Step 1: 7,7-Difluoro-8,9-dihydropyrazino[1,2-a]indole-1,6(2H,7H)-dione The target compound was prepared using ethyl 6,6-fluoro-7-oxo-4,5,6,7-tetrahydro-1H-indole-2-carboxylate according to the corresponding steps of intermediate I-1. [M+H] + 239.0

[0261] Step 2: 7,7-Difluoro-6-hydroxyl-6,7,8,9-tetrahydropyrazino[1,2-a]indol-1(2H)-one To a solution of 7,7-difluoro-8,9-dihydropyrazino[1,2-a]indole-1,6(2H,7H)-dione (500 mg, 2.1 mmol) in methanol (10 mL) was added sodium borohydride (239 mg, 6.3 mmol) under nitrogen at 0-5 °C, and the mixture was reacted at the same temperature for 10 min. Saturated aqueous ammonium chloride solution (5 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (10 mL × 2). The organic phases were collected, combined, and concentrated in vacuo under reduced pressure to give the desired product, which was used directly in the next step.

[0262] Step 3: 7,7-Difluoro-6,7,8,9-tetrahydropyrazino[1,2-a]indol-1(2H)-one To a solution of 7,7-difluoro-6-hydroxyl-6,7,8,9-tetrahydropyrazino[1,2-a]indol-1(2H)-one obtained in the previous step in trifluoroacetic acid (5 mL) was added triethylsilane (771 mg, 6.3 mmol) under nitrogen. The mixture was reacted at room temperature for 1 hour, concentrated under reduced pressure, and saturated aqueous sodium bicarbonate solution (10 mL) was added to the resulting residue. The mixture was extracted with dichloromethane (10 mL × 2). The organic phases were collected, combined, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (methanol / water) to give the desired product (120 mg, 26% yield over two steps). [M+H] + 225.0

[0263] Step 4: 4-chloro-2-(7,7-difluoro-1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde Intermediate I-58 was prepared according to the corresponding steps of intermediate I-1 using 7,7-difluoro-6,7,8,9-tetrahydropyrazino[1,2-a]indol-1(2H)-one and the corresponding reagents. [M+H] + 364.0

[0264] The intermediates in the table below were prepared using the corresponding materials and reagents according to the process for preparing intermediate I-58. [Table 12]

[0265] Intermediate I-61 4-chloro-2-(8,10-difluoro-1-oxopyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde [ka]

[0266] Step 1: Ethyl 3,5-difluoro-1H-indole-2-carboxylate To a solution of ethyl 5-fluoro-1H-indole-2-carboxylate (4.14 g, 20 mmol) in acetonitrile (100 mL) under nitrogen at 0-5 °C, Selectfluor (7.08 g, 20 mmol) was added, and the mixture was allowed to react at the same temperature for 16 hours. Saturated aqueous ammonium chloride solution (20 mL) and water (100 mL) were added, and the mixture was extracted with ethyl acetate (50 mL x 2). The organic phases were collected, combined, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether) to give the desired product (2.4 g, 53% yield). [M+H] + 226.0

[0267] Step 2: 4-chloro-2-(8,10-difluoro-1-oxopyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde Intermediate I-61 was prepared according to the corresponding steps of intermediate I-52 using ethyl 3,5-difluoro-1H-indole-2-carboxylate and the corresponding reagents. [M+H] + 360.0

[0268] Intermediate I-62 Acetic acid (2-(9-bromo-7,7-dimethyl-1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)-4-chloropyridin-3-yl)methyl ester [ka]

[0269] To a solution of acetic acid (4-chloro-2-(7,7-dimethyl-1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)pyridin-3-yl)methyl ester (800 mg, 2.07 mmol) in dichloromethane (30 mL) was added NBS (367 mg, 2.07 mmol) at 0 °C. The mixture was reacted at room temperature for 16 hours, quenched with saturated aqueous ammonium chloride solution, and extracted with ethyl acetate. The organic phases were collected and combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (800 mg, 83% yield). [M+H] + 464.0, 466.0

[0270] Intermediate I-63 4-chloro-2-(7,7-dimethyl-4-oxo-4,6,7,8-tetrahydro-3H-cyclopenta[4,5]pyrrolo[2,1-f][1,2,4]triazin-3-yl)nicotinaldehyde [ka]

[0271] Step 1: 1-amino-5,5-dimethyl-1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carboxylate ethyl To a solution of ethyl 5,5-dimethyl-1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carboxylate (5.0 g, 24.1 mmol) in DMF (30 mL) was added 60% sodium hydride (mineral oil dispersion) (1.06 g, 26.5 mmol) under nitrogen at 0-5 °C. The mixture was reacted at 0-5 °C for 30 min. O-(2,4-dinitrophenyl)hydroxylamine (5.3 g, 26.5 mmol) was then added and the mixture was reacted at room temperature for 3 h. The mixture was concentrated under reduced pressure in vacuo, and the resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (4.3 g, 75% yield). [M+H] + 223.0

[0272] Step 2: 7,7-dimethyl-7,8-dihydro-3H-cyclopenta[4,5]pyrrolo[2,1-f][1,2,4]triazin-4(6H)-one To a mixture of ethyl 1-amino-5,5-dimethyl-1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carboxylate (4.3 g, 19.3 mmol) and formamide (30 mL) under nitrogen, ammonium acetate (7.4 g, 96.5 mmol) was added. The mixture was reacted at 140 °C for 16 hours and then cooled to room temperature. The mixture was filtered, and the filter cake was collected and washed with methanol to give the desired product (3.1 g, 80% yield). [M+H] + 204.0

[0273] Step 3: 4-chloro-2-(7,7-dimethyl-4-oxo-4,6,7,8-tetrahydro-3H-cyclopenta[4,5]pyrrolo[2,1-f][1,2,4]triazin-3-yl)nicotinaldehyde Intermediate I-63 was prepared according to the corresponding steps of intermediate I-1 using 7,7-dimethyl-7,8-dihydro-3H-cyclopenta[4,5]pyrrolo[2,1-f][1,2,4]triazin-4(6H)-one and the corresponding reagents. [M+H] + 343.1

[0274] The intermediates in the table below were prepared using the corresponding materials and reagents according to the process for preparing intermediate I-63. [Table 13]

[0275] Intermediate I-68 (8-((tert-butoxycarbonyl)(1-ethyl-1H-1,2,3-triazol-4-yl)amino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)boronic acid [ka]

[0276] Intermediate I-68 was prepared using intermediate I-21 and the corresponding reagents according to step 1 of intermediate I-74 and step 6 of intermediate I-2. [M+H] + 374.1

[0277] The intermediates in the table below were prepared using the corresponding materials and reagents according to the process for preparing intermediate I-68. [Table 14]

[0278] Intermediate I-74 4-chloro-2-(7-methyl-1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde [ka]

[0279] Step 1: 7-oxo-4,5,6,7-tetrahydro-1H-indole-1,2-dicarboxylic acid 1-(tert-butyl) ester 2-ethyl ester To a solution of ethyl 7-oxo-4,5,6,7-tetrahydro-1H-indole-2-carboxylate (2.07 g, 10 mmol) and di-tert-butyl dicarbonate (7.51 g, 30 mmol) in tetrahydrofuran (30 mL) was added 4-dimethylaminopyridine (0.12 g, 1.0 mmol). The mixture was reacted at room temperature for 16 hours. The mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (3.07 g, 100% yield). [M+Na] + 330.3

[0280] Step 2: 6-methyl-7-oxo-4,5,6,7-tetrahydro-1H-indole-2-carboxylate ethyl To a solution of 7-oxo-4,5,6,7-tetrahydro-1H-indole-1,2-dicarboxylic acid 1-(tert-butyl)ester 2-ethyl ester (3.07 g, 10 mmol) in tetrahydrofuran (50 mL) was added dropwise 1M HMDSLi / tetrahydrofuran solution (24 mL, 24 mmol) at -78 °C under nitrogen, and the mixture was allowed to warm to 0 °C and react for 30 minutes. To the reaction mixture was added iodomethane (3.41 g, 24 mmol) dropwise at -78 °C, and the mixture was allowed to warm to room temperature and react for 4 hours. The reaction mixture was cooled to 0 °C and quenched by the addition of saturated aqueous ammonium chloride solution, followed by extraction with ethyl acetate (50 mL × 2). The organic phases were collected, combined, dried over anhydrous sodium sulfate, and concentrated in vacuo under reduced pressure. A solution of the resulting residue in trifluoroacetic acid (10 mL) was stirred at room temperature under nitrogen for 30 minutes, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (water / methanol) to give the desired product (1.19 g, 54% yield). [M+H] + 221.1

[0281] Step 3: ethyl 6-methyl-4,5,6,7-tetrahydro-1H-indole-2-carboxylate To a solution of ethyl 6-methyl-7-oxo-4,5,6,7-tetrahydro-1H-indole-2-carboxylate (1.19 g, 5.38 mmol) in trifluoroacetic acid (10 mL) was added triethylsilane (2.5 mL) under nitrogen. The mixture was reacted at room temperature for 16 hours, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (methanol / water) to give the desired product (980 mg, 88% yield). [M+H] + 208.1

[0282] Step 4: 4-chloro-2-(7-methyl-1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde Intermediate I-74 was prepared according to the corresponding steps of intermediate I-1 using ethyl 6-methyl-4,5,6,7-tetrahydro-1H-indole-2-carboxylate and the corresponding reagents. [M+H] + 342.0

[0283] Intermediate I-75 4-chloro-2-(7,7-dimethyl-1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-d][1,2,4]triazin-2-yl)nicotinaldehyde [ka]

[0284] Step 1: 5,5-dimethyl-1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carbohydrazide A solution of ethyl 5,5-dimethyl-1,4,5,6-tetrahydrocyclopentadieno[b]pyrrolo-2-carboxylate (2.49 g, 12 mmol) and aqueous hydrazine hydrate (20 mL, 36 mmol) in ethanol (8 mL) was reacted in a microwave reactor at 150 °C for 2 hours and then cooled to room temperature. The reaction mixture was filtered, washed with water, and the filter cake was collected and dried under reduced pressure to give the desired product (2.09 g, 90% yield). [M+H] + 194.1

[0285] Step 2: 7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-d][1,2,4]triazin-1(6H)-one A solution of 5,5-dimethyl-1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carbohydrazide (2.09 g, 10 mmol) and triethyl orthoformate (3.11 g, 21.0 mmol) in DMF (8 mL) was reacted under nitrogen at 160 °C for 16 hours. The reaction mixture was cooled to room temperature, filtered, washed with methanol, and the filter cake was collected and dried under reduced pressure to give the desired product (1.65 g, 77% yield). [M+H] + 204.1

[0286] Step 3: 4-chloro-2-(7,7-dimethyl-1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-d][1,2,4]triazin-2-yl)nicotinaldehyde Intermediate I-75 was prepared according to the corresponding steps of intermediate I-1 using 7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-d][1,2,4]triazin-1(6H)-one and the corresponding reagents. [M+H] + 343.1

[0287] The intermediates in the table below were prepared using the corresponding materials and reagents according to the process for preparing intermediate I-75. [Table 15]

[0288] Intermediate I-83 2-(4-chloro-3-(fluoromethyl)pyridin-2-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one [ka]

[0289] Step 1: (2-Bromo-4-chloropyridin-3-yl)methanol To a solution of 2-bromo-4-chloronicotinaldehyde (2.7 g, 12.2 mmol) in dichloromethane (30 mL) and methanol (10 mL) was added sodium borohydride (325 mg, 8.6 mmol) at 0-5 °C and stirred at the same temperature for 30 minutes. The reaction mixture was quenched by adding water, extracted with dichloromethane, and the organic phase was collected and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (2.5 g, 92% yield).

[0290] Step 2: (2-Bromo-4-chloropyridin-3-yl)methyl methanesulfonate To a solution of (2-bromo-4-chloropyridin-3-yl)methanol (1.0 g, 4.5 mmol) in dichloromethane (30 mL) was added methanesulfonyl chloride (573 mg, 5.0 mmol) at 0-5°C and stirred at the same temperature for 30 minutes. The reaction was quenched by adding water, extracted with dichloromethane, and the organic phase was collected and dried over anhydrous sodium sulfate. The reaction was filtered, and the filtrate was collected and concentrated under reduced pressure to give the desired product (1.35 g, 100% yield), which was used directly in the next step. [M+H] + 299.9, 301.9

[0291] Step 3: 2-Bromo-4-chloro-3-(fluoromethyl)pyridine To a solution of methyl (2-bromo-4-chloropyridin-3-yl)methanesulfonate (1.35 g, 5.0 mmol) in dry tetrahydrofuran (20 mL), 1 M tetrabutylammonium fluoride / tetrahydrofuran (5.0 mL, 5.0 mmol) was added and stirred at 65° C. for 2 hours. The reaction mixture was quenched by adding water, extracted with ethyl acetate, and the organic phase was collected and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (700 mg, 62% yield). [M+H] + 223.9, 225.9

[0292] 2-(4-chloro-3-(fluoromethyl)pyridin-2-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one was prepared using the corresponding materials and reagents according to step 8 of preparation of intermediate I-1. [M+H] + 346.1

[0293] Intermediate I-91 4-chloro-2-(10-fluoro-1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde [ka]

[0294] Step 1: ethyl 3-fluoro-1H-indole-2-carboxylate To a solution of ethyl 1H-indole-2-carboxylate (35.0 g, 185 mmol) in acetonitrile (1.75 L), 1-chloromethyl-4-fluoro-1,4-diazobicyclo[2.2.2]octanedi(tetrafluoroborate) (65.5 g, 1185 mmol) was added and stirred at room temperature for 45 minutes. The reaction was quenched by the addition of saturated brine, and the organic phase was collected and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the desired product (18.0 g, 47% yield).

[0295] Step 2: 3-fluoro-4,5,6,7-tetrahydro-1H-indole-2-carboxylate ethyl To a solution of ethyl 3-fluoro-1H-indole-2-carboxylate (10.5 g, 50.7 mmol) in acetic acid (210 mL) was added platinum dioxide (1.57 g, 1185 mmol). Hydrogen was introduced into the reaction mixture while stirring at room temperature, and the mixture was allowed to react for 8 hours. The reaction mixture was filtered, the filtrate was collected, and concentrated under reduced pressure in vacuo. The resulting residue was diluted with water and neutralized to pH 8 with aqueous ammonia. The reaction mixture was extracted with ethyl acetate, and the organic phase was collected and concentrated under reduced pressure in vacuo to obtain the desired product (10.5 g, 98% yield). [M+H] + 212.0

[0296] 4-Chloro-2-(10-fluoro-1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde was prepared using the corresponding materials and reagents according to steps 5 to 8 of the preparation of intermediate I-1. [M+H] + 346.0

[0297] Intermediate I-92 (RS)-2-(4-chloro-3-pyridinecarboxaldehyde-2-yl)-7,7-dimethyl-1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-6-yl acetate [ka]

[0298] To a solution of intermediate I-55 (1.0 g, 3.0 mmol) in 1,4-dioxane (15 mL), lead acetate (2.0 g, 4.5 mmol) was added, and the reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure in vacuo, and the resulting residue was diluted with water and neutralized to pH 8 with aqueous ammonia. The reaction mixture was extracted with ethyl acetate, and the organic layer was collected and concentrated under reduced pressure in vacuo. The resulting residue was purified by silica gel column chromatography (methanol / water) to give the desired product (600 mg, 50% yield). [M+H] + 400.0

[0299] Intermediate I-99 Methyl (5-bromo-2'-(7,7-dimethyl-1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-3'-yl)acetate [ka]

[0300] A solution of 3-bromo-5-iodo-1-methylpyridin-2(1H)-one (626 mg, 2.0 mmol), Intermediate I-4 (790 mg, 2.0 mmol), Pd(dppf)Cl2CH2Cl2 (162 mg, 0.20 mmol), Xphos (94 mg, 0.20 mmol), and potassium phosphate (848 mg, 4.0 mmol) in acetonitrile (40 mL) and water (2 mL) was reacted under nitrogen at 30 °C for 3 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (methanol / water) to give the desired product. [M+H] + 537.1, 539.1

[0301] Intermediate I-107 N-(5-bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)propanamide [ka]

[0302] To a solution of 3-amino-5-bromo-1-methylpyridin-2(1H)-one (609 mg, 3.0 mmol) and propionyl chloride (416 mg, 4.5 mmol) in dichloromethane (20 mL), triethylamine (455 mg, 4.5 mmol) was added dropwise under nitrogen and the mixture was allowed to react at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure in vacuo, and the resulting residue was purified by silica gel column chromatography (methanol / dichloromethane) to give the desired product. [M+H] + 259.0, 261.0

[0303] The intermediates in the table below were prepared using the corresponding materials and reagents according to the process for preparing intermediate I-107. [Table 16]

[0304] compound 1 2-(5-((5-(ethyl(2-methoxyethyl)amino)pyridin-2-yl)amino)-3'-(hydroxymethyl)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one [ka]

[0305] Step 1: Acetic acid (2'-(7,7-dimethyl-1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)-5-((5-(ethyl(2-methoxyethyl)amino)pyridin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-3'-yl)methyl ester To a solution of intermediate I-3 (126 mg, 0.33 mmol) and intermediate I-4 (134 mg, 0.33 mmol) in 1,4-dioxane (5.0 mL) and water (0.5 mL) under nitrogen, Xphos (31 mg, 0.066 mmol), Pd(dppf)Cl2CH2Cl2 (27 mg, 0.033 mmol), and potassium phosphate trihydrate (264 mg, 0.99 mmol) were added. The mixture was reacted at 100 °C for 4 hours and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure in vacuo, and the resulting residue was purified by silica gel column chromatography (methanol / water) to give the desired product. [M+H] + 652.3

[0306] Step 2: 2-(5-((5-(ethyl(2-methoxyethyl)amino)pyridin-2-yl)amino)-3'-(hydroxymethyl)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one To a solution of acetic acid (2'-(7,7-dimethyl-1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)-5-((5-(ethyl(2-methoxyethyl)amino)pyridin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-3'-yl)methyl ester obtained in Step 1 in methanol (5 mL), potassium carbonate (137 mg, 0.99 mmol) was added and the mixture was allowed to react at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure in vacuo, and the resulting residue was purified by thin-layer chromatography (methanol / dichloromethane = 1 / 20) to give the desired product (100 mg, 50% yield for two steps). [M+H] + 610.3. 1H NMR (400 MHz, CD3OD): δ 8.57-8.51 (m, 1H), 8.42-8.37 (m, 1H), 7.77-7.74 (m, 1H), 7.60-7.57 (m, 1H), 7.48-7.45 (m, 1H), 7.23-7.19 (m, 2H), 7.01-6.97 (m, 1H), 6.95-6.91 (m, 1H), 6.80-6.76 (m, 1H), 4.61-4.57 (m, 1H), 4.50-4.45 (m, 1H), 3.69 (s, 3H), 3.53-3.50 (m, 2H), 3.44-3.40 (m, 2H), 3.39- 3.34 (m, 2H), 3.32 (s, 3H), 2.78-2.69 (m, 2H), 2.66-2.57 (m, 2H), 1.30-1.27 (m, 6H), 1.13-1.08 (m, 3H)

[0307] The compounds in the table below were prepared according to the process for preparing Compound 1 using the corresponding intermediates and reagents. [Table 17-1] [Table 17-2] [Table 17-3] [Table 17-4] [Table 17-5] [Table 17-6] [Table 17-7] [Table 17-8] [Table 17-9] Table 17-10 Table 17-11 Table 17-12 Table 17-13 Table 17-14 Table 17-15 Table 17-16 Table 17-17 Table 17-18 Table 17-19 Table 17-20 Table 17-21 Table 17-22 Table 17-23 Table 17-24 Table 17-25 Table 17-26 Table 17-27 Table 17-28 Table 17-29 Table 17-30 Table 17-31 Table 17-32 Table 17-33 Table 17-34

[0308] compound 2 2-(5-((5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-3'-(hydroxymethyl)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one

change

[0309] Step 1: 5-((5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-1-methyl-6-oxo-2'-(1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)-1,6-dihydro-[3,4'-bispyridine]-3'-carbaldehyde (5-((5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)boronic acid (171 mg, 0.41 mmol) and 4-chloro-2-(1-oxo-1,6, To a solution of 7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)nicotinaldehyde (100 mg, 0.32 mmol) under nitrogen, Xphos (20 mg, 0.03 mmol), Pd(dppf)Cl2CH2Cl2 (25 mg, 0.03 mmol), and cesium carbonate (260 mg, 0.8 mmol) were added. The mixture was reacted at 90 °C for 4 hours and then cooled to room temperature. Water (30 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL x 2). The organic phases were collected, combined, and concentrated under reduced pressure in vacuo to give the desired product (180 mg, 68% yield), which was used directly in the next step. [M+H] + 647.3

[0310] Step 2: 2-(5-((5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-3'-(hydroxymethyl)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one To a solution of 5-((5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-1-methyl-6-oxo-2'-(1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)-1,6-dihydro-[3,4'-bispyridine]-3'-carbaldehyde (180 mg, 0.28 mmol) in methanol (4 mL) and dichloromethane (10 mL) was added sodium borohydride (16 mg, 0.42 mmol) under nitrogen at 0-5 °C and the reaction was allowed to proceed at room temperature for 15 min. The reaction mixture was quenched by adding water (0.5 mL) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol / water) and then by thin-layer chromatography (methanol / dichloromethane = 1 / 20) to give the desired product (80 mg, 44% yield). [M+H] + 649.3. 1H NMR (400 MHz, CD3OD): δ 8.73 (d, J = 2.2 Hz, 1H), 8.54 (d, J = 5.1 Hz, 1H), 8.00 (d, J = 2.6 Hz, 1H), 7.59-7.46 (m, 3H), 7.24 (d, J = 5.9 Hz, 1H), 7.03 (d, J = 8.8 Hz, 1H), 6.94 (s, 1H), 6.79 (d, J = 5.9 Hz, 1H), 4.77-4.55 (m, 5H), 4.49-4.47 (m, 1H), 3.81-3.64 (m, 4H), 3.20-3.18 (m, 1H), 2.91-2.87 (m, 3H), 2.77-2.73 (m, 4H), 2.62-2.42 (m, 3H), 1.94-1.92 (m, 1H), 0.89-0.86 (m, 6H)

[0311] The compounds in the table below were prepared according to the process for preparing Compound 2 using the corresponding intermediates and reagents. [Table 18-1] [Table 18-2] [Table 18-3] [Table 18-4] [Table 18-5] [Table 18-6] [Table 18-7] [Table 18-8] [Table 18-9] [Table 18-10] [Table 18-11] [Table 18-12] [Table 18-13] [Table 18-14] [Table 18-15] [Table 18-16] [Table 18-17] [Table 18-18] [Table 18-19] [Table 18-20]

[0312] compound 68 2-(5-((5-acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-3'-(hydroxymethyl)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one [ka]

[0313] Compound 68 was prepared using compound 68a and the corresponding reagents according to step 2 of intermediate I-4 and step 2 of compound 2 [M+H] + 595.3 1H NMR (400 MHz, CD3OD): δ 8.55-8.50 (m, 1H), 8.07-8.01 (m, 1H), 7.58-7.54 (m, 1H), 7.43 (s, 1H), 7.24-7.19 (m, 1H), 6.93 (s, 1H), 6.81-6.74 (m, 1H), 5.98-5.91 (m, 1H), 4.77-4.70 (m, 2H), 4.62-4.52 (m, 1H), 4.51-4.40 (m, 1H), 4.10-4.07 (m, 1H), 4.06-3.93 (m, 3H), 3.68 (s, 3H), 2.78-2.70 (m, 2H), 2.64-2.59 (m, 2H), 2.21-2.16 (m, 3H), 1.30-1.27 (m, 6H)

[0314] compound 69 2-(3'-(hydroxymethyl)-1-methyl-5-((5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one [ka]

[0315] Compound 69 was prepared using compound 68a and the corresponding reagents according to step 3 of intermediate I-2 and step 2 of compound 2. [M+H] + 576.2 1 H NMR (400 MHz, CD3OD): δ 8.57-8.50 (m, 1H), 8.04-7.96 (m, 1H), 7.59-7.55 (m, 1H), 7.46-7.41 (m, 1H), 7.24-7.19 (m, 1H), 6.93 (s, 1H), 6.81-6.73 (m, 1H), 5.86 (s, 1H), 4.60-4.53 (m, 1H), 4.50-4.41 (m, 1H), 4.09-3.97 (m, 2H), 3.68 (s, 3H), 3.64-3.58 (m, 2H), 2.98-2.88 (m, 2H), 2.78-2.69 (m, 2H), 2.66-2.58 (m, 2H), 2.46 (s, 3H), 1.30-1.27 (m, 6H)

[0316] compound 70 2-(3'-(hydroxymethyl)-5-((5-(2-methoxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one [ka]

[0317] Compound 70 was prepared using compound 68a and the corresponding reagents according to step 2 of intermediate I-10 and compound 2. [M+H] + 611.3 1 H NMR (400 MHz, CD3OD): δ 8.51 (d, J = 5.1 Hz, 1H), 7.96 (d, J = 2.2 Hz, 1H), 7.54 (d, J = 5.1 Hz, 1H), 7.41 (d, J = 2.2 Hz, 1H), 7.19 (d, J = 5.9 Hz, 1H), 6.92 (s, 1H), 6.76 (d, J = 5.9 Hz, 1H), 5.84 (s, 1H), 4.55 (d, J = 12.0 Hz, 1H), 4.44 (d, J = 12.0 Hz, 1H), 4.03-3.98 (m, 2H), 3.71-3.68 (m, 2H), 3.66 (s, 3H), 3.59-3.55 (m, 2H), 3.33 (s, 3H), 3.03-2.97 (m, 2H), 2.78-2.73 (m, 2H), 2.73-2.70 (m, 2H), 2.62-2.58 (m, 2H), 1.29-1.26 (m, 6H)

[0318] compound 96 (S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methylpiperazin)-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one [ka]

[0319] A solution of intermediate I-168 (108 mg, 0.37 mmol), intermediate I-99 (200 mg, 0.37 mmol), Pd(dba) (37 mg, 0.04 mmol), Xantphos (23 mg, 0.04 mmol), and cesium carbonate (241 mg, 0.74 mmol) in 1,4-dioxane (20 mL) was reacted under nitrogen at 100 °C for 12 h.

[0320] The reaction mixture was concentrated under reduced pressure in vacuo, potassium carbonate (276 mg, 5.0 mmol) and methanol (10 mL) were added, and the mixture was stirred at room temperature for 15 minutes. The reaction mixture was concentrated under reduced pressure in vacuo, and the resulting residue was purified by silica gel column chromatography (methanol / water) to give a yellow solid (120 mg, 42% yield over two steps). [M+H] + 707.4

[0321] To a solution of the yellow solid in methanol (2 mL) was added concentrated hydrochloric acid and stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure in vacuo, and the resulting residue was purified by silica gel column chromatography (methanol / dichloromethane) to give compound 96 (50 mg, 49% yield). [M+H] + 607.3 1 H NMR (400 MHz, CD3OD) δ 8.67 (d, J = 1.8 Hz, 1H), 8.53 (d, J = 5.1 Hz, 1H), 7.94 (d, J = 2.6 Hz, 1H), 7.56-7.52 (m, 2H), 7.44-7.42 (m, 1H), 7.20 (d, J = 5.9 Hz, 1H), 7.01 (d, J = 8.9 Hz, 1H), 6.92 (s, 1H), 6.77 (d, J = 5.9 Hz, 1H), 4.55-4.41 (m, 2H), 3.68 (s, 3H), 3.38-3.32 (m, 1H), 3.07-2.86 (m, 5H), 2.77-2.55 (m, 5H), 1.29-1.27 (m, 6H), 0.90 (d, J = 6.3 Hz, 3H)

[0322] The compounds in the table below were prepared using intermediate I-99 and the corresponding amine intermediates and reagents according to the process for preparing compound 96. [Table 19-1] [Table 19-2] [Table 19-3] [Table 19-4] [Table 19-5] [Table 19-6]

[0323] compound 98 2-(5-amino-3'-(hydroxymethyl)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one [ka]

[0324] A solution of intermediate I-148 (220 mg, 0.60 mmol), intermediate I-4 (237 mg, 0.60 mmol), Pd(dppf)Cl2CHCl2 (49 mg, 0.06 mmol), Xphos (57 mg, 0.12 mmol), and potassium phosphate trihydrate (479 mg, 1.80 mmol) in 1,4-dioxane (10 mL) and water (1 mL) was reacted under nitrogen at 100 °C for 4 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (methanol / water) to give a yellow solid (268 mg, 70% yield). [M+H] + 638.3

[0325] To a solution of the yellow solid in methanol (5 mL) was added trifluoroacetic acid (2 mL) and stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure in vacuo, and potassium carbonate (174 mg, 1.26 mmol) and methanol (5 mL) were added to the resulting residue, and the mixture was stirred at room temperature for 15 minutes. The reaction mixture was concentrated under reduced pressure in vacuo and purified by silica gel column chromatography (methanol / water) to give compound 98 (48 mg, 26% yield). [M+H] + 432.2 1 H NMR (400 MHz, CD3OD) δ 8.55-8.48 (m, 1H), 7.52-7.48 (m, 1H), 7.36-7.30 (m, 1H), 7.24-7.20 (m, 1H), 6.95-6.91 (m, 1H), 6.91-6.86 (m, 1H), 6.78-6.72 (m, 1H), 4.55-4.49 (m, 1H), 4.47-4.41 (m, 1H), 3.64 (s, 3H), 2.79-2.68 (m, 2H), 2.66-2.56 (m, 2H), 1.30-1.27 (m, 6H)

[0326] Compounds 119 and 120 2-(3'-(hydroxymethyl)-5-((5-(2-methoxyethyl)-4-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amido)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-d][1,2,4]triazin-1(6H)-one Optically pure enantiomer [ka]

[0327] (RS)-2-(3'-(hydroxymethyl)-5-((5-(2-methoxyethyl)-4-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amido)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-d][1,2,4]triazin-1(6H)-one (compound 110, 110 mg) was separated by chiral HPLC into a pair of optically pure enantiomers, (R)-2-(3'-(hydroxymethyl)-5-((5-(2-methoxyethyl)-4-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amido)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-d][1,2,4]triazin-1(6H)-one. (S)-2-(3'-(hydroxymethyl)-5-((5-(2-methoxyethyl))-4-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amido)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-d][1,2,4]triazin-1(6H)-one and (S)-2-(3'-(hydroxymethyl)-5-((5-(2-methoxyethyl))-4-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amido)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-d][1,2,4]triazin-1(6H)-one were obtained. Chiral HPLC separation conditions: Column: AD-H (inner diameter 0.46 cm × length 15 cm); Mobile phase: CO2 / ethanol = 60:40; Flow rate: 2.5 mL; Detector wavelength: UV 254 nm).

[0328] The compound obtained by removing the solvent from the first eluate under the above conditions was named Compound 119 (40 mg, yield 36%), ee% = 100%, MS (m / z): 626.3 [M+H] + . 1H NMR (400 MHz, CD3OD) δ 8.57-8.51 (m, 1H), 8.43-8.38 (m, 1H), 7.97-7.91 (m, 1H), 7.60-7.57 (m, 1H), 7.41-7.38 (m, 1H), 7.07-7.01 (m, 1H), 5.93-5.89 (m, 1H), 4.60-4.51 (m, 2H), 4.04-3.91 (m, 2H), 3.83-3.76 (m, 1H), 3.68 (s, 3H), 3.60-3.53 (m, 2H), 3.40-3.35 (m, 1H), 2.99-2.87 (m, 2H), 2.86-2.81 (m, 2H), 2.73-2.62 (m, 3H), 1.43-1.39 (m, 3H), 1.31 (s, 6H).

[0329] The compound obtained by removing the solvent from the second eluate obtained under the above conditions was named Compound 120 (42 mg, yield 38%), ee% = 99.68%, MS (m / z): 626.3 [M+H] + . 1 H NMR (400 MHz, CD3OD) δ 8.56-8.52 (m, 1H), 8.42-8.38 (m, 1H), 7.95-7.92 (m, 1H), 7.60-7.57 (m, 1H), 7.41-7.38 (m, 1H), 7.06-7.02 (m, 1H), 5.93-5.89 (m, 1H), 4.60-4.49 (m, 2H), 4.03-3.93 (m, 2H), 3.82-3.76 (m, 1H), 3.68 (s, 3H), 3.59-3.52 (m, 2H), 3.40-3.34 (m, 1H), 2.99-2.87 (m, 2H), 2.86-2.81 (s, 2H), 2.73-2.62 (m, 3H), 1.43-1.39 (m, 3H), 1.30 (s, 6H).

[0330] [Table 20-1] [Table 20-2] [Table 20-3]

[0331] The optically pure enantiomers / diastereomers in the table above were obtained by chiral HPLC separation. The separation conditions were: flow rate: 2.5 mL, detector wavelength: UV 254 nm; the chiral column and mobile phase used, as well as the ee (de) values ​​of the obtained compounds, are shown in the table below. (For each pair of enantiomeric compounds, the first numbered compound is the compound obtained after removing the solvent from the first eluent obtained from the chiral column, and the second numbered compound is the compound obtained after removing the solvent from the second eluent obtained from the chiral column.) [Table 21]

[0332] compound 135 2-((2'-(7,7-dimethyl-1-oxo-1,6,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)-3'-(hydroxymethyl)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bispyridin]-5-yl)amino)-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-nitrile [ka]

[0333] To a solution of compound 135a (250 mg, 0.36 mmol) in methanol (5 mL) was added concentrated hydrochloric acid (2 mL) and stirred at 50° C. for 30 minutes. The reaction mixture was concentrated under reduced pressure in vacuo, and acetonitrile (20 mL) was added. Potassium carbonate (150 mg, 1.08 mmol) and cyanogen bromide (45 mg, 0.43 mmol) were added to the reaction mixture, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, extracted with dichloromethane, and the organic phase was collected and concentrated under reduced pressure in vacuo. The resulting residue was purified by silica gel column chromatography (methanol / water) to give compound 135 (60 mg, 29% yield). [M+H] + 578.3 1H NMR (400 MHz, CD3OD) δ 8.49 (d, J = 5.1 Hz, 1H), 8.05 (d, J = 1.8 Hz, 1H), 7.51 (d, J = 7.2 Hz, 1H), 7.41 (d, J = 1.8 Hz, 1H), 7.18 (d, J = 5.9 Hz, 1H), 6.90 (s, 1H), 6.75 (d, J = 5.9 Hz, 1H), 5.89 (s, 1H), 4.57-4.37 (m, 4H), 4.10 (t, J = 5.3 Hz, 2H), 3.77-3.58 (m, 5H), 2.78-2.53 (m, 4H), 1.28-1.24 (m, 6H)

[0334] The compounds in the table below were prepared according to the process for preparing compound 135 using the corresponding intermediates and reagents. [Table 22]

[0335] compound 223 (S)-2-(3'-(methoxymethyl)-1-methyl-5-(methyl(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bispyridin]-2'-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one [ka]

[0336] To a solution of compound 19 (100 mg, 0.15 mmol) in DMF (10 mL) was added 60% NaH (38 mg, 0.95 mmol) at 0-5°C and stirred at the same temperature for 30 min. Iodomethane (123 mg, 0.87 mmol) was added, and the reaction mixture was allowed to react at room temperature for 30 min. The reaction mixture was poured into water, extracted with ethyl acetate, and the organic phase was collected and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (methanol / water) to give compound 223 (18 mg, 7% yield). [M+H] + 691.2. 1H NMR (400 MHz, CD3OD) δ 8.61-8.54 (m, 1H), 7.96-7.89 (m, 1H), 7.85-7.79 (m, 1H), 7.78-7.71 (m, 1H), 7.62-7.56 (m, 1H), 7.47-7.39 (m, 1H), 7.24-7.17 (m, 1H), 6.91 (s, 1H), 6.77-6.66 (m, 2H), 4.72-4.67 (m, 2H), 4.64-4.58 (m, 3H), 4.42-4.35 (m, 1H), 4.27-4.19 (m, 1H), 3.68 (s, 3H), 3.54-3.47 (m, 1H), 3.34 (s, 3H), 3.14 (s, 3H), 3.07-2.96 (m, 2H), 2.78-2.71 (m, 2H), 2.67-2.59 (m, 3H), 2.59-2.51 (m, 1H), 2.43-2.34 (m, 1H), 2.14-2.05 (m, 1H), 1.29 (s, 6H), 0.93-0.90 (m, 3H)

[0337] compound 228 [ka]

[0338] To a solution of compound 19 (200 mg, 0.30 mmol) in DMF (10 mL) was added 60% NaH (38 mg, 0.95 mmol) at 0-5°C and stirred at the same temperature for 30 min. Iodomethane (111 mg, 0.78 mmol) was added, and the reaction mixture was allowed to react at room temperature for 30 min. The reaction mixture was poured into water, extracted with ethyl acetate, and the organic phase was collected and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (methanol / water) to give compound 228 (45 mg, 9% yield). [M+H] + 677.3. 1H NMR (400 MHz, CD3OD) δ 8.74-8.68 (m, 1H), 8.55-8.49 (m, 1H), 7.98-7.89 (m, 1H), 7.57-7.51 (m, 1H), 7.43-7.39 (m, 1H), 7.37-7.32 (m, 1H), 7.22-7.14 (m, 1H), 7.01-6.95 (m, 1H), 6.91 (s, 1H), 6.79-6.71 (m, 1H), 4.70-4.65 (m, 2H), 4.63-4.55 (m, 2H), 4.42-4.34 (m, 1H), 4.28-4.21 (m, 1H), 3.68 (s, 3H), 3.51-3.44 (m, 2H), 3.11 (s, 3H), 3.09-2.98 (m, 2H), 2.76-2.69 (m, 2H), 2.63-2.58 (m, 2H), 2.56-2.50 (m, 1H), 2.49-2.38 (m, 2H), 2.23-2.15 (m, 1H), 1.27 (s, 6H), 0.97-0.91 (m, 3H)

[0339] Example 2: Biochemical BTK Measurement 1. Reagents and Materials BTK recombinant protein: Invitrogen, catalog number PV3363; Z'-LYTE® Kinase Test Kit-Tyrosine 1 Peptide: Invitrogen, catalog number PV3190; 384-well low flange black flat bottom polystyrene NBS microplate, no lid, nonsterile: Corning, catalog number 3575; 96-well polystyrene conical-bottom MicroWell™ plates sealed with lids: Thermo Scientific™ Nunc™, catalog number 277143; Vision multimode plate reader: PerkinElmer; Mixmate® Shaker: Eppendorf; TS-2102 Shaking Incubator: TENSUC

[0340] 2. Method The Z'-LYTE® biochemical assay employs a fluorescence resonance energy transfer (FRET)-based coupled enzyme format, based on the differential sensitivity of phosphorylated and non-phosphorylated peptides to proteolytic cleavage. Both ends of a short peptide substrate are labeled with two fluorescent groups, forming a FRET pair. In the primary reaction (kinase reaction), a kinase transfers the γ-phosphate of ATP to a single serine or threonine residue on the short peptide substrate. In the secondary reaction (unfolding reaction), the unphosphorylated short peptide is recognized and cleaved by a site-specific protease (unfolding reagent). Phosphorylated short peptides can withstand such cleavage. While cleavage of the short peptide can destroy the donor (e.g., coumarin) and acceptor fluorophores (e.g., fluorescein) of the short peptide, the phosphorylated short peptide maintains FRET. The ratio is calculated as follows: The ratio of the emission signals generated by the donor fluorophore (after excitation at 400 nm) to those emitted by the acceptor is calculated. The emission signal ratio = coumarin emission (445 nm) / fluorescein emission (520 nm). When the FRET short peptide is phosphorylated (e.g., in the absence of a kinase inhibitor), the emission ratio remains at a low level. When the FRET short peptide is not phosphorylated (e.g., in the presence of a kinase inhibitor), the emission ratio becomes higher. In this way, the inhibitory effects of various compound inhibitors on BTK kinase activity can be distinguished.

[0341] The experiment was performed according to the instructions for the Z'-LYTE® Kinase Test Kit - Tyrosine 1 Peptide. Reagent preparation: 1.33x kinase buffer: 5x kinase buffer was diluted with water to make 1.33x kinase buffer; enzyme solution: kinase was dissolved in 1.33x kinase buffer to a final working concentration of 3.32 nM; short peptide solution: short peptide stock solution (1 mM in DMSO) was dissolved in 1.33x kinase buffer to a final working concentration of 2 μM; Z'-LYTE For the short peptide solution phosphorylated at Tyr01, 0.6 μl of stock solution (1 mM dissolved in DMSO) was dissolved in 149.4 μl of 1.33× kinase buffer; ATP solution: ATP stock solution (10 mM in water) was dissolved in 1.33× kinase buffer to a final working concentration of 32 μM; Chromogen solution: Chromogen solution B was dissolved in chromogen buffer to a final working concentration of 1× chromogen solution; 4× compound preparation: Compounds were diluted in a 3-fold concentration gradient to obtain eight concentration points in 4% DMSO containing different concentrations of compounds, with final working concentrations of 3000 nM, 1000 nM, 333.33 nM, 111.11 nM, 37.04 nM, 12.35 nM, 4.12 nM, and 1.37 nM.

[0342] Experimental Procedure: Three control groups, each with eight replicate wells, were used in the experiment: C1 (100% inhibition group without ATP), C2 (0% inhibition group with ATP), and C3 (100% phosphorylation group). 2.5 μl of serially diluted compound was added to each well of a 384-well plate in duplicate, and 4% DMSO solution was added to wells C1, C2, and C3. 2.5 μl of BTK enzyme solution was then added to each of the remaining wells except for well C3, and the plates were incubated at 4°C for 30 minutes. 2.5 μl of short peptide solution was then added to each well except for well C3, to which 5 μl of phosphorylated short peptide solution was added. 2.5 μl of 1.33x kinase buffer was added to each of wells C1 and C3, and 2.5 μl of ATP solution was added to each of the remaining wells. The wells were centrifuged transiently, and the plate was shaken at 1000 rpm for 30 seconds for a transient centrifugation. The 384-well plate was placed in a shaking incubator protected from light and incubated at room temperature for 1 hour. After the enzyme reaction was completed, 5 μl of developer solution was added to each well and centrifuged transiently. The plate was shaken at 1000 rpm for 30 seconds for a transient centrifugation. The 384-well plate was placed in a shaking incubator protected from light and incubated at room temperature for 1 hour until the color reaction was complete.

[0343] 3. Detection After the development reaction was completed, the 384-well plate was removed and read using an Envision multimode plate reader. The optical signal was detected at an emission wavelength of 405 nm and an excitation wavelength of 460 nm / 535 nm. The signal value for each well was recorded using the readings at 460 nm / 535 nm.

[0344] 4.Calculation The average signal value of C3 was considered to be 100% phosphorylation, the average signal value of C1 was considered to be 0% phosphorylation, and the average signal value of C2 was used to calculate the phosphorylation rate of the short peptide in the presence of BTK kinase. The inhibition rate (%) of each compound concentration was calculated from the signal value of each well, and the IC was calculated using the 205 model of XL-Fit 5.3 software (ID Business Solutions Limited). 50 The value was calculated.

[0345] The phosphorylation rate was calculated as follows: Phosphorylation rate (%) = 100 - 100 × [(luminescence signal ratio × F 100% )-C 100% ] / {(C 0% -C 100% ) + [luminescence signal ratio × (F100% - F0%)]} where, luminescence signal ratio = coumarin luminescence signal (460 nm) / fluorescein luminescence signal (535 nm); C 100% = average coumarin emission signal of C3; C 0% = average coumarin emission signal of C1; F 100% = average value of fluorescein emission signal of C3; F 0% = average value of fluorescein emission signal of C1.

[0346] The inhibition rate was calculated as follows: Inhibition rate (%) = 100 × (phosphorylation rate of C2 - phosphorylation rate of test well) / phosphorylation rate of C2

[0347] 5. Test Results [Table 23-1] [Table 23-2]

[0348] Example 3: Measurement of phosphorylated BTK in Ramos cells 1. Reagents and Materials Ramos cells: Ramos cells were purchased from the American Standard Biological Collection Center ATCC Cell Bank and cultured in PRMI1640 medium containing L-glutamine, 1.5 g / L sodium bicarbonate, 2.383 g / L HEPES solution, 0.11 g / L sodium pyruvate, and 4.5 g / L glucose supplemented with 10% fetal bovine serum (FBS) in a 5% CO2, 37°C cell incubator. PRMI1640 medium: GIBCO, catalog number A10491-01; Fetal bovine serum (FBS): GIBCO, catalog number 100100-147; Hanks' Balanced Salt Solution (HBSS): GIBCO, catalog number 14025-092; Immunoglobulin M (IgM): Jackson Immuno, catalog number 109-006-129; 3% hydrogen peroxide (3% H2O2): Sigma, catalog number 88597-100ML-F; Phosphorylated BTK HTRF detection kit (BTKphospho-Y223HTRF kit): Cisbio, catalog number 63ADK017PEH; Microwell plate reader: Envision, Perkin Elmer; 384-well plate Cultur Plate™384: Perkin Elmer, catalog number 6007680; 96-well plates: Corning, catalog number 3799.

[0349] 2. Method Ramos cells were starved for 2 hours in PRMI 1640 medium containing 1% FBS. Starved Ramos cells were diluted to 5.0 × 10 in Hank's balanced salt solution. 6 Dilute to 1.0 x 10 cells / ml and plate 20 µL / well in a 96-well plate. 5The cells were seeded with 1000 cells / well and cultured in a cell incubator at 37°C with 5% CO2. After 1 hour of culture, the test compounds were diluted to the corresponding concentrations in a 4-fold gradient with Hank's balanced salt solution, and then 5 μL / well of the diluted test compounds (final concentrations of the test compounds were 3.0 μM, 0.75 μM, 0.188 μM, 0.047 μM, 0.012 μM, 0.0029 μM, 0.0007 μM, and 0.00018 μM, with a final DMSO concentration of 0.3%, in duplicate wells) or a control solution (1.5% DMSO) was added. 5 μL / well of 5 μg / mL human immunoglobulin M (10 μg / mL final concentration) and 20 μL / well of 8 replicate wells of the cell culture system were added and incubated for another 1 hour. 5 μL / well of a mixture of human immunoglobulin M (10 μg / mL final concentration) and hydrogen peroxide (3.3 mM final concentration) diluted in Hank's balanced salt solution was then added to the test compound-treated wells and the anti-human immunoglobulin M control-treated wells. 5 μL / well of Hank's balanced salt solution was added to the negative control-treated wells. The plate was incubated in a cell incubator at 37°C with 5% CO2 for 10 minutes.

[0350] 10 μL / well of cell lysis buffer was added to each well of a 96-well plate, mixed thoroughly, and lysed at room temperature for 30 minutes. 16 μL / well of lysis buffer was pipetted into a new 384-well plate, followed by the addition of 4 μL / well of phospho-BTK antibody. The plate was then centrifuged (1000 rpm) for 1 minute, shaken for 1 minute, centrifuged (1000 rpm) for another 1 minute, and finally placed in a constant temperature incubator overnight. Detection was performed the next day.

[0351] 3. Detection After overnight incubation in a constant temperature incubator, the 384-well plate was removed and the luminescence signal was detected using an Envision microwell plate reader with an emission wavelength of 320 nm and an excitation wavelength of 665 nm / 615 nm. The readings at 665 nm / 615 nm for each well were recorded at 100 Hz. 4 The multiplied value was used as the signal value for each well.

[0352] 4.Calculation The average signal value of wells to which a mixed solution of human immunoglobulin M (final concentration 10 μg / mL) and hydrogen peroxide (final concentration 3.3 mM) without test compound was added was defined as high, and the average signal value of wells without immunoglobulin M stimulation and without test compound was defined as low. The inhibition rate (%) of each compound concentration was calculated from the signal value of each well, and IC was calculated using the 205 model of XL-Fit 5.3 software (ID Business Solutions Limited). 50 The value was calculated.

[0353] The percent inhibition was calculated as follows: Inhibition rate (%)=100%−{(test compound-treated wells−negative control-treated wells) / (anti-human immunoglobulin M-treated control wells−negative control-treated wells)}×100%. Test compound treated wells: Signal values ​​of Ramos cells treated with anti-human immunoglobulin M, hydrogen peroxide and test compounds are shown. Anti-human IgM treated control wells: The signal values ​​of Ramos cells treated with anti-human immunoglobulin M and hydrogen peroxide without test compound are shown. Negative control treated wells: The signal values ​​of Ramos cells without immunoglobulin stimulation and without test compound are shown.

[0354] 5. Test Results [Table 24-1] [Table 24-2]

[0355] Example 4: Measurement of B cell activity in rat whole blood 1. Reagents and Materials Peripheral blood from female Wistar rats; Phosphate buffer PBS: GIBCO, catalog number C20012500BT; Anti-rat B220PE antibody (PE anti-rat B220): eBioscience, catalog number 12-0460-82; Anti-rat CD86 FITC antibody (FITC anti-rat CD86): eBioscience, catalog number 11-0860-82; 10x Lysis Buffer (10x Lysis Buffer): BD Biosciences, catalog number 555899; Fixation buffer (IC fixation buffer): Invitrogen, catalog number 00-8222-49; U-bottom 96-well: Nunc, catalog number 163320; V-bottom 96-well: Nunc, catalog number 49952; Dimethyl sulfoxide (DMSO): Sigma-Aldrich, catalog number 34869-4L; Anti-rat immunoglobulin D (mouse anti-rat IgD): Bio-rad, catalog number MCA190; Flow cytometer: BDFACSCantoII, BD.

[0356] 2. Method To measure compound activity, 80 μL / well of collected rat peripheral whole blood was added to a 96-well plate and cultured in a cell incubator at 37°C under 5% CO2. After 30 minutes, the test compounds were diluted with PBS in a 3-fold gradient to the corresponding concentrations, and then 10 μL / well of the diluted test compounds at different concentrations were added to the rat whole blood culture system (final concentrations of the test compounds were 1.0 μM, 0.33 μM, 0.11 μM, 0.037 μM, 0.012 μM, 0.0041 μM, 0.0014 μM, and 0.0005 μM, final DMSO concentration was 0.3%, in duplicate wells), or control solution (0.3% DMSO, 6 replicate wells) was added to the corresponding wells at 10 μL / well, and the culture was incubated in a cell incubator for 1 hour. Then, 10 μL / well of anti-rat immunoglobulin D diluted in PBS (final concentration 10 μg / mL) was added to the test compound-treated wells and the anti-rat immunoglobulin D-treated control wells, or 10 μL / well of PBS was added to the negative control wells, mixed thoroughly, and culture was continued in a cell incubator at 37°C with 5% CO for 18 hours.

[0357] On day 2, the 96-well plate was removed, and a flow cytometry antibody mixture (anti-rat B220PE antibody at a final concentration of 1 μg / mL and anti-rat CD86 FITC antibody at a final concentration of 1 μg / mL) diluted with PBS was added to each well of the plate and incubated in the dark for 30 minutes. Then, 50 μL of blood from each well was pipetted into 500 μL of freshly prepared lysis buffer to lyse red blood cells. The plate was shaken for 20 minutes, centrifuged to remove the supernatant, and then washed, fixed, and detected by flow cytometry.

[0358] 3. Detection B cell activation in the samples was determined by flow staining.

[0359] 4.Calculation The average percentage of activated B cells in wells to which anti-rat immunoglobulin D without test compound was added was used as the anti-rat immunoglobulin D-treated control well, and the average percentage of activated B cells in wells without immunoglobulin D stimulation and without test compound was used as the negative control well. The inhibition rate (%) for each concentration was calculated from the B cell activation rate in each well, and the IC was calculated using the 205 model of XL-Fit 5.3 software (ID Business Solutions Limited). 50 The value was calculated.

[0360] The percent inhibition was calculated as follows: Inhibition rate (%)=100%−{(test compound-treated wells−negative control-treated wells) / (anti-rat immunoglobulin D-treated control wells−negative control-treated wells)}×100%. Test compound treated wells: 1 shows the rate of B cell activation in whole blood of rats treated with anti-rat immunoglobulin D and test compounds. Anti-rat immunoglobulin D treated control wells: 1 shows the rate of B cell activation in whole blood of rats treated with anti-rat immunoglobulin D without test compound. Negative control treated wells: This shows the B cell activation rate in rat whole blood without immunoglobulin stimulation and without the test compound.

[0361] From the above test, the compounds of the present invention have the efficacy to inhibit B cell activation in rat whole blood.

[0362] [Table 25]

[0363] Example 5: Stability study in liver microsomes 1. Experimental materials: Both pooled liver microsomes from male CD-1 mice and pooled liver microsomes from male SD rats were purchased from Bioreclamation IVT Corporation, USA.

[0364] Phenacetin, glucose-6-phosphate dehydrogenase (G-6-PDH), and nicotinamide adenine dinucleotide phosphate (NADP) were all purchased from Sigma-Aldrich Corporation, USA. Glucose-6-phosphate (G-6-P) was purchased from Shanghai Eybridge Chemical Technology Co., Ltd.

[0365] 2. Preparation of solutions: 10 mM test compound stock solution: A fixed amount of test compound was weighed and dissolved in an appropriate amount of DMSO to prepare a stock solution with a working concentration of 10 mM.

[0366] Reaction stop solution: An appropriate amount of phenacetin, an internal standard compound, was dissolved in acetonitrile at room temperature to prepare a reaction stop solution with a working concentration of 1000 ng / mL.

[0367] 3. Experimental Method: Test compound stock solutions were diluted with organic solvent (typically a mixture of acetonitrile, methanol, and water in various proportions depending on the compound's solubility; 1N hydrochloric acid or 1N sodium hydroxide was added as needed to promote solubilization) to 0.1 mM (final compound concentration in the reaction system: 1 μM). The concentration of organic solvent in the incubation system was 1% or less (DMSO concentration of 0.1% or less was required). Appropriate amounts of 100 mM NADP, 500 mM G-6-P, and 100 units / mL G-6-PDH were mixed and diluted with ultrapure water (the final system contained 1 mM NADP, 5 mM G-6-P, and 1 unit / mL G-6-PDH). The mixture was preincubated in a 37°C water bath for 10 minutes and then placed on ice for use as the NADPH regeneration solution. A 20 mg / mL liver microsome solution and 200 mM phosphate buffer were mixed and diluted with ultrapure water to obtain a liver microsome solution containing 2.5 mg / mL liver microsomes (final concentration of 0.5 mg / mL in the reaction system) and 50 mM phosphate buffer. The diluted liver microsome solution was mixed with a 0.1 mM compound solution, and an appropriate amount of a mixture of 100 mM EDTA, 300 mM MgCl2, 200 mM phosphate buffer (final system: 3 mM MgCl2, 1 mM EDTA, and 50 mM phosphate buffer) and water was added. Finally, NADPH regeneration solution was added, and the reaction mixture was placed in a 37°C water bath to initiate the reaction (reaction time: 30 min). The reaction was stopped by adding ice-cold acetonitrile stop solution containing an internal standard. The 0-minute sample was not incubated in a 37°C water bath and differed from the 30-minute sample in that ice-cold acetonitrile quench solution containing the internal standard was added first, followed by the NADPH regeneration solution. The sample containing the quench internal standard solution was vortexed to thoroughly mix it, then centrifuged at 4400 rpm for 10 minutes. The supernatant was collected and diluted 10-fold with 50% methanol for LC-MS / MS analysis.

[0368] 4.Analysis method: The compound concentrations in the samples were determined using LC-MS / MS. The metabolic stability of the compounds was evaluated by calculating the percentage of the compound remaining in the sample after 30 minutes of incubation compared to the sample after 0 minutes of incubation using the peak area ratio of the compound to the internal standard. Equipment: API4500, API4000 or LTQ mass spectrometer; liquid phase: UHPLC system (Shimadzu LC-30AD, model NexraX2) including liquid supply unit, column thermostat, detector and autosampler; or Agilent 1200 Binary Pump series HPLC and CTC autosampler. Chromatography column: Waters XSELECT Hss T3 C 18 (2.5 μm, 2.1 × 50 mm) or CAPCELLPAK MG (5 μm, 2.0 × 50 mm) Mobile phase: A: Water containing 0.1% FA (formic acid) with or without 0.1% ACN (acetonitrile) B: Acetonitrile containing 0.1% FA (formic acid).

[0369] As a result, the stability of compounds 2, 9, 19, 22, 34, 44, 56, 58, 63, 64, 74, 75, 78, and 79 of the present invention in rat and mouse liver microsomes was superior to that of the reference compound GDC-0853.

[0370] [Table 26]

[0371] Example 6: In vivo pharmacokinetic studies in mice 1. Experimental materials: Solutol HS15 was purchased from BASF, Germany; ethanol (absolute) was purchased from Nanjing Chemical Reagent Co., Ltd.; saline was purchased from Huayu (Wuxi) Pharmaceutical Co., Ltd.; dimethyl sulfoxide (DMSO) and carboxymethylcellulose sodium 800-1200 (CMC-Na) were purchased from Sinopharm Chemical Reagent Co., Ltd.

[0372] 2. Preparation of solutions: Preparation of ethanol / Solutol mixed solution (1:1, v / v): An appropriate amount of Solutol HS15 was placed in a centrifuge tube, placed in a 37°C water bath until dissolved, and then left on a table to reach room temperature. 1 mL of Solutol was placed in a centrifuge tube containing 1 mL of ethanol and mixed thoroughly to obtain a mixed solution.

[0373] Preparation of intravenous formulation: Accurately weigh appropriate amounts of Compound 19 powder and GDC-0853 into a centrifuge tube, add appropriate amounts of dimethyl sulfoxide, and vortex to completely dissolve. Then, add appropriate amounts of the stock solution to an empty centrifuge tube, add appropriate amounts of the prepared ethanol / Solutol mixture, vortex, and then add appropriate amounts of saline and mix thoroughly until a clear liquid is obtained.

[0374] Preparation of formulation for intragastric administration: Appropriate amounts of Compound 19 powder and GDC-0853 were accurately weighed and placed in a centrifuge tube. An appropriate amount of CMC-Na, whose pH had been adjusted to 2.1 with hydrochloric acid, was added, and the mixture was vortexed and sonicated to form a uniform suspension.

[0375] 3. Animal Dosing and Sample Collection: Male ICR mice were purchased from Shanghai Lingchang Biotechnology Co., Ltd. Eighteen mice were randomly divided into an intravenous administration group and an intragastric administration group. Mice were fasted overnight before administration. Food was withheld within 4 hours after administration, but water was available ad libitum. After 4 hours, food and water were available ad libitum. After isoflurane anesthesia, blood was collected from the retroorbital plexus and placed in a centrifuge tube containing anticoagulant. The centrifuge tube was stored in a box containing wet ice until plasma was centrifuged.

[0376] 4. Sample analysis: Plasma samples were pretreated and then analyzed by liquid chromatography-tandem mass spectrometry (LC-MS / MS) using an API5500 instrument model. The analytical chromatography column was a Waters XSELECT HSS T3 C18 column (50 × 2.1 mm, 2.5 μm). The mobile phase consisted of deionized water containing 0.1% formic acid and 0.1% acetonitrile as the aqueous phase, and acetonitrile containing 0.1% formic acid as the organic phase. The concentrations of compounds in the samples were determined as follows. First, a calibration curve was constructed, and the peak area ratio of compound 19 relative to the internal standard in the calibration curve was used as an index. The theoretical concentration of compound 19 and the peak area ratio of compound 19 relative to the internal standard were fitted to a quadratic regression equation to obtain a regression equation. The sample concentrations were calculated by measuring the peak area ratio of the test sample compounds relative to the internal standard according to the calibration curve. The concentration of GDC-0853 in the samples was determined using the same procedure.

[0377] 5. Data Analysis: The pharmacokinetic parameters of compound 19 and GDC-0853 in mice were calculated by Thermo Kinetica software using the mean drug concentrations in plasma at each time point by non-compartmental analysis.

[0378] As a result, Compound 19 of the present invention showed a plasma exposure (AUC 0-∞) was high, approximately 1.7 times that of the reference GDC-0853. max ) was similar to that of GDC-0853 (C of compound 19). max was 3807ng / mL, and the C max The elimination half-life (T 1 / 2 ) was longer (T 1 / 2 is 2.7 hours, and the T of GDC-0853 1 / 2 (The mean mean time was 1.5 hours.) The plasma concentration of compound 19 at 8 hours was approximately 3.9-fold higher than that of GDC-0853 (555 ng / mL for compound 19 and 143 ng / mL for GDC-0853), and the plasma concentration of compound 19 at 24 hours was still detectable (mean concentration 8.5 ng / mL), while the plasma concentration of GDC-0853 at 24 hours was below the lower limit of quantification (2.4 ng / mL). The test results are shown in the table below.

[0379] [Table 27]

[0380] Example 7: Evaluation of the in vivo efficacy of compounds of the present invention in a TMD8 subcutaneous xenograft model

[0381] the purpose: To investigate the antitumor activity of compound 19 in a TMD8 subcutaneous xenograft model in nude mice.

[0382] method: Human diffuse large B-cell lymphoma cells, TMD8 (licensed from Tokyo Medical and Dental University), were cultured in RPMI 1640 medium containing 10% fetal bovine serum. 1 × 10 cells were suspended in RPMI 1640 medium thoroughly mixed with Matrigel (purchased from Corning, USA) at a 1:1 ratio. 7Tumor cells were subcutaneously implanted into the right flank of each male Balb / c nude mouse (Shanghai Lingchang Biotechnology Co., Ltd.) and pretreated with cyclophosphamide (intraperitoneally injected at a dose of 200 mg / kg 24 hours before cell inoculation). The average tumor volume was approximately 400 mm. 3 At the time of tumor volume reaching 1000 mg / kg, animals were randomly assigned to the following groups, each containing 8 animals, according to tumor volume: vehicle control, the positive reference compound ibrutinib (Shanghai Tianxi Chemical Co., LTD) (50 mg / kg), the reference compound GDC-0853 (10 mg / kg), and compound 19 (10 mg / kg and 30 mg / kg). Ibrutinib was formulated in 0.5% sodium methylcellulose solution, while GDC-0853 and compound 19 were prepared in 0.5% hydroxypropyl methylcellulose solution (pH = 3). All drugs were administered orally by gavage once daily, while the vehicle control group was orally administered 0.5% hydroxypropyl methylcellulose solution (pH = 3).

[0383] The tumor volume of the mouse (tumor volume = 0.5 × major axis × minor axis) 2 ) and body weight were measured periodically. Changes in tumor volume and body weight were statistically analyzed, with p<0.05 considered statistically significant and p<0.01 considered highly statistically significant.

[0384] Antitumor activity was assessed by tumor growth inhibition. Tumor growth inhibition (TGI%) = 100% × (1-(TV Dt(処理群) -TV D0(処理群) ) / (TV Dt(対照群) -TV D0(対照群) )) Relative body weight (RBW%) = BW Dt / BW D0 ×100% And TV D0 represents the tumor volume at the first measurement, i.e., the tumor volume before drug administration, and TV Dt represents the tumor volume on the day of measurement; BW D0 represents the body weight of the animal at the first measurement, i.e., the body weight of the animal before drug administration; BW Dtindicates the body weight of the animal on the day of measurement.

[0385] result: The experimental results are shown in Table 1 and Figure 1. After 21 days of treatment, compared with the vehicle control group, 50 mg / kg ibrutinib reduced tumor growth by 42.4%; 10 mg / kg GDC-0853 was associated with a TGI of -12.8%. Compound 19 of the present invention showed a dose-dependent antitumor effect with TGIs of 76.5% and 114% at 10 mg / kg and 30 mg / kg, respectively, demonstrating a highly significant statistical difference compared with the vehicle control group. All eight mice in the compound 19 (30 mg / kg) treatment group showed complete tumor regression (CR) on day 21. Therefore, compound 19 demonstrated statistically significantly greater efficacy than ibrutinib or GDC-0853 at the doses tested in the TMD-8 model. Furthermore, the changes in tumor volume in the two dose groups of compound 19 were statistically significant or highly significant compared with the two reference groups, indicating that compound 19 of the present invention demonstrated significantly superior antitumor efficacy than the two reference groups at the doses tested. Furthermore, the changes in tumor volume in the two dose groups of compound 19 compared with the two references were statistically significant or highly significant, indicating that the antitumor effect of compound 19 of the present invention was significantly superior to that of the two reference compounds at the doses tested. In this experiment, no weight loss was observed in mice regardless of treatment, indicating that all compounds at the doses tested were well tolerated.

[0386] The results showed that compound 19 of the present invention exhibited dose-dependent antitumor activity in a TMD8 subcutaneous xenograft model, and complete tumor regression could be achieved by continuous daily administration of compound 19 at 30 mg / kg.

[0387] [Table 28]

[0388] Example 8: Evaluation of in vivo efficacy of inhibitors against BTK targets the purpose:B cells in mouse whole blood were induced and activated using an anti-IgD antibody, and the inhibitory effect of the compounds of the present invention on B cell activation in vivo was examined, confirming the inhibitory effect of the compounds of the present invention on the BTK target in vivo.

[0389] method: C57BL / 6 mice (female, 18-20 g, purchased from Shanghai Lingchang Biotechnology Co., Ltd.) were divided into groups according to Table 2.

[0390] [Table 29]

[0391] Animals in each group were administered the dose, and then at the designated time points, rats were placed in CO2 for anesthesia. Blood samples were collected from the rats by retro-orbital bleeding and anticoagulated with heparin. 90 μL of whole blood was collected from each group of mice and added to a 96-well culture plate. Anti-mouse IgD antibody (BIO-RAD, catalog number MCA4693) was added to each well at a final concentration of 0.01 μg / μL (each drug-treated group and the anti-IgD antibody-inducing carrier group). Furthermore, 90 μL of whole blood from the carrier group mice was collected and added to a 96-well culture plate. PBS (phosphate buffer, GIBCO, catalog number C20012500BT) was added to each well at a final concentration of 0.01 μg / μL (i.e., the carrier control group). Each group was thoroughly mixed and incubated in a 37°C / 5% CO2 incubator for 4 hours. Furthermore, blood from the drug-treated mice was centrifuged to separate plasma for blood concentration analysis.

[0392] Fluorescently labeled antibodies including anti-CD19-APC (BD Biosciences, Cat. No. 550992) and anti-CD69-PE (BD Biosciences, Cat. No. 553237) were added to the cultured whole blood, mixed thoroughly, and incubated at room temperature in the dark for 30 minutes; 50 μL of the sample was dissolved in 380 μL of fresh lysis buffer (BD Biosciences, Cat. No. 553237). The cells were transferred to a deep V-bottom 96-well culture plate containing 1% PBS containing 1% PBS (GIBCO Biosciences, Cat. No. 555899), shaken, and left to stand at room temperature in the dark for 15 minutes to remove red blood cells; 400 μL of FACS buffer (2% FBS / PBS, FBS: fetal bovine serum, GIBCO, Cat. No. 100100-147; PBS: GIBCO, Cat. No. C20012500BT) was added and centrifuged at 1200 rpm for 8 minutes at 4°C; the supernatant was removed, the cell mass was washed twice with FACS buffer, centrifuged, and the cells were resuspended in 400 μL of FACS buffer. The expression of CD69+ on CD19+ positive cells (B cells) was detected using a BD FACS LSRFortessa flow cytometer, and the data were analyzed.

[0393] Calculation of B cell activation rate: B cell activation rate = CD69 + CD19 + Percentage of double positive B cells / CD19 + Percentage of single positive B cells

[0394] Calculation of percent inhibition: Inhibition rate = (B cell activation rate in the anti-IgD antibody-inducing carrier group - B cell activation rate in the drug-treated group) / (B cell activation rate in the anti-IgD antibody-inducing carrier group - B cell activation rate in the carrier control group) x 100%

[0395] All data are expressed as mean ± standard error. For comparisons between each drug-treated group and the anti-IgD antibody-induced vehicle group, p values ​​were calculated using one-way ANOVA and Dunnett's test with Graphpad Prism. For comparisons between each drug-treated group, p values ​​were calculated using an unpaired t-test.

[0396] result: The experimental results are shown in Figure 2 and Table 3. In this experiment, 16 hours after administration, GDC-0853 at 20 mg / kg inhibited B cell activation by 9%. Compound 232 of the present invention at a dose of 20 mg / kg inhibited B cell activation by 89%, which was statistically significantly different from the anti-IgD antibody-induced control group.

[0397] [Table 30]

[0398] According to the above method, the inhibitory effects on BTK targets in vivo were further measured between Compound 19 and Compound 176 (referred to as "Reference Compound 176") in PCT Patent Application WO2013067274, and the results were grouped according to Table 4 below.

[0399] [Table 31]

[0400] result: The experimental results are shown in Figure 3 and Table 5. In this experiment, 16 hours after administration, the inhibitory rate of reference compound 176 at a dose of 5 mg / kg on B cell activation was 48%. The inhibitory rate of compound 19 of the present invention at a dose of 5 mg / kg on B cell activation was 80%, which is significantly different from the anti-IgD antibody-induced carrier group.

[0401] [Table 32]

[0402] Example 9: Therapeutic effect of the compound of the present invention on type II collagen-induced rat arthritis model Research method An appropriate amount of bovine type II collagen (CII, Chondrex, Redmond, WA, USA, catalog number 20021) was weighed and dissolved in 0.1 M acetic acid (SPGC Sinopharm Chemical Reagent Co., Ltd, Shanghai, China, catalog number 10000218) to prepare a 6 mg / mL solution. The solution was stirred overnight at 4°C and then thoroughly emulsified with an equal volume of Freund's incomplete adjuvant (Sigma-Aldrich, St. Louis, MO, USA, catalog number SLBW0366) to prepare an emulsion with a CII concentration of 3 mg / mL.

[0403] Female Lewis rats were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (certificate number 1100111911070522, initial body weight 110-130 grams). Three rats were randomly selected as the normal group, and the remaining rats were divided into groups according to the table below. For the first immunization on day 0, rats other than those in the normal group were anesthetized with isoflurane (Hebei Yipin Pharmaceutical Co., Ltd., lot number C002170601) and then disinfected with 75% alcohol. 0.2 mL of emulsion was injected intradermally at the base of the tail. The second injection was performed on day 7 using the same method, with 0.2 mL of emulsion injected intradermally.

[0404] [Table 33]

[0405] After grouping and modeling, the normal group was not administered, and the rats in the other groups were orally administered with the control vehicle, 4 mg / kg of reference GDC-0853, and various doses of Compound 19 once a day until the end of the experiment. The grouping and administration schedule are shown in Table 6.

[0406] The paw volume was measured on day 8 after immunization, and after an increase in paw volume was detected, the volumes (V) of the left and right hind paws were measured every day.

[0407] The arthritic paw volume of the left and right hind paws of each animal was measured, and the mean paw volume (APV, which indicates the change in swelling of the animal's paw) was calculated according to the following formula: Average foot volume APV=(V 左 +V 右 ) / 2.

[0408] The effect of drugs on mean paw volume was subjected to significance analysis by GraphPad with repeated measures ANOVA and Dunnett's multiple comparison test, and p values ​​were calculated. ## p<0.01 indicates a significant difference compared with the normal group. ** p<0.01 indicates a significant difference compared to the vehicle control group.

[0409] The mean arthritic paw volume for each animal before dosing was used as the baseline (or considered as 100% inhibition of inflammation). The mean paw swelling (APS) for each animal was calculated according to the following formula: where APV = d1 is the mean paw volume of treated animals on day 1, and APV dt is the mean paw volume of treated animals on day t: Average foot swelling APS dt =(APV dt -APV d1 ).

[0410] The area under the mean paw volume change curve (AUC) is the area under the arthritis score change curve calculated by the trapezoidal method, and the calculation formula is as follows: AUC 足体積 =1 / 2×(APS d1 +APS d2 )×(d2-d1)+1 / 2×(APS d2 +APS d3 )×(d3-d2)+······+1 / 2×(APS dn +APS d(n-1) )×(d n -d n-1 ).

[0411] ED 50is calculated by XLfit software according to the AUC inhibition rate of the area under the mean paw volume change curve. The model selected is "log(inhibitor) vs response-variable slope":

number

[0412] result Lewis rats began to develop symptoms 11 days after the first immunization with bovine type II collagen, and the volume of the right hind paw gradually increased as the disease progressed. The increase in paw volume of rats in the carrier control group was compared with that of the normal group, and there was a statistically significant difference ( ## p<0.01). Paw volume in rats treated with GDC-0853 was significantly reduced compared to the vehicle control group ( ** Oral administration of compound 19 solution at 0.06 mg / kg, 0.25 mg / kg, 1 mg / kg, 4 mg / kg, and 16 mg / kg QD once daily doses dose-dependently inhibited paw swelling, with the area under the curve inhibition rates of 58.8%, 91.3%, 95.9%, 93.2%, and 97.5%, respectively; the minimum effective dose was 0.06 mg / kg / day, and the ED 50 <0.06 mg / kg / day, ED 90 =0.26 mg / kg. Compound 19 at 0.25 mg / kg / day (91.3% inhibition of the area under the curve) had a similar effect to GDC-0853 at 4 mg / kg / day (87.1% inhibition of the area under the curve), and there was no statistical difference between the two groups. Both compounds were able to significantly improve paw volume growth compared with the model group (p<0.001, paired t-test by Graphpad). There was a statistical difference between compound 19 at 4 mg / kg / day (93.2% inhibition of the area under the curve) and GDC-0853 at the same dose (87.1% inhibition of the area under the curve), and compound 19 significantly improved paw volume growth (p<0.001, paired t-test by Graphpad). The results are shown in Figure 4.

Claims

1. Compounds of formula (I): 【Chemistry 1】 [In the formula, X １ and X ２ are each independently CH or N; or X １ is N and X ２ is CR １４ and R １４ is C １－６ is alkyl; X ３ is N; X ４ is C; Y １ is CH; Y ２ is CH or N; R １ and R ２ are each independently hydrogen, deuterium, halogen, C １－６ Alkyl, C ２－６ Alkynyl, C １－６ Haloalkyl, C ３－６ cycloalkyl and phenyl; or R １ and R ２ The carbon atoms to which they are attached have the following structure: 【Chemistry 2】 and R ６ are independently deuterium, halogen, hydroxyl, C １－６ Alkyl, C ２－６ Alkynyl, C １－６ Deuterated alkyl and C １－６ haloalkyl; or two R ６ together with the carbon atoms to which they are attached form a 3- to 6-membered cycloalkyl; m is 0, 1, 2, 3, or 4; p is 1, 2, 3, or 4; Z is N or CR ７ and R ７ is hydrogen, deuterium, C １－６ Alkyl, halogen and C １－６ haloalkyl; or R １ and R ２ along with the carbon atoms to which they are attached 【Transformation 3】 where R ３ is a halogen, or X １ and X ２ Both are not simultaneously CH; R ３ is hydrogen, deuterium, halogen or C １－６ haloalkyl; R ４ is hydrogen, halogen, -CN, C １－６ Alkyl, C ２－６ Alkynyl, -(C １－３ alkyl)-OH, -(C １－３ alkyl)-O-(C １－３ alkyl), —O—(C １－３ alkyl), —CHO, —C(O)NH ２ , -C(O)NHCH ３ , -C(O)N(CH ３ ) ２ or 3-hydroxyl-oxetan-3-yl, １－６ Alkyl or C １－３ each alkyl optionally substituted with one or more deuterium or halo; Cy is 【Chemistry 4】 and R １１ is C １－６ alkyl, １－６ alkyl is optionally substituted with one or more deuterium atoms; U and V are each independently N or CH; W is N or CR １２ and R １２ is F; R ５ is hydrogen, C １－６ Alkyl, —C(O)—(C １－６ alkyl), —C(O)—(C ３－６ cycloalkyl), —C(O)-phenyl, —C(O)NH—(C １－６ alkyl), —C(O)NH—(C ３－６ cycloalkyl), —C(O)N(C １－６ alkyl) ２ , phenyl, 5- to 6-membered monocyclic heteroaryl or 8- to 10-membered bicyclic heteroaryl, １－６ Alkyl, C ３－６ Each cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl is optionally substituted with one or more groups selected from: 1) halogens; 2) oxo; 3) -CN; 4) C １－６ Alkyl; 5) C ２－６ Alkenyl; 6) C ２－６ Alkynyl; 7) C １－６ Alkoxy; 8) C １－６ haloalkyl; 9) - (C １－６ alkyl)-OH; 10)-(C １－６ alkyl)-O-(C １－６ alkyl); 11) C ３－６ cycloalkyl; 12) Deuterium, halogen, hydroxyl, oxo, -CN, C １－６ Alkyl, C １－６ Haloalkyl, C ３－６ Cycloalkyl, C ２－６ Alkynyl, C １－６ Alkoxy, -(C １－６ alkyl)-CN, -(C １－６ alkyl)-O-(C １－６ alkyl), -(C １－６ alkyl)-OH, 4- to 6-membered heterocyclyl, and deuterated 4- to 6-membered heterocyclyl, １－６ Alkyl, C ３－６ Cycloalkyl and 4- to 6-membered heterocyclyl are each independently selected from deuterium, halogen, -NH ２ , -OH, -NH(C １－６ alkyl), -N(C １－６ alkyl) ２ and —NH(C ３－６ the 3- to 12-membered heterocyclyl optionally substituted by one or more groups selected from 13) Halogen, -CN, -(C １－６ alkyl)-CN, -(C １－６ alkyl)-OH, C １－６ Alkyl, C ３－６ Cycloalkyl, C １－６ Alkoxy, -(C １－６ alkyl)-O-(C １－６ alkyl), -(C １－６ alkyl)-NH ２ , -(C １－６ alkyl)-NH(C １－６ alkyl), -(C １－６ alkyl)-N(C １－６ alkyl) ２ , -(C １－６ alkyl)-NH(C ３－６ 5- to 6-membered monocyclic heteroaryl optionally substituted with one or more groups selected from cycloalkyl and 4- to 6-membered heterocyclyl; 14) Halogen, -CN, -(C １－６ alkyl)-CN, -(C １－６ alkyl)-OH, C １－６ Alkyl, C ３－６ Cycloalkyl, C １－６ Alkoxy, -(C １－６ alkyl)-O-(C １－６ alkyl), -(C １－６ alkyl)-NH ２ , -(C １－６ alkyl)-NH(C １－６ alkyl), -(C １－６ alkyl)-N-(C １－６ alkyl) ２ , -(C １－６ alkyl)-NH(C ３－６ phenyl optionally substituted with one or more groups selected from 4- to 6-membered heterocyclyl; 15) -NR ａ 'R ａ '', and R ａ ' and R ａ '' are each independently hydrogen, C １－６ Alkyl, C ３－６ cycloalkyl, -(C １－６ alkyl)-O-(C １－６ alkyl) and 4- to 6-membered heterocyclyl, wherein said 4- to 6-membered heterocyclyl is —(C １－６ and optionally substituted with one or more substituents of (alkyl)-OH, １－６ alkyl is one or more -NR ｅ 'R ｅ Optionally substituted with '' and R ｅ ' and R ｅ '' are each independently hydrogen, C １－６ Alkyl, -(C １－６ alkyl)-OH and 4- to 6-membered heterocyclyl ａ 'R ａ ''; 16)-C(O)NR ｂ 'R ｂ '', and R ｂ ' and R ｂ '' together with the N atom to which they are attached, deuterium, halogen, -OH, C １－６ Alkyl, -(C １－６ alkyl)-NH ２ , -(C １－６ alkyl)-NH(C １－６ alkyl), -(C １－６ alkyl)-N(C １－６ alkyl) ２ , -(C １－６ alkyl)-NH(C ３－６ cycloalkyl), -NH ２ , —NH(C １－６ alkyl), -N(C １－６ alkyl) ２ , —NH(C ３－６ cycloalkyl) and -(C １－６ the —C(O)NR forming a 4- to 6-membered heterocyclyl optionally substituted with one or more groups selected from —C(O)NR ｂ 'R ｂ ''; and 17) -C(O)R ｃ and R ｃ is hydrogen, C １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, -(C １－６ alkyl)-OH and -(C １－６ alkyl)-O-(C １－６ alkyl) ｃ ; However, R １ and R ２ together with the carbon atoms to which they are attached form the following structure: 【Transformation 5】 and Cy 【Transformation 6】 When substituted, the 3- to 12-membered heterocyclyl is １－６ is not an alkyl-substituted piperazin-1-yl.], or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

2. R １ and R ２ along with the carbon atoms to which they are attached 【Transformation 7】 and wherein said compound is a compound of formula (IA): 【Transformation 8】 2. The compound of claim 1, wherein:

3. R １ and R ２ along with the carbon atoms to which they are attached 【Chemistry 9】 Forming X ３ is N and X ４ is C and Y １ is CH and Cy is 【Chemistry 10】 and the compound is a compound of formula (II): 【Chemistry 11】 [In the formula, X １ and X ２ are each independently CH or N; or X １ is N and X ２ is CR １４ and R １４ is CH ３ and Y ２ is CH or N; R ３ is hydrogen, deuterium, halogen or C １－６ haloalkyl; R ４ is hydrogen, halogen, -CN, C １－６ Alkyl, -(C １－３ alkyl)-OH, -(C １－３ Deuterated alkyl)-OH, -(C １－３ alkyl)-O-(C １－３ alkyl), —O—(C １－３ alkyl), —CHO, —C(O)NH ２ , -C(O)NHCH ３ , -C(O)N(CH ３ ) ２ or 3-hydroxyl-oxetan-3-yl, １－６ alkyl is optionally substituted with one or more halo; W is N or CR １２ and R １２ is F; R ５ is hydrogen, C １－６ Alkyl, —C(O)—(C １－６ alkyl), —C(O)—(C ３－６ cycloalkyl), —C(O)-phenyl, —C(O)NH—(C １－６ alkyl), —C(O)NH—(C ３－６ cycloalkyl), —C(O)N(C １－６ alkyl) ２ , phenyl, 5- to 6-membered monocyclic heteroaryl or 8- to 10-membered bicyclic heteroaryl, １－６ Alkyl, C ３－６ Each cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl is optionally substituted with one or more groups selected from: 1) halogens; 2) oxo; 3) -CN; 4) C １－６ Alkyl; 5) C ２－６ Alkenyl; 6) C ２－６ Alkynyl; 7) C １－６ Alkoxy; 8) C １－６ haloalkyl; 9) - (C １－６ alkyl)-OH; 10)-(C １－６ alkyl)-O-(C １－６ alkyl); 11) C ３－６ cycloalkyl; 12) Halogen, hydroxyl, oxo, -CN, C １－６ Alkyl, C １－６ Haloalkyl, C ３－６ Cycloalkyl, C ２－６ Alkynyl, C １－６ Alkoxy, -(C １－６ alkyl)-CN, -(C １－６ alkyl)-O-(C １－６ alkyl), -(C １－６ alkyl)-OH, 4- to 6-membered heterocyclyl, 4- to 6-membered fluoroheterocyclyl, and deuterated 4- to 6-membered heterocyclyl, wherein the C １－６ the above 3- to 12-membered heterocyclyl, wherein the alkyl is optionally substituted with one or more —OH; 13) Halogen, -CN, -(C １－６ alkyl)-CN, -(C １－６ alkyl)-OH, C １－６ Alkyl, C ３－６ Cycloalkyl, C １－６ Alkoxy, -(C １－６ alkyl)-O-(C １－６ alkyl), -(C １－６ alkyl)-NH ２ , -(C １－６ alkyl)-NH(C １－６ alkyl), -(C １－６ alkyl)-N(C １－６ alkyl) ２ , -(C １－６ alkyl)-NH(C ３－６ 5- to 6-membered monocyclic heteroaryl optionally substituted with one or more substituents selected from cycloalkyl and 4- to 6-membered heterocyclyl; 14) Halogen, -CN, -(C １－６ alkyl)-CN, -(C １－６ alkyl)-OH, C １－６ Alkyl, C ３－６ Cycloalkyl, C １－６ Alkoxy, -(C １－６ alkyl)-O(C １－６ alkyl), -(C １－６ alkyl)-NH ２ , -(C １－６ alkyl)-NH(C １－６ alkyl), -(C １－６ alkyl)-N(C １－６ alkyl) ２ , -(C １－６ alkyl)-NH(C ３－６ phenyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl; 15) -NR ａ 'R ａ '', and R ａ ' and R ａ '' are each independently hydrogen, C １－６ Alkyl, C ３－６ cycloalkyl, -(C １－６ alkyl)-O-(C １－６ alkyl) and 4- to 6-membered heterocyclyl, wherein said 4- to 6-membered heterocyclyl is —(C １－６ and optionally substituted with one or more substituents of (alkyl)-OH, １－６ alkyl is one or more -NR ｅ 'R ｅ Optionally substituted with '' and R ｅ ' and R ｅ '' are each independently hydrogen, C １－６ Alkyl, -(C １－６ alkyl)-OH and 4- to 6-membered heterocyclyl ａ 'R ａ ''; 16)-C(O)NR ｂ 'R ｂ '', and R ｂ ' and R ｂ '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and the 4- to 6-membered heterocyclyl is selected from the group consisting of halogen, —OH, C １－６ Alkyl, -(C １－６ alkyl)-NH ２ , -(C １－６ alkyl)-NH(C １－６ alkyl), -(C １－６ alkyl)-N(C １－６ alkyl) ２ , -(C １－６ alkyl)-NH(C ３－６ cycloalkyl) and -(C １－６ the —C(O)NR optionally substituted with one or more substituents selected from ｂ 'R ｂ ''; and 17) -C(O)R ｃ and R ｃ But hydrogen, C １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl and -(C １－６ alkyl)-O-(C １－６ alkyl) ｃ ; R ６ is halogen, C １－６ alkyl or hydroxyl; and m is 0, 1, 2, or 3.

3. The compound of claim 2, wherein: or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

4. R １ and R ２ along with the carbon atoms to which they are attached 【Chemistry 12】 Forming X ３ is N and X ４ is C and Y １ is CH and Cy is 【Chemistry 13】 and the compound is a compound of formula (III): 【Chemistry 14】 [In the formula, X １ and X ２ are each independently CH or N; or X １ is N and X ２ is CR １４ And R １４ is CH ３ and Y ２ is CH or N; R ３ is hydrogen, deuterium, halogen or C １－６ haloalkyl; R ４ is hydrogen, halogen, -CN, C １－６ Alkyl, -(C １－３ alkyl)-OH, -(C １－３ Deuterated alkyl)-OH, -(C １－３ alkyl)-O-(C １－３ alkyl), —O—(C １－３ alkyl), —CHO, —C(O)NH ２ , -C(O)NHCH ３ , -C(O)N(CH ３ ) ２ or 3-hydroxyl-oxetan-3-yl, １－６ alkyl is optionally substituted with one or more halo; U and V are each independently selected from N or CH; R ５ is hydrogen, C １－６ Alkyl, —C(O)—(C １－６ alkyl), —C(O)—(C ３－６ cycloalkyl), —C(O)-phenyl, —C(O)NH—(C １－６ alkyl), —C(O)NH—(C ３－６ cycloalkyl), —C(O)N(C １－６ alkyl) ２ , phenyl, 5- to 6-membered monocyclic heteroaryl or 8- to 10-membered bicyclic heteroaryl, １－６ Alkyl, C ３－６ Each cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl is optionally substituted with one or more groups selected from: 1) halogens; 2) oxo; 3) -CN; 4) C １－６ Alkyl; 5) C ２－６ Alkenyl; 6) C ２－６ Alkynyl; 7) C １－６ Alkoxy; 8) C １－６ haloalkyl; 9) - (C １－６ alkyl)-OH; 10)-(C １－６ alkyl)-O-(C １－６ alkyl); 11) C ３－６ cycloalkyl; 12) Halogen, hydroxyl, oxo, -CN, C １－６ Alkyl, C １－６ Haloalkyl, C ３－６ Cycloalkyl, C ２－６ Alkynyl, C １－６ Alkoxy, -(C １－６ alkyl)-CN, -(C １－６ alkyl)-O-(C １－６ alkyl), -(C １－６ alkyl)-OH, 4- to 6-membered heterocyclyl, 4- to 6-membered fluoroheterocyclyl, and deuterated 4- to 6-membered heterocyclyl, wherein the C １－６ the above 3- to 12-membered heterocyclyl, wherein the alkyl is optionally substituted with one or more —OH; 13) Halogen, -CN, -(C １－６ alkyl)-CN, -(C １－６ alkyl)-OH, C １－６ Alkyl, C ３－６ Cycloalkyl, C １－６ Alkoxy, -(C １－６ alkyl)-O-(C １－６ alkyl), -(C １－６ alkyl)-NH ２ , -(C １－６ alkyl)-NH(C １－６ alkyl), -(C １－６ alkyl)-N(C １－６ alkyl) ２ , -(C １－６ alkyl)-NH(C ３－６ 5- to 6-membered monocyclic heteroaryl optionally substituted with one or more substituents selected from cycloalkyl and 4- to 6-membered heterocyclyl; 14) Halogen, -CN, -(C １－６ alkyl)-CN, -(C １－６ alkyl)-OH, C １－６ Alkyl, C ３－６ Cycloalkyl, C １－６ Alkoxy, -(C １－６ alkyl)-O(C １－６ alkyl), -(C １－６ alkyl)-NH ２ , -(C １－６ alkyl)-NH(C １－６ alkyl), -(C １－６ alkyl)-N(C １－６ alkyl) ２ , -(C １－６ alkyl)-NH(C ３－６ phenyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl; 15) -NR ａ 'R ａ '', and R ａ ' and R ａ '' are each independently hydrogen, C １－６ Alkyl, C ３－６ cycloalkyl, -(C １－６ alkyl)-O-(C １－６ alkyl) and 4- to 6-membered heterocyclyl, wherein said 4- to 6-membered heterocyclyl is —(C １－６ and optionally substituted with one or more substituents of (alkyl)-OH, １－６ alkyl is one or more -NR ｅ 'R ｅ Optionally substituted with '' and R ｅ ' and R ｅ '' are each independently hydrogen, C １－６ Alkyl, -(C １－６ alkyl)-OH and 4- to 6-membered heterocyclyl ａ 'R ａ ''; 16)-C(O)NR ｂ 'R ｂ '', and R ｂ ' and R ｂ '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and the 4- to 6-membered heterocyclyl is selected from the group consisting of halogen, —OH, C １－６ Alkyl, -(C １－６ alkyl)-NH ２ , -(C １－６ alkyl)-NH(C １－６ alkyl), -(C １－６ alkyl)-N(C １－６ alkyl) ２ , -(C １－６ alkyl)-NH(C ３－６ cycloalkyl) and -(C １－６ the —C(O)NR optionally substituted with one or more substituents selected from ｂ 'R ｂ ''; and 17) -C(O)R ｃ and R ｃ But hydrogen, C １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl and -(C １－６ alkyl)-O-(C １－６ alkyl) ｃ ; R ６ is halogen, C １－６ alkyl or hydroxyl; m is 0, 1, 2, or 3; and R １１ is CH ３ or CD ３ and When the 3- to 12-membered heterocyclyl is substituted, both the 2- and 6-positions are C １－６ It is not piperazin-1-yl substituted with alkyl.

3. The compound of claim 2, wherein: or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

5. X １ and X ２ are both CH, or X １ and X ２ and the other is CH, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

6. Y ２ is CH, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

7. R ３ is hydrogen or halogen, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

8. R ４ is C １－６ Alkyl, -(C １－３ alkyl)-OH, -(C １－３ Deuterated alkyl)-OH, -(C １－３ alkyl)-O-(C １－３ alkyl) or —CHO, １－６ 8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein alkyl is optionally substituted with one or more halo.

9. R ３ is hydrogen, and R ４ But-(C １－３ 9. The compound of any one of claims 1 to 8, wherein R is (alkyl)-OH, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

10. R ５ but, 【Chemistry 15】 Selected from; R ２１ But C １－６ Alkyl, C １－６ Haloalkyl and -(C １－６ alkyl)-O-(C １－６ alkyl); n is 0, 1 or 2; R ２２ and R ２３ are each independently hydrogen, —CN, C １－６ Alkyl, C １－６ Haloalkyl, -(C １－６ alkyl)-O-(C １－６ alkyl), 4- to 6-membered heterocyclyl or —C(O)R ｃ and R ｃ But hydrogen, C １－６ Alkyl or -(C １－６ alkyl)-O-(C １－６ alkyl); R ２４ But hydrogen, C １－６ Alkyl, -(C １－６ alkyl)-O-(C １－６ alkyl) or —C(O)NR ｂ 'R ｂ '', and R ｂ ' and R ｂ '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl; A １ , A ２ and A ３ are each independently CH or N, and R １３ is selected from the following: 1) Hydrogen; 2) C １－６ Alkyl; 3) C １－６ Alkoxy; 4) halogens; 5) C ３－６ cycloalkyl; 6) oxo, -CN, C １－６ Alkyl, C １－６ Alkoxy, -(C １－６ alkyl)-CN, -(C １－６ alkyl)-O-(C １－６ alkyl), 4- to 6-membered heterocyclyl, and deuterated 4- to 6-membered heterocyclyl, wherein the C １－６ the above 3- to 12-membered heterocyclyl, wherein the alkyl is optionally substituted with one or more —OH; 7) phenyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl; 8) -NR ａ 'R ａ '', and R ａ ' and R ａ '' are each independently hydrogen, C １－６ Alkyl, -(C １－６ alkyl)-O-(C １－６ alkyl) and 4- to 6-membered heterocyclyl, wherein said 4- to 6-membered heterocyclyl is —(C １－６ alkyl)-OH, １－６ alkyl is one or more -NR ｅ 'R ｅ Optionally substituted with R ｅ ' and R ｅ '' are each independently hydrogen, C １－６ Alkyl, -(C １－６ alkyl)-OH and 4- to 6-membered heterocyclyl ａ 'R ａ ''; and 9) —C(O)NR ｂ 'R ｂ '', and R ｂ ' and R ｂ '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and said 4- to 6-membered heterocyclyl is one or more C １－６ the —C(O)NR optionally substituted with alkyl; ｂ 'R ｂ ''; R １ and R ２ together with the carbon atoms to which they are attached form the following structure: 【Chemistry 16】 and Cy forms 【Chemistry 17】 When the 3- to 12-membered heterocyclyl is substituted, both the 2- and 6-positions are C １－６ 10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, which is not alkyl-substituted piperazin-1-yl.

11. R １３ But C １－６ piperazinyl optionally substituted with one or more substituents selected from alkyl and 4- to 5-membered heterocyclyl; R １ and R ２ together with the carbon atoms to which they are attached form the following structure: [Chemistry 18] and Cy forms 【Chemistry 19】 When the 3- to 12-membered heterocyclyl is substituted, both the 2- and 6-positions are C １－６ 11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, which is not alkyl-substituted piperazin-1-yl.

12. R ５ but, 【Chemistry 20】 is selected from R ２４ , R ２４ ', R ２５ , R ２５ ', R ２７ and R ２７ ' are each independently hydrogen, oxo, and C １－６ alkyl; R ２６ is C １－６ Alkyl, -(C １－６ alkyl)-O-(C １－６ alkyl) or tetrahydrofuranyl; R ２８ is C １－６ is alkoxy; R ２９ is hydrogen or -(C １－６ alkyl)-OH; R ３０ is C １－６ is alkyl; and A １ , A ２ and A ３ are each independently CH or N; 11. A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

13. R ５ but, 【Chemistry 21】 and A １ , A ２ and A ３ are each independently CH or N, and R ２４ and R ２４ ' are each independently hydrogen, oxo, and C １－６ 13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein R is selected from the group consisting of aryl, arylsulfonyl ...

14. R ２４ and R ２４ ' are each independently hydrogen and C １－６ 14. The compound of claim 13, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein R is selected from the group consisting of alkyl, aryl, arylsulfonyl ...

15. A １ , A ２ and A ３ are all CH or A １ is N and A ２ and A ３ are both CH, or A ３ is N and A １ and A ２ are CH, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

16. R ５ but, 【Chemistry 22】 is selected from R ２１ is C １－６ alkyl; R ２２ But hydrogen, C １－６ selected from alkyl and 4-membered heterocyclyl; A １ and A ２ are each CH; R ２４ and R ２４ ' are each independently hydrogen and C １－６ 11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein R is selected from the group consisting of aryl, arylsulfonyl ... 【Request Item 17】 【Chemistry 23】 but, 【Chemistry 24】 and R １１ is CH ３ or CD ３ 17. The compound of any one of claims 4 to 16, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein:

18. X １ and X ２ are both CH, or X １ and X ２ one of which is N and the other is CH; Y ２ is CH; R ３ is hydrogen; R ４ But-(C １－３ alkyl)-OH; U is CH, V is N or CH, and R １１ is CH ３ and R ５ but, 【Chemistry 25】 and R ２４ and R ２４ ' are each independently hydrogen, oxo, and C １－６ alkyl, and A １ and A ２ are both CH, or A １ is N and A ２ is CH; R ６ is C １－６ 5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein m is alkyl; and m is 0 or 2.

19. Both U and V are CH, and R １１ 19. The compound of any one of claims 4 to 18, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein is methyl.

20. R ６ is C １－３ and m is 2, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

21. R ６ together with the five-membered ring to which they are attached 【Chemistry 26】 21. The compound of any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, which forms:

22. X １ and X ２ are both CH; ２ is CH; R ３ is hydrogen; R ４ But-(C １－３ alkyl)-OH; both U and V are CH, and R １１ is methyl; R ５ but 【Chemistry 27】 and R ２４ is C １－３ is alkyl, and A １ and A ２ are both CH; and R ６ together with the five-membered ring to which they are attached 【Chemistry 28】 Forming 5. A compound according to claim 4, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

23. The compound is represented by formula (IB) 【Chemistry 29】 2. The compound of claim 1, which is a compound of formula (I): or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

24. The compound has the formula (IV) 【Transformation 30】 [In the formula, X １ and X ２ are each independently CH or N; or X １ is N and X ２ is CR １４ and R １４ is CH ３ and Y ２ is CH or N; R ３ is hydrogen, deuterium, halogen or C １－６ haloalkyl; R ４ is hydrogen, halogen, -CN, C １－６ Alkyl, -(C １－３ alkyl)-OH, -(C １－３ Deuterated alkyl)-OH, -(C １－３ alkyl)-O-(C １－３ alkyl), —O—(C １－３ alkyl), —CHO, —C(O)NH ２ , -C(O)NHCH ３ , -C(O)N(CH ３ ) ２ or 3-hydroxyl-oxetan-3-yl, １－６ alkyl is optionally substituted with one or more halo; U and V are each independently selected from N or CH; Z is N or CH; R ５ is hydrogen, C １－６ Alkyl, —C(O)—(C １－６ alkyl), —C(O)—(C ３－６ cycloalkyl), —C(O)-phenyl, —C(O)NH—(C １－６ alkyl), —C(O)NH—(C ３－６ cycloalkyl), —C(O)N(C １－６ alkyl) ２ , phenyl, 5- to 6-membered monocyclic heteroaryl or 8- to 10-membered bicyclic heteroaryl, １－６ Alkyl, C ３－６ Each cycloalkyl, phenyl, 5- to 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl is optionally substituted with one or more groups selected from: 1) halogens; 2) oxo; 3) -CN; 4) C １－６ Alkyl; 5) C ２－６ Alkenyl; 6) C ２－６ Alkynyl; 7) C １－６ Alkoxy; 8) C １－６ haloalkyl; 9) - (C １－６ alkyl)-OH; 10)-(C １－６ alkyl)-O-(C １－６ alkyl); 11) C ３－６ cycloalkyl; 12) Halogen, hydroxyl, oxo, -CN, C １－６ Alkyl, C １－６ Haloalkyl, C ３－６ Cycloalkyl, C ２－６ Alkynyl, C １－６ Alkoxy, -(C １－６ alkyl)-CN, -(C １－６ alkyl)-O-(C １－６ alkyl), -(C １－６ alkyl)-OH, 4- to 6-membered heterocyclyl, 4- to 6-membered fluoroheterocyclyl, and deuterated 4- to 6-membered heterocyclyl, wherein the C １－６ the above 3- to 12-membered heterocyclyl, wherein the alkyl is optionally substituted with one or more —OH; 13) Halogen, -CN, -(C １－６ alkyl)-CN, -(C １－６ alkyl)-OH, C １－６ Alkyl, C ３－６ Cycloalkyl, C １－６ Alkoxy, -(C １－６ alkyl)-O-(C １－６ alkyl), -(C １－６ alkyl)-NH ２ , -(C １－６ alkyl)-NH(C １－６ alkyl), -(C １－６ alkyl)-N(C １－６ alkyl) ２ , -(C １－６ alkyl)-NH(C ３－６ 5- to 6-membered monocyclic heteroaryl optionally substituted with one or more substituents selected from cycloalkyl and 4- to 6-membered heterocyclyl; 14) Halogen, -CN, -(C １－６ alkyl)-CN, -(C １－６ alkyl)-OH, C １－６ Alkyl, C ３－６ Cycloalkyl, C １－６ Alkoxy, -(C １－６ alkyl)-O(C １－６ alkyl), -(C １－６ alkyl)-NH ２ , -(C １－６ alkyl)-NH(C １－６ alkyl), -(C １－６ alkyl)-N(C １－６ alkyl) ２ , -(C １－６ alkyl)-NH(C ３－６ phenyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl; 15) -NR ａ 'R ａ '', and R ａ ' and R ａ '' are each independently hydrogen, C １－６ Alkyl, C ３－６ cycloalkyl, -(C １－６ alkyl)-O-(C １－６ alkyl) and 4- to 6-membered heterocyclyl, wherein said 4- to 6-membered heterocyclyl is —(C １－６ and optionally substituted with one or more substituents of (alkyl)-OH, １－６ alkyl is one or more -NR ｅ 'R ｅ Optionally substituted with '' and R ｅ ' and R ｅ '' are each independently hydrogen, C １－６ Alkyl, -(C １－６ alkyl)-OH and 4- to 6-membered heterocyclyl ａ 'R ａ ''; 16)-C(O)NR ｂ 'R ｂ '', and R ｂ ' and R ｂ '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and the 4- to 6-membered heterocyclyl is selected from the group consisting of halogen, —OH, C １－６ Alkyl, -(C １－６ alkyl)-NH ２ , -(C １－６ alkyl)-NH(C １－６ alkyl), -(C １－６ alkyl)-N(C １－６ alkyl) ２ , -(C １－６ alkyl)-NH(C ３－６ cycloalkyl) and -(C １－６ the —C(O)NR optionally substituted with one or more substituents selected from ｂ 'R ｂ ''; and 17) -C(O)R ｃ and R ｃ But hydrogen, C １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl and -(C １－６ alkyl)-O-(C １－６ alkyl) ｃ ; R ６ is halogen, C １－６ alkyl or hydroxyl; m is 0, 1, 2 or 3; and R １１ is CH ３ or CD ３ It is.] 24. The compound of claim 23, which is a compound of the formula: or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

25. Y ２ 25. The compound of claim 23 or 24, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, wherein is CH.

26. R ５ but, 【Chemistry 31】 is selected from R ２１ But C １－６ Alkyl, C １－６ Haloalkyl and -(C １－６ alkyl)-O-(C １－６ alkyl); n is 0, 1 or 2; R ２２ and R ２３ are each independently hydrogen, —CN, C １－６ Alkyl, C １－６ Haloalkyl, -(C １－６ alkyl)-O-(C １－６ alkyl), 4- to 6-membered heterocyclyl or —C(O)R ｃ and R ｃ But hydrogen, C １－６ Alkyl or -(C １－６ alkyl)-O-(C １－６ alkyl); R ２４ But hydrogen, C １－６ Alkyl, -(C １－６ alkyl)-O-(C １－６ alkyl) or —C(O)NR ｂ 'R ｂ '', and R ｂ ' and R ｂ '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl; A １ , A ２ and A ３ are each independently CH or N; and R １３ but, 1) Hydrogen; 2) C １－６ Alkyl; 3) C １－６ Alkoxy; 4) halogens; 5) C ３－６ cycloalkyl; 6) oxo, -CN, C １－６ Alkyl, C １－６ Alkoxy, -(C １－６ alkyl)-CN, -(C １－６ alkyl)-O-(C １－６ alkyl), 4- to 6-membered heterocyclyl, and deuterated 4- to 6-membered heterocyclyl, wherein １－６ 4-8 membered heterocyclyl, wherein the alkyl is optionally substituted with one or more —OH; 7) phenyl optionally substituted with one or more substituents selected from 4- to 6-membered heterocyclyl; 8) -NR ａ 'R ａ '', and R ａ ' and R ａ '' are each independently hydrogen, C １－６ Alkyl, -(C １－６ alkyl)-O-(C １－６ alkyl) and 4- to 6-membered heterocyclyl, wherein the 4- to 6-membered heterocyclyl is selected from one or more —(C １－６ alkyl)-OH, １－６ alkyl is one or more -NR ｅ 'R ｅ Optionally substituted with '' and R ｅ ' and R ｅ '' are each independently hydrogen, C １－６ Alkyl, -(C １－６ alkyl)-OH and 4- to 6-membered heterocyclyl ａ 'R ａ ''; and 9) —C(O)NR ｂ 'R ｂ '', and R ｂ ' and R ｂ '' together with the N atom to which they are attached form a 4- to 6-membered heterocyclyl, and said 4- to 6-membered heterocyclyl is one or more C １－６ the —C(O)NR optionally substituted with alkyl; ｂ 'R ｂ 26. The compound of any one of claims 23 to 25, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof, selected from:

27. X １ and X ２ are both CH, or X １ and X ２ one of which is N and the other is CH; Y ２ is CH; R ３ is hydrogen; R ４ But-(C １－３ alkyl)-OH; Z is CH; U is CH and V is N or CH; R ５ but 【Chemistry 32】 and A １ and A ２ are each independently CH or N, and R １３ But, oxo, C １－６ Alkyl, C １－６ Alkoxy, -(C １－６ alkyl)-O-(C １－６ alkyl) and 4- to 6-membered heterocyclyl optionally substituted with one or more substituents selected from R ２２ is hydrogen, -CN, C １－６ Alkyl, C １－６ Haloalkyl, -(C １－６ alkyl)-O-(C １－６ alkyl), 4- to 6-membered heterocyclyl or —C(O)R ｃ and R ｃ But hydrogen, C １－６ Alkyl or -(C １－６ alkyl)-O-(C １－６ alkyl); R ６ is a halogen; m is 0, 1 or 2; and R １１ CH ３ That is, 27. A compound according to any one of claims 23 to 26, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof.

28. A compound selected from the following: or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer thereof. 【Chemistry 33-1】 【Chemistry 33-2】 【Chemistry 33-3】 【Chemistry 33-4】 【Chemistry 33-5】 【Chemistry 33-6】 【Chemistry 33-7】 【Chemistry 33-8】 【Chemistry 33-9】 【Chemistry 33-10】 【Chemistry 33-11】 【Chemistry 33-12】 【Chemistry 33-13】 【Chemistry 33-14】 【Chemistry 33-15】 【Chemistry 33-16】 【Chemistry 33-17】 【Chemistry 33-18】 【Chemistry 33-19】 【Chemistry 33-20】 【Chemistry 33-21】 【Chemistry 33-22】 【Chemistry 33-23】

29. 29. A pharmaceutical composition comprising a compound according to any one of claims 1 to 28 and / or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

30. 29. A pharmaceutical composition for treating or preventing a disease mediated by, or at least in part by, BTK, comprising a compound of any one of claims 1 to 28 and / or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

31. 31. The pharmaceutical composition of claim 30, wherein the disease is selected from the group consisting of cancer, inflammatory diseases and autoimmune diseases.

32. 31. The pharmaceutical composition of claim 30, wherein the disease is selected from the group consisting of solid tumors and hematological malignancies.

33. 31. The pharmaceutical composition of claim 30, wherein the disease is selected from the group consisting of lymphoma, leukemia, and myeloma.

34. The disease may be B-cell malignant tumor, diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, Burkitt's lymphoma, non-Burkitt's high-grade B-cell malignant lymphoma, extranodal marginal zone B-cell lymphoma, small lymphocytic lymphoma (SLL), lymphoblastic lymphoma, lymphocytic leukemia, myeloid leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), human acute monocytic leukemia, acute lymphocytic leukemia (ALL), B-cell acute lymphocytic leukemia ( 31. The pharmaceutical composition of claim 30, wherein the therapeutic agent is selected from the group consisting of: myelodysplastic syndrome (MYC), hairy cell leukemia, chronic lymphocytic leukemia (CLL), myelodysplastic syndrome, acute lymphoblastic leukemia, multiple myeloma or graft-versus-host disease; systemic inflammation and local inflammation, arthritis, rheumatoid arthritis, inflammation associated with immunosuppression, organ transplant rejection, allergic diseases, ulcerative colitis, Crohn's disease, dermatitis, asthma, lupus erythematosus, Sjogren's syndrome, scleroderma, multiple sclerosis, osteoporosis, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, antineutrophil cytoplasmic antibody vasculitis, chronic obstructive pulmonary disease, psoriasis, psoriatic syndrome, pemphigus vulgaris, and diseases associated with kidney transplantation.

35. 31. The pharmaceutical composition of claim 30, wherein the disease is high-risk CLL.

36. A compound according to any one of claims 1 to 28 and / or a pharmaceutically acceptable salt thereof for use as a pharmaceutical.

37. 30. A compound according to any one of claims 1 to 28 and / or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of an inflammatory disease, an autoimmune disease, a solid tumor, a lymphoma, a leukemia, a myeloma or graft-versus-host disease.

38. 29. A pharmaceutical combination comprising a compound according to any one of claims 1 to 28 and / or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent, wherein said therapeutic agent is selected from anti-inflammatory agents, immunomodulatory agents and anti-tumor active agents.

39. Compound of formula (VI): 【Transformation 34】 or solvates, racemic mixtures, enantiomers, diastereomers and tautomers thereof, X １ , X ２ , X ３ , X ４ , R １ , R ２ and R ３ is as defined in any one of claims 1 to 28; R ３１ ' is -CHO, -C １－３ Alkyl-OH, -C １－３ Alkyl-OAc, C １－３ Alkyl, —C(O)—C １－３ Alkyl or C １－３ haloalkyl, and R ３２ is halogen, -B(OH) ２ , -B(OC １－６ alkyl) ２ , 【Chemistry 35】 and R ｄ is hydrogen or C １－６ The compound is alkyl. [Request Item 40] [Chemistry 36] and Z is N or CR ７ and R ７ and R ８ are each independently hydrogen or halogen; R ９ is halogen or C １－６ 40. The compound of claim 39, wherein n is alkyl; and n is 1 or 2.

41. 40. The compound of claim 39 selected from: 【Chemistry 37-1】 【Chemistry 37-2】

Images